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FOREWORD 
 
The School of Pharmacy and Pharmaceutical Sciences, Cardiff University, is the only school 
of pharmacy in Wales and is one of the top schools of pharmacy in the UK. Our students 
graduate well-prepared and satisfied, as seen by the consistently high pass rate in the 
pharmacist registration examination and high ranking in the National Student Survey 
respectively. 
 
In addition to supporting individual pharmacists in their initial and ongoing education and 
development, the School is active in research that has been independently judged to be 
predominantly of international standing, more than half of which is recognised as world-
leading or internationally excellent and with many interdisciplinary and external 
collaborators. Research at the School encompasses medicinal chemistry, drug delivery and 
microbiology, pharmacology and physiology, and pharmacy practice and clinical pharmacy, 
and it impacts on healthcare and pharmaceutical sciences throughout the UK and the world. 
Further information on the School’s research activities and degree programmes, along with 
contact details for academic staff can be found at http://www.cardiff.ac.uk/phrmy. 
 
At the Cardiff School of Pharmacy and Pharmaceutical Sciences, the combination of these 
strengths allows us to successfully deliver research-led learning and teaching. All of our 
MPharm students undertake a significant, independent Masters level research project in the 
final year of the four-year degree, and present and defend their research. The high numbers 
of well-qualified UK, EU and international students that we attract to our postgraduate 
diplomas and degrees also contribute significantly to our research output. 
 
This is the 17th year in which we have published the abstracts of our students’ research. 
Within this publication the student is the first named author, and collaborators and 
supervisors follow. An alphabetical list of authors appears in the index. 
 
Many thanks to our colleagues for their assistance in collating this book. 
 
Rebecca Price-Davies & Dean Routledge 
June 2017 
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Exploring the interprofessional interactions between community pharmacists and 
other healthcare professionals 
Lauren Akers, A Jenkins and MW Smith 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Interprofessional interactions (IPI) have been defined as ‘a group of individuals from different disciplines or 
professions working and communicating with each other. In the environment of interprofessional learning, 
every member provides his/her knowledge, skills and attitudes to augment and support the contributions of 
others’.1 Enhanced IPIs are paving the way to safer, more efficient and knowledgeable multidisciplinary 
healthcare teams. To develop these interactions, there needs to be effective interprofessional education (IPE) 
within the undergraduate pharmacy course to develop relationships between professions early on.2 However, 
to develop effective IPE, there needs to be knowledge on what the interactions involve. 
The aim was to explore the topics of interactions that community pharmacists have with other healthcare 
professionals through face-to-face semi-structured interviews with 15 practicing pharmacists, results were 
transcribed, coded and then analysed by inductive thematic analysis. From this, 5 themes emerged; problem 
solving, learning, stock, relationships and access to healthcare professionals.  
From these findings, barriers to interactions emerged; frequent comments included the need for enhanced 
training between professions to form understanding of each other’s roles, limitations and abilities. Additional 
training was suggested for the GP receptionist, who appeared to be a barrier to accessing the GP, especially 
if there was a lack of understanding of the pharmacists’ role. Many commented that the GP receptionist often 
thought the pharmacists’ aim was to gain more revenue, however if there was a good relationship with the 
receptionist then they appeared to facilitate the access to the GP.  
In conclusion, pharmacists interact with other healthcare professionals frequently and about a multitude of 
topics however there are many barriers to overcome to improve interactions within a multidisciplinary team. 
The underlying foundations to successful IPI these appear to be having effective IPE sessions early within 
education, to enforce collaboration before healthcare professionals are working within practice, this is 
supported in literature, along with educating receptionists in practice and other professionals on the role of the 
pharmacist.  
 Hall, P and Weaver, L. Interdisciplinary education and teamwork: A long and winding road, Medical education, 2001:35(9), pp. 867–
75. (Hall and Weaver, 2001)  
 Dhaliwal, K. Benefits of interprofessional education, Health Professional Student Journal, 2015:1(2). 
 
 
Discovering the cellular location of STAT3 during mitosis 
Sarah Albert, S Ziliotto and KM Taylor 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Signal Transducer and Activator of Transcription 3 (STAT3) is a protein which is essential for many cellular 
functions including cell proliferation, differentiation and apoptosis.1 STAT3 is found to be constitutively 
activated in breast cancers.2 The transcriptionally active form of STAT3 activated at the Tyrosine 705 residue 
(pY705STAT3) has been widely studied and shown to be elevated in many cancers. Recent preliminary data 
has found that another form of STAT3 is present in mitotic cells. Therefore this project sought to confirm the 
presence of STAT3 in mitotic breast cancer cells, and to understand more about its cellular location and 
whether it localises with any of the tubulin subunits. α/β tubulin heterodimers are the structural components 
which form microtubules3 and γ-tubulin is located at the centrosomes involved in microtubule nucleation4.  
MCF-7 breast cancer cells were probed for pS10HistoneH3 (a marker of mitosis), STAT3 and the different 
tubulin subunits (α,β and γ), followed by nuclear staining with DAPI. Cells were viewed using 
immunofluorescence microscopy, and cells at all stages of mitosis were imaged, then optimised by altering 
contrast and brightness.  
The presence of STAT3 throughout all stages of mitosis was confirmed, and it was still present at the end of 
telophase, by which point pS10HistoneH3 was dephosphorylated. Similar cellular locations of STAT3 and γ-
tubulin were demonstrated from the images obtained, most notably during metaphase and anaphase.  
The above findings indicate that STAT3 most likely plays an important role in the division of cancer cells. This 
shows potential for it to be a viable target for chemotherapeutic drugs or as a marker for rapidly proliferating 
MPharm 
4 
cancers. More work is needed such as proximity ligation assays, in order to establish whether it binds to γ-
tubulin.  
 Bowman T, Garcia R, Turkson J and Jove R. STATs in oncogenesis. Oncogene 2000:19(21), pp. 2474-2488  
 Berclaz G, Altermatt HJ, Rohrbach V, Siragusa A, Dreher E and Smith PD. EGFR dependent expression of STAT3 (but not STAT1) 
in breast cancer. International Journal of Oncology 2001:19(6), pp.1155-1160.  
 Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nature reviews Cancer 2010:10(3), pp.194-204.  
 Stearns T, Evans L and Kirschner M. Gamma-tubulin is a highly conserved component of the centrosome. Cell 1991:65(5), pp.825-
836.  
 
 
What learning needs do cluster pharmacists have when commencing their role and 
after one year of practice? 
 
Gayathri Balasubramaniam and D Roberts 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and Wales Centre for Pharmacy Professional Education (WCPPE), 8 North Road, Cardiff, CF10 3DY, Wales, UK. 
In Autumn 2015, thirty-four cluster pharmacists began their roles in GP surgeries in South Wales as part of the 
Welsh Government’s plan for a new primary care service. The plan supports the Welsh Government’s vision 
to move services from secondary to primary care and advocates that all healthcare professionals use their 
clinical skills and abilities to their maximum.1 Cluster pharmacists have the potential to optimise patient 
medication, reduce drug wastage and costs and ultimately transform the way that patient care is delivered in 
primary care.2 The Wales Centre for Pharmacy Professional Education (WCPPE) was asked to develop a 
training programme to support these pharmacists. This project aims to explore the initial learning needs on 
commencement of the role and the on-going training that is required following a year of practice.  
An initial literature review was conducted to inform the creation of a semi-structured interview schedule. All 
cluster pharmacists in South Wales (n=34) were invited to participate by email. Semi-structured interviews 
were conducted (n=11), recorded and then transcribed ad verbatim, before being analysed using inductive 
thematic analysis. Ethical approval was obtained from Cardiff School of Pharmacy and Pharmaceutical 
Sciences.  
A response rate of 32.3% was achieved. The main finding were that pharmacists from different backgrounds 
(hospital or community) had different clinical learning needs on commencement of these roles but everyone 
felt there was a need for a mentor and training in a range of soft skills. On-going learning needs after a year in 
practice included formalised GP computer system training and more peer support / networking opportunities.  
The recommendations made are steps towards cluster pharmacists feeling integrated within the primary care 
team. The WCPPE’s training programme was found to be useful, especially for networking with other 
pharmacists. Further improvements included wanting more case-based training and differentiating aspects of 
the training for participants from different clinical backgrounds.  
 Public Health Wales - Primary care services for Wales up to March 2018. Available from: 
http://www.wales.nhs.uk/document/251949  
 Martin C, Scott-Thomas S, Walker PR. Models of care for pharmacy within primary care clusters. Royal Pharmaceutical Society; 
2015 Dec 
 
 
Understanding and determining critical quality attributes for coated microneedles 
Abigail Bennett, JC Birchall and SA Coulman 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Coated microneedles (MNs) are solid micron-sized needles that are coated with a drug or vaccine.1 They are 
applied to the skin surface and breach the stratum corneum to facilitate enhanced permeation of the drug in 
the epidermis and dermis, where it can act locally or enter dermal microcirculation to elicit a systemic effect.2 
Coated MNs are approaching clinical utility, however there are currently no standards against which MN 
products can be tested to allow their regulatory approval.3 The aim of this work was to define critical quality 
attributes (CQAs) of general coated MN products and to suggest tests to demonstrate that the quality of the 
product is of the necessary standard to ensure efficacy and patient safety.  
A systematic literature review of 133 published papers and regulatory guidelines was conducted to inform the 
recommendations made in this research. An iterative process was employed by the research team, which 
included two experts in the MN field, who met eleven times during the six-week data collection period to 
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rationalise attributes and potential tests. At the end of the data collection period, a meeting was held with a 
pharmaceutical assessor from the MHRA to rationalise and confirm the draft table of CQAs that had been 
produced.  
The final table contained twelve CQAs for coated MNs. These attributes included sterility, sharpness, coating 
uniformity, stability and dissolution. CQAs were accompanied by a rationale for their inclusion and at least one 
appropriate test was suggested for each.  
The findings presented in this work constitute significant progress towards the establishment of specifications 
to allow the regulatory approval of coated MN products. The results have been ratified with a representative 
from the MHRA and future work should engage the international MN community more widely, including both 
developers and regulators, to refine the suggestions and ensure harmonisation. 
 Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Advanced Drug Delivery Reviews. 2012; 64(14), pp. 
1547-68.  
 Donnelly RF, Singh T, Garland M, Migalska K, Majithiya R, McCrudden C et al. Hydrogel-forming microneedle arrays for enhanced 
transdermal delivery. Advanced Functional Materials. 2012;22(23), pp. 4879-90. 
 Lutton, RE, Moore J, Larrañeta E, Ligett S, Woolfson AD, Donnelly RF. Microneedle characterisation: the need for universal 
acceptance criteria and GMP specifications when moving towards commercialisation. Drug Delivery and Translational Research. 
2015;5(4), pp. 313-31. 
 
 
The influence of ageing and gender on oestrogen receptor expression 
Khadija Bibi, JS Bice and EJ Kidd 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Alzheimer’s disease (AD) has now been named as the number one cause of death in England and Wales, 
along with other dementias.1 It is a progressive neurodegenerative disease, with patients at later stages being 
unable to perform everyday activities. Two of the main risk factors for AD are age and gender but the reasons 
for this association are not yet understood.2 There are no current treatments available that cure the disease3 
and, with growing diagnoses and an ageing population, this poses a big problem. Changes in oestrogen 
receptor (ER) expression have been suggested to be involved in the development of AD, as they have been 
found to be neuroprotective.4 The aim of this study was to determine whether the expression of ERs is affected 
by age and/or gender, with the prediction that expression would differ with age in women.  
Western blot analysis using specific antibodies for ERα and ERβ was carried out on cortical brain samples 
from men and women aged 20 to 99.  
The main findings of this study were that ER expression decreased significantly in women as they got older, 
whereas little fluctuation was seen in men as they aged. In addition, it was found that expression levels of ERs 
did not differ between young men and women, howeve,r there was an apparent trend for a decrease in women 
as they got older, compared with men.  
Future work could include investigations into the proteins that are involved in neuroprotection. These findings 
support the development of new treatments for AD involving ERs.  
 Siddique, H. 2016. Dementia and Alzheimer’s Leading Cause of Death in England and Wales [Online]. The Guardian. Available at: 
https://www.theguardian.com/society/2016/nov/14/dementia-and-alzheimers-leading-cause-of-death-england-and-wales [Accessed: 
6th December 2016]. 
 Alzheimer’s Society. 2014a. What is Alzheimer’s Disease? [Online]. London: Available at: 
https://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=100 [Accessed: 15th December 2016].  
 Lakhan, SE. 2016. Alzheimer’s Disease Treatment & Management [Online]. Medscape. Available at: 
http://emedicine.medscape.com/article/1134817-treatment [Accessed: 3rd January 2017].  
 Levinta, A and Mukovozov, I. 2016. Neuroprotective Role of Estrogen Receptor-β in Alzheimer’s Disease Pathology. University of 
Toronto Medical Journal[Online]93(2), pp. 27-30. Available at: http://utmj.org/index.php/UTMJ/article/view/1687/1414 [Accessed: 
30th December 2016].  
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Comparison of the effect of relative humidity (RH) on aerosolisation performance of 
hard gelatin (HG) and hydroxypropylmethylcellulose (HPMC) capsules 
Zhang Min Bong and JC Birchall  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The choice of capsules is important to ensure sufficient formulation protection and effective aerosolisation 
performance in dry powder inhalers (DPIs).1 This study aimed to compare the aerosolisation performance of 
budesonide-lactose formulations emitted from a DPI using either HG or HPMC capsules under the influence 
of various storage relative humidity (RH).  
Capsules were loaded with budesonide-lactose formulations and conditioned at 11, 33, 53, 85% RH before 
evaluating the moisture content of capsules. The aerosol performance of HG or HPMC capsules was 
measured using the dosage unit sampling apparatus (DUSA) and next generation impactor (NGI) and analysed 
using UV-vis spectrometry. Two-way ANOVA was performed to analyse the capsule types and the effect of 
RH on emitted dose (ED), fine particle dose (FPD) and fine particle fraction (FPF) parameters.  
The HG capsules were shown to have higher moisture content than HPMC capsules at all %RH studied. The 
ED aerosolised from both capsules showed no significant difference, whereas the FPF value was found to be 
statistically (p<0.05) different between the capsules when the storage humidity was increased from 22 to 85% 
RH. HPMC capsules, which showed higher FPD and FPF, demonstrated a better aerosolisation profile than 
HG capsules under different storage humidities.  
The findings have shown that the aerosol performance of the DPI is dependent on the capsule types and 
storage humidity. The RH of the environment is suggested to affect the interparticulate forces between the 
formulation particles through moisture transfer from the environment into capsule shells and then the 
encapsulated formulation.2 HPMC capsules, having lower moisture contents than HG capsules, are found to 
have improved aerosolisation profiles at all RH conditions investigated. Therefore, HPMC capsules appear to 
be a better capsule choice in protecting the contents of a DPI formulation, particularly when the formulation is 
stored at high humidity.  
 Jones BE. Quali-V-I: A new key for dry powder inhalers. Drug Deliv Technol. 2003;3(6), pp. 52–7. 
 Zhu K, Tan RBH, Kiong Ng W, Shen S, Zhou Q and Heng PWS. Analysis of the influence of relative humidity on the moisture 
sorption of particles and the aerosolization process in a dry powder inhaler. J Aerosol Sci. 2008;39(6), pp. 510–24. 
 
The association of zinc transporter ZIP7 with lamins in MCF-7 breast 
adenocarcinoma cells 
Ella Boothby, S Ziliotto and KM Taylor 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Zinc is an intriguing essential element that has an indispensable role in a myriad of cellular and biological 
processes.1 Belonging to the SLC39A subfamily of zinc transporters, ZIP7 co-ordinates zinc homeostasis 
through release of labile zinc from intracellular stores to the cytosol.4 Current literature has provided 
immunofluorescent imaging demonstrating ZIP7 localisation the endoplasmic reticulum.3 Observed in imaging 
is presence of a perinuclear band representing ZIP7 localisation to the outer membrane of the nuclear 
envelope. The primary aim of the project was to establish if ZIP7 also localised to the inner membrane of the 
nuclear envelope.  
MCF-7 cells were cultivated and treated with antibiotics. At 80% confluence cells were tranfected with 
recombinant wild type ZIP7. Cells were harvested, stained with primary antibodies and conjugated to 
fluorescently labelled secondary antibodies. Images of cells were taken on a Leica microscope using a 
Hammamatsu camera on Openlab software.  
Co-localisation identified areas of fluorophore overlap in imaging. ZIP7 was not found to demonstrate co-
localisation with nuclear pore complexes. ZIP7 antibodies appeared to co-localise with Lamin A/C and Lamin 
B Receptor antibodies, proteins known to reside on the inner nuclear envelope membrane. 
Results suggested that ZIP7 was in close regional proximity to Lamin A/C and Lamin B Receptor inferring ZIP7 
localisation to the inner membrane of the nuclear envelope. Supporting evidence from super resolution 
microscopy is required to reinforce this finding. ZIP7 is known to have a role within carcinogenesis2 when 
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localised to the endoplasmic reticulum. It may be valuable to analyse nuclear located ZIP7 as it too could be 
implicated in breast tissue malignancy.  
 Frassinetti, S. et al. 2006. The role of zinc in life: a review. Journal of Environmental Pathology, Toxicology and Oncology [Online] 
 25(3), pp. 597–610. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17073562 [Accessed: 3 January 2017]. 
 Hogstrand, C. et al. 2009. Zinc transporters and cancer: a potential role for ZIP7 as a hub for tyrosine kinase activation. Trends in 
Molecular Medicine 15(3), pp. 101–111. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19246244 [Accessed: 3 January 2017]. 
 Taylor, K.M. et al. 2008. ZIP7-Mediated Intracellular Zinc Transport Contributes to Aberrant Growth Factor Signaling in 
Antihormone-Resistant Breast Cancer Cells. Endocrinology [Online] 149(10), pp. 4912–4920. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/18583420 [Accessed: 3 January 2017]. 
 Taylor, K.M. and Nicholson, R.I. 2003. The LZT proteins; the LIV-1 subfamily of zinc transporters. Biochimica et Biophysica Acta 
[Online] 1;1611(1–2), pp. 16–30. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12659941 [Accessed: 3 January 2017].  
 
 
Validating Optical Coherence Tomography (OCT) as a method to characterise 
capsule shell thickness and puncture by a dry powder inhaler (DPI) 
 
Fatima Bukhari, JC Birchall, BE Jones and SA Coulman 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Two-piece hard capsules used in dry powder inhalers (DPI) are predominately made from gelatin and 
hypromellose.1 The manufacturing process of hard capsules can result in slight variation of the capsule wall 
thickness.2 Differences in thickness could potentially influence puncture by the DPI. This study aims to use 
optical coherence tomography (OCT) to develop a valid and reliable method to measure the thickness of a 
hard shell capsules for quality control purposes, using Scanning Electron microscope (SEM) as the 
established comparator. It also explores variability in capsule shell thickness between different capsule 
formulations and moisture contents. An additional aim was to investigate whether OCT can gather 3D 
information of puncturing event in a capsule punctured by a four pin DPI. 
Gelatin and two types of hypromellose capsules were conditioned at three different relative humidities (RH: 
11%, 34% and 55%). An OCT method was developed to analyse capsule thickness at two locations, the 
join between the two pieces of a capsule and at the centre of the dome. Capsules were observed under 
both SEM and OCT. Four empty capsule specimen from each different formulation and different RH were 
examined. Statistical differences in the thickness of capsule shells for the three capsule formulation were 
assessed using one-way ANOVA tests. Comparison of capsule wall thickness for OCT and SEM was 
evaluated using the Bland-Altman plot. 
OCT provided very reproducible measurements of capsule thickness observed at both the join and dome. 
The study showed the type of capsule and condition has no effect on the capsules wall thickness (p-value 
>0.05). SEM and OCT imaging technologies produced different absolute values with the average difference 
of -25.88μm. 
Since the two methods are inequivalent, further work is needed to determine if OCT or SEM is the most 
accurate tool to measure capsule wall thickness. Other imaging techniques could be used to observe 
capsule wall thickness or a correction factor could be applied if OCT measurements consistently under- or 
over-estimate capsule wall thickness. This study is the first to use OCT to characterise four pin capsule 
puncture by a DPI. 
1. Jones B. The evolution of DPI capsules. Inhalation. 2008;(December), pp. 16-19. 
2. Jones B. Manufacture and properties of two-piece hard capsule. In: Podczek F, Jones B, editors. Pharmaceutical Capsules. 2nd ed. 
London: Pharmaceutical Press; 2004. pp. 79-100. 
 
 
Phenylalanyl-tRNA synthetase inhibitors as potential agents for the treatment of 
Methicillin-resistant Staphylococcus aureus 
Wei Sheng Cheah, C Williamson and C Simons 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Staphylococcus aureus is a common Gram-positive bacterium that is usually commensal and non-pathogenic 
which colonises a small percentage of the human population. However, in the case of an infection, it is capable 
of presenting itself as bacteraemia, bacterial endocarditis and also skin and soft tissue infections.1,2 However, 
Methicillin-resistant Staphylococcus aureus (MRSA) do not respond well to conventional treatments of S. 
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aureus and the increasing percentage of resistant proportions globally is concerning when coupled with the 
numbers of hospital-acquired infections and community-acquired MRSA infections in countries throughout the 
globe.3,4 The aim of this study was to attempt to synthesise and characterise a series of compounds that can 
potentially be used for the treatment of MRSA.  
The design of novel compounds was first done using Molecular Operating Environment (MOE) with a homology 
model of phenylalanyl-tRNA synthetase (PheRS) from an unpublished PhD study as the reference protein. 
Computerised docking analysis was performed prior to synthesis of compounds. Synthesised compounds 
were then prepared and purified using recrystallisation, column chromatography and preparative-TLC. 
Characterisation of compounds was done with 1H and 13C NMR and melting point analysis.  
Docking results showed that all 3 of the designed compound were expected to have good affinity for the binding 
pocket and satisfy the interactions identified in the homology model. However, the final compounds contained 
impurities or could not be confirmed owing to the lack of characteristic signals expected for individual 
compounds from NMR data. However the usage of T3P as the coupling agent was found to be optimal to 
produce promising yields with improved purity.  
Some limitations to this study include the absence of rmsd calculations in docking results due to the lack of a 
crystal structure for PheRS with a bound ligand and the lack of time to explore different coupling reagents and 
solvent systems. Further work can be done in these areas in hopes of obtaining a pure compound with high 
yield for biological testing.  
 Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG. Staphylococcus aureus Infections: Epidemiology, Pathophysiology, 
Clinical Manifestations, and Management. Clinical Microbiology Reviews. 2015 05/27;28(3), pp. 603-61. 
 Antimicrobial resistance: global report on surveillance 2014. World Health Organisation; 2014 [accessed. Available from: 
http://www.who.int/drugresistance/documents/surveillancereport/en/. 
 Auwaeter P. Staphylococcus Aureus. John Hopkins Antibiotic Guide; 2016. 
 Stefani S, Chung DR, Lindsay JA, Friedrich AW, Kearns AM, Westh H, et al. Meticillin-resistant Staphylococcus aureus (MRSA): 
global epidemiology and harmonisation of typing methods. International Journal of Antimicrobial Agents. 2012 4//;39(4):273-82. 
 
 
Assessment of inhaler technique and implementation of an extended asthma care 
plan in a community pharmacy setting 
Thomas M Chilvers and WR Ford 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Asthmatics are offered an annual review.1 Subsequently we see many patients with poor inhaler technique 2 
who are unlikely to get the full benefit of their treatment due to insufficient drug deposition in the lung, going 
against National Institute of Clinical Excellence (NICE) guidelines.3 This reduction in the dose getting to the 
target could be one factor leading to high hospitalisation and mortality rates associated with asthma.4 This 
study aims to evaluate the current state of asthma in the community from a pharmacy setting. 
Patients were recruited by opportunistic sampling across seven community pharmacies across South Wales. 
The following parameters were measured: Inhaler technique (using an aerosol inhalation monitor (AIM)), level 
of asthma control (using an asthma control survey (ACS) modelled on the asthma control test (ACT)) and lung 
function (using spirometry). Data was analysed using a Kruskal-Wallis test supported by Dunn’s post hoc test 
in conjunction with chi-squared tests. The Cardiff School of Pharmacy and Pharmaceutical Sciences Research 
Ethics committee granted ethical approval. 
The data collected found that asthma control was very poor as only 56.5% of the sample were controlled using 
the ACS. Patients using meter dose inhalers (MDI) had the worst technique compared to dry powder inhalers 
(DPI) or MDIs used with spacers (P<0.05) and were more commonly prescribed steroids as a rescue therapy. 
A key finding of this data was that there are no differences in the outcome from advice provided by all 
healthcare professionals (HCPs), highlighting flaws within the current schemes put in place by the National 
Health Service (NHS).  
The poor state of asthma control and inhaler technique seen coupled with ineffective schemes run by HCPs 
suggests a need for change in approach towards the issue. Aiming to provide better care and education to 
asthmatics to help them achieve adequate control of their condition.  
1. Asthma | QUALITY-STATEMENT-5-REVIEW | GUIDANCE AND GUIDELINES | NICE [Internet]. Nice.org.uk. 2013 [cited 4 January 
2017]. Available from: https://www.nice.org.uk/guidance/qs25/chapter/Quality-statement-5-Review 
2. Harnett C et al. A study to assess inhaler technique and its potential impact on asthma control in patients attending an asthma clinic. 
Journal of Asthma. 2014;51(4), pp. 440-445. 
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3. NICE. Asthma | quality-statement-4-inhaler-technique | Guidance and guidelines | NICE [Internet]. Nice.org.uk. 2013 [cited 28 
November 2016]. Available from: https://www.nice.org.uk/guidance/qs25/chapter/Quality-statement-4-Inhaler-technique 
4. Royal College of Physicians. Why asthma still kills: The National Review of Asthma Deaths (NRAD) Confidential Enquiry report. 
London: RCP, 2014, 2014. 
 
Evaluation of endotoxin capture materials for use in a point of care exhaled breath 
sensor to differentiate between viral and bacterial pneumonia in children 
Sonal Chotai, G Makuta, C Gregory and JL Bowen 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, and School of Medicine, Heath Park, Cardiff, CF14 4XW, Wales, UK 
Pneumonia is the single largest infectious cause of death in children worldwide. 1 In developing countries, 
children are particularly susceptible to pneumonia and find it more difficult to access healthcare services, 
resulting in high mortality rates.1,2 Currently there is no simple point-of-care test available to determine the 
cause of pneumonia.2 Endotoxin or lipopolysaccharide (LPS) is found in the cell wall of Gram-negative 
bacteria. Many types of Gram-negative bacteria can cause pneumonia, including Haemophilus influenzae; the 
second most common cause of bacterial pneumonia in children.1 This project aims to find the best material to 
enable capture and recovery of endotoxin from exhaled breath, for use in a 3D printed prototype device, so 
that the cause of pneumonia can be determined.  
Three types of syringe filters were screened for their ability to capture LPS. Fluorescently labelled LPS was 
filtered through the membranes, which were then washed with two 0.5 ml WFI washes. Fluorescent 
spectroscopy was used to determine level of LPS in filtrate. A nebuliser setup was used to simulate breathing 
into the prototype device. Various methods of endotoxin recovery were used on the filters. The Endosafe® 
Nexgen-PTS™ was used to quantify recovered LPS.3  
Initial tests with the syringe filters at LPS concentrations of 0.01-5 μg/ml demonstrated that nylon was able to 
capture the greatest amount of LPS, followed by PTFE. Mixed cellulose failed to capture any LPS, with 
fluorescent readings being slightly higher than those observed in the ‘no filter’ calibration.The nylon GNWP 
filters were unusable, as endotoxin could not be recovered effectively using any method. The Hybond nylon 
blotting membrane had background endotoxin, but better recovery. Aluminium had lower capturing ability but 
the easiest recovery. 
Nylon is the filter of choice for use in the device. The best type of nylon filter and method of recovery is yet to 
be confirmed. 
 WHO. World Health Organization. Pneumonia; 2016 Nov 11 Available from: http://www.who.int/mediacentre/factsheets/fs331/en/. 
[Accessed 7th Dec 2016].  
 UNICEF. Health - Pneumonia; 2009 Nov 2 Available from: https://www.unicef.org/health/index_43828.html. [Accessed 7th Dec 
2016]. 
 Charles River. Endosafe® Nexgen-PTSTM. [Online] Available from: http://www.criver.com/products-services/rapid-
micro/endosafe/endotoxin-rapid-testing-systems/nexgen-pts [Accessed: 17th January 2017]  
 
Numerical approach to investigate adhesion between orthopaedic biomaterials and 
gram negative bacteria: Influence of material roughness and surface characteristics 
Jillian Connelly and P Prokopovich 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
In a surveillance between 2014 and 2015, 102,496 orthopaedic surgeries were conducted across 138 NHS 
trusts in England and on average 0.9% of these surgeries resulted in infection.1 The majority of these infections 
occur in deep tissue or organ spaces with roughly 10% caused by gram negative bacteria.1 Infections occur 
due to bacterial adhesion to materials and forming a layer called a biofilm. Treatment of such infections are 
more challenging and result in additional costs to the NHS.2 The aim of this project was to study the effect of 
material and surface properties of orthopaedic biomaterials and bacteria and the effect of surface roughness 
on adhesion. 
An in-house developed numerical procedure3 was used in order to collect relevant data. The procedure is 
based on the Johnson-Kendall-Roberts (JKR) multi-asperity adhesion model and allows the generation of 
adhesive force data between two interacting surfaces3. With fixed roughness adhesive force data were 
generated between six orthopaedic biomaterials and 5 strains of gram negative bacteria. From those results 
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the most and least adhesive bacteria were chosen, after that effect of surface roughness of selected materials 
against these two bacteria were studied 
With fixed roughness, Pseudomonas aeruginosa AK1 was identified as the most adhesive bacteria and E. coli 
0157K the least adhesive bacteria. The least adhesive material overall was determined to be stainless steel 
and increasing the material surface roughness increases the total adhesive force between bacteria and 
material. 
Although it is seen that rougher material surfaces increase adhesion, will using smoother surfaces have an 
effect on the effectiveness and reliability of the prosthesis? There are also other techniques that could be used 
to evaluate bacterial adhesion such as the as Derjaguin and Landau, Verwey and Overbeek (DLVO) theory4 
and ways to coat the material so roughness wouldn’t be affected. 
 Public Health England. Surveillance of surgical site infections in NHS hospitals in England, 2014/15. London: Public Health England, 
December 2015. Available from: www.gov.uk/phe  
 Graves N, Wloch C, Wilson J, Barnett A, Sutton A, Cooper N, et al. A cost-effectiveness modelling study of strategies to reduce risk 
of infection following primary hip replacement based on a systematic review. Health Technol Assess 2016;20(54 
 Prokopovich P, Perni S. Multiasperity contact adhesion model for universal asperity height and radius of curvature distributions. 
Langmuir. 2010 October 6, 2010;26(22), pp. 17028-36 
 Liu, Y. and Zhao, Q. Influence of surface energy of modified surfaces on bacterial adhesion. Biophysical Chemistry. 2005;117(1), 
pp.39-45. 
 
An investigation into the prescribing of antipsychotics in care homes 
Gavin Coward, M Gumbleton and MW Smith 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Care home residents remain some of the most frail and vulnerable members of society; most are elderly, and 
have multiple co-morbidities.1 A study by Shah et al highlights that 20.92% of care home residents were 
prescribed an antipsychotic.2 Maguire et.al suggests that elderly patients are more likely to be prescribed an 
antipsychotic when residing in a care home.3 The aim of this investigation was to identify the trends of 
antipsychotic prescribing in care homes.  
EMAR data for a sample of 12 care homes in south Wales was provided and administrations were filtered to 
isolate data specific to the prescribing of antipsychotics. Quantitative analysis was conducted to determine the 
prevalence and nature of antipsychotic agents prescribed to residents, in addition to the frequency that 
residents were prescribed a dementia management agent. The appropriateness of the doses of antipsychotics 
received by residents was assessed. A Pearson’s Correlation test was used to establish any correlation 
between the prescribing of antipsychotics and other psychotropic agents to care home residents. 
Out of a total of 23 antipsychotic agents, 5 first-generation and 6 second-generation antipsychotic agents were 
found to be in use. Residents in the care homes were found to be nearly three-times as likely to be prescribed 
a second-generation over first-generation antipsychotic. A high positive correlation between the prescribing of 
antipsychotics and other psychotropic agents across the subject care homes, was found.  
21.05% of residents in the care homes were prescribed an antipsychotic, closely mirroring that found in the 
Shah et.al study.3 Second generation antipsychotics were prescribed preferentially over first generation to 
residents, in line with BNF recommendations, to minimise adverse effects and falls. However, the prescribing 
of both an antipsychotic alongside a dementia management agent to residents in the care homes remained, 
despite the potential severe health implications and the National Strategy to reduce this.4 
 Centre for Policy on Ageing (CPA). “Managing and Administering Medication in Care Homes for Older People”: October 2011 
[Accessed 07/01/2017]. 
Available from: http://www.cpa.org.uk/information/reviews/Managing_and_Administering_Medication_in_Care_Homes.pdf  
 Shah SM et. al. “Antipsychotic prescribing to older people living in care homes and the community in England and Wales”. 
International Journal of Geriatric Psychiatry. 2011 Apr: volume 26(4):423-34  
 Maguire A, Hughes C, Cardwell C, and O'Reilly D. “Psychotropic medications and the transition into care: a national data linkage 
study”. Journal of American Geriatrics Society. 2013 Feb;61(2):215-21 
 Banerjee S. The use of antipsychotic medication for people with dementia - Time for action - A report for the Minister of State for 
Care Services”. Department of Health; November 2009. [Accessed 07/01/2017]. Available from: 
https://www.rcpsych.ac.uk/pdf/Antipsychotic%20Bannerjee%20Report.pdf 
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Perceptions of Parkinson's patients on the utility of iPad based apps to collect data 
in a Parkinson's clinic 
Rachel Cunliffe, S Ellis, NA Samuel and EL Lane 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Parkinson’s disease (PD) has a wide range of both motor and non motor symptoms which can affect patients 
very differently.1 Paper records in PD clinics can make it difficult to track changes in symptoms and disease 
progression, especially when patients only usually attend clinics every six months. The use of mobile 
technology for PD and in clinics has been studied and shown promising results.2 An iPad based app has been 
developed for use in PD clinics.3 The app features two validated questionnaires on quality of life and non motor 
symptoms, and a finger tapping test to assess motor function. The aim of this study was to assess the usability 
of this app for people with Parkinson’s and its potential for use in PD clinics using focus groups. 
Six focus groups were run with participants recruited from Parkinson's UK support groups using purposive 
non-random sampling.4 Each session was audio-recorded and then transcribed verbatim. Transcripts were 
coded and analysed using thematic analysis, with both inductive and deductive analysis used. Ethical approval 
was obtained. 
Three main themes were identified from results: attitudes towards technology, electronic data collection, and 
use of the app. Many subthemes were identified within each of these. Experience of technology varied between 
participants and this gave mixed responses towards the app. Concerns surrounded security and the effect the 
app may have on care. 
The overall opinion from focus groups was that the app should continue in development. Many solutions were 
found to the issues identified and barriers to the apps introduction. Most participants felt that the app would be 
beneficial and useable, and despite concerns surrounding technology and electronic data collection, felt that 
the app had a future for use in clinics. Once improvements are made this app could go on to greatly improve 
patient care.  
 Rang HP et al. Rang & Dale’s Pharmacology. 8th ed. Edinburgh: Elsevier Churchill Livingstone; 2016.  
 Zapata BC et al. 2015. Empirical studies on usability of mHealth apps: a systematic literature review. Journal of Medical Systems 
[Online] 39:1. Available from: http://link.springer.com.abc.cardiff.ac.uk/article/10.1007/s10916-014-0182-2 [accessed 12 Nov 2016]. 
 Mohamed B et al. 2016. iPad-based preassessment questionnaires are feasible in a Parkinson’s service (from the meeting 
abstracts of the 20th international congress of Parkinson’s disease and movement disorders. Berlin; Germany, 19-23 June, 2016). 
Movement Disorders 31 (suppl. 2) Available at: http://www.mdsabstracts.org/abstract/ipad-based-preassessment-questionnaires-
are-feasible-in-a-parkinsons-service [Accessed 27 November 2016].  
 Morgan DL. 1997. Focus groups as qualitative research. 2nd ed. London: SAGE Publications.  
 
Synthesis of αB-crystallin Inhibitors as potential therapy against triple-negative 
breast cancer 
Ibrahim Dali, N Fosu-Mensah and AD Westwell  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Triple negative breast cancer (TNBC) is a subtype of breast cancer which is increasingly recognized as a 
disease very diverse in its clinical and biological behaviour. Treatment options for patients are problematic due 
to lack of targeted therapy hence the need of novel and improved therapeutics for TNBC remains as one of 
the highest priorities of current breast cancer research.1 Recently, a novel strategy developed by Chen et al 
(2014) that target interaction between αB-crystallin and vascular endothelial growth factor served as promising 
new targeted therapy for TNBC.2 Through virtual screening, two lead hit compounds were proposed to inhibit 
CRYAB-VEGF interaction. Therefore, the aim of this study was to synthesis potential inhibitors of CRYAB 
based on one of the two lead compound, 6-mercapto-2-(alkylthio)-7,9-dihydro-8H-purin-8-one. 
The synthesis of proposed purine derivatives was first attempted via four step reactions which consist of 
cyclisation, S-alkylation, chlorination and thiolation. Subsequently, the synthetic route was switched to six steps 
reactions in order to rectify the introduction of thio-keto group instead of desired keto group in the compound. 
Commercially available 4,5-diamino-6-hydroxy-2-mercaptopyrimidine was used as the starting compound. 
Docking studies were carried out to investigate the ligands binding activities with the proposed binding pocket. 
Docking studies despite preliminary showed a promising result as two of the proposed derivatives bind to the 
proposed binding pocket and thus, might had favourable biological activity against triple negative breast cancer 
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cell lines. Characterisation by 1H-NMR and 13C-NMR also showed that the compounds synthesised contain 
several impure intermediates and the yield for final compounds was very low due to several steps involved in 
the synthetic process. 
In conclusion, in term of new targeted therapy for TNBC treatment, CRYAB inhibitor has shown a promising 
potential breakthrough for treating TNBC. Growing evidence and studies to support the rationale of this newly 
validated target could bring a powerful impact in clinical management of this complicated disease. 
1. Fosu-Mensah N, Peris M, Weeks H, Cai J and Westwell A. 2015. Advances in small-molecule drug discovery for triple-negative 
breast cancer. Future Medicinal Chemistry 7(15), pp. 2019-2039.  
2. Chen Z, Ruan Q, Han S, Xi L, Jiang W, Jiang H and Ostrov D et al. 2014. Discovery of structure-based small molecular inhibitor of 
αB-crystallin against basal-like/triple-negative breast cancer development in vitro and in vivo. Breast Cancer Research and 
Treatment 145(1), pp. 45-59.  
 
 
MAP Kinase and STYK1 signalling in breast cancer 
Amandeep Dhaliwal, P Finlay, H Mottram, S Kyme, L Farrow, A Green and JMW Gee 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK and Academic Unit of Oncology, Nottingham City Hospital, Hucknall Road, Nottingham, NG51PB, UK 
Endocrine treatment of ER+ breast cancer is limited by resistance.1 A novel tyrosine protein kinase, STYK1, 
is expressed in clinical breast cancer and can drive endocrine (faslodex) resistance in vitro, while in other 
cancers signals through MAPK.2 Thus, STYK1 acting via MAPK activation may also contribute to endocrine 
resistance but this remains unexplored. The aim was to determine if MAPK activity and STYK1 associate in 
breast cancer patient samples and in faslodex resistant (FasR) pre-clinical material. 
Immunohistochemistry (IHC) was optimised for activated nuclear MAPK (pMAPK) in archival clinical breast 
cancer sections, FasR pellets and xenografts, using pH6 microwave retrieval. The optimised IHC was applied 
to a clinical breast cancer series (n=93) pre-assayed for STYK1. After H-Scoring pMAPK staining, statistical 
analysis explored its relationship to STYK1 and to further biological parameters available for the series. 
STYK1 and nuclear pMAPK significantly correlated (p=0.013) in ER+ patients, with a weak positive trend 
between EGFR and pMAPK (p=0.061). In the ER- cohort, there was no association with STYK1 but significant 
correlations for pMAPK were shown with IGFR (p=0.046), IGF1 (p=0.026), erbB ligand HRG (p=0.005), 
transcription factor FOS (p=0.008) and mTOR element p-RPS6 (p=0.039). FasR pellets and xenograft stained 
positive for both nuclear pMAPK and STYK1, although there was some discordance in their profile for all model 
and clinical samples. 
This project has uncovered a novel relationship between STYK1 and nuclear MAPK activity in ER+ clinical 
breast cancer. However there was some discordance in all examined material including ER- tumours, 
suggesting that STYK1 may also act through other kinases in breast cancer.3 Additional pathways previously 
reported as interactive with MAPK were also prevalent in clinical breast cancers.4 The association found in 
ER+ disease and FASR material emphasises that STYK1 may contribute to emergence of endocrine 
resistance in part by activating MAPK. 
1. Zhao M, Ramaswamy B. Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer. World J 
Clin Oncol. 2014 Aug 10;5(3):248-62  
2. Cao Q, Chen M, Ye X, Tong M, Li Z, Huang W and Jin Y. High novel oncogene with kinase-domain (NOK) gene expression is 
associated with the progression of renal cell carcinoma. Clin Lab. 2016;62(1-2):179-86 
3. Li J, Wu F, Sheng F, Li YJ, Jin D, Ding X et al. NOK/STYK1 interacts with GSK-3β and mediates Ser9 phosphorylation through 
activated Akt. FEBS Lett. 2012; 586(21):3787-92 
4. Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton J et al. RAS/ERK signalling promotes site-specific ribosomal protein 
S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem. 2007 May 11;282(19):14056-64 
 
Critical quality attributes of biodegradable microneedles 
Joshua Dorward and JC Birchall 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Microneedles (MNs) are devices consiting of a baseplate with microscopic needles attached1, designed to 
breach the stratum corneum barrier of skin, to deliver drug transdermally.2 MNs are currently transitioning from 
the laboratory to clinical trials. There are currently no regulations on their manufacture and regulators have 
highlighted the need for this information. The aim of this project was to identify and define critical quality 
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attributes (CQAs) to assist the regulatory acceptance and clinical adoption of biodegradable MNs and suggest 
standardised tests to demonstrate these attributes. 
Online searches, through Web of Science, with combined search terms was used to identify studies focused 
on current MNs and similar devices and the various performance and quality tests used. There were several 
meetings with researchers and supervisors doing similar projects for other MNs where ideas and data were 
compared. A telephone conference was held with a member of the MHRA regulatory body who voiced their 
personal opinions on the topics raised. 
Results were presented in two tables. One focused on pre-clinical development and the other focused on the 
end product attributes. The attributes were listed in descending order of importance to the device. The order 
was determined by considering how each attribute would affect the safety, efficacy or usability of the device. 
Each attribute was given a description of why it was critical. They were also assigned a standardised test to 
demonstrate them and specifications they had to meet. 
Biodegradable MNs are safer and easier to produce than other MNs3. The main issues identified were the 
stability and sterility of the device. Challenges to overcome include GMP manufacture and protective 
packaging along with an appropriate expiry date. Cooperation with cosmetic companies was identified as an 
opportunity to enhance knowledge in the area.4 Identification of CQAs is essential in assissting the introduction 
of a regulatory framework for MN devices. 
 Kim YC, Park JH, Prausnitz MR. Microneedles for Drug and Vaccine Delivery. Advanced Drug Delivery Reviews. 2012; 64(14): 
1547-1568 
 Prausnitz MR, Langer R. Transdermal Drug Delivery. Nature Biotechnology. 2008; 26(11): 1261-1268 
 Park JH, Allen MG, Prausnitz MR. Biodegradable Polymer Microneedles: Fabrication, Mechanics and Transdermal Drug Delivery. 
Journal of Controlled Release. 2005; 104(1): 51-66  
 Kalluri H, Kolli CS, Banga AK. Characterization of Microchannels Created by Metal Microneedles: Formation and Closure. AAPS 
Journal. 2011; 13(3): 473-481 
 
Anti-hormone-induced Herceptin resistance in breast cancer cells in vitro 
Rebecca Duxbury, RA McClelland, C Dutkowski, P Finlay and JMW Gee 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Oestrogen receptor-positive (ER+) breast cancers are routinely treated with endocrine therapy1 and are further 
subdivided into luminal A and B types according to absence or presence respectively of the ErbB receptor 
ErbB2. Resistance to endocrine therapy emerges in approximately 40% of all patients2 but ErbB2+ breast 
cancers can also be treated with the ErbB2 monoclonal antibody Herceptin (trastuzumab) which may extend 
response to anti-hormones.2 Unfortunately, 70% of patients develop Herceptin resistance within 12 months of 
therapy.3 Interestingly, prolonged endocrine treatment (e.g. Faslodex [fulvestrant]) can promote such 
Herceptin resistance in vitro but its mechanisms are unknown. This project aimed to identify any changes in 
ErbB2 or further receptor signalling that may underpin anti-hormone-induced Herceptin resistance in prolonged 
Faslodex-treated ErbB2-overexpressing breast cancer cells in vitro. 
7 day triplicate preparations of Herceptin-responsive BT474 control (BT474(con)) and Herceptin-resistant 
BT474 Faslodex-resistant (BT474(FasR)) cells treated with or without Herceptin were studied. Western blotting 
was performed for ErbB2 expression and activation, downstream kinases and further growth factor receptors, 
quantifying by densitometry. Immunocytochemistry also analysed ErbB2 localisation in coverslip preparations. 
GeneSifter™ software compared ErbB receptor mRNA profiles in both sublines using pre-assembled 
Affymetrix microarray data. 
Herceptin promoted a significant fall in ErbB2 (p=0.026), ErbB2 membrane downregulation, and pAKT decline 
(p=0.001) in BT474(con) but not BT474(FasR) cells. Basally, the latter line also had depleted ErbB3 expression 
and activation (p=0.001 and p=0.001 respectively) and decreased pAKT (p<0.01). Conversely higher basal 
ErbB4 mRNA was noted in BT474(FasR) cells (p<0.001). Significant increases in EGFR activation (p=0.014 
and p=0.027 respectively), retained MAPK activity, and IGF-1R induction was also seen in the models with 
Herceptin. 
Prolonged anti-hormone treatment results in failure of BT474(FasR) cells to regulate ErbB2 and a parallel shift 
in ErbB signalling away from ErbB3/pAKT and towards ErbB4. Such anti-hormone induced signalling changes 
may underpin Herceptin resistance, alongside further Herceptin-induced signalling changes. 
 Benson JR, Jatoi I. The global breast cancer burden. Future Oncol. 2012;8:697-702 
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 National Institute for Health and Care Excellence (NICE). Hormonal therapies for the adjuvant treatment of early oestrogen-receptor 
positive breast cancer; 2006 [accessed 18 Dec 2012]. Available from: 
https://www.nice.org.uk/guidance/ta112?unlid=10667578412016108212727 
 Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011; 62: 233–247. 
 
Perception of Parkinson’s patients on the utility of iPad based apps to collect data 
in a Parkinson’s clinic 
Samuel Ellis, ML Hughes and EL Lane 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Parkinson’s disease is a chronic, neurological condition that mainly affects the elderly population. The motor 
symptoms are tremor, slow movement and rigidity. Non-motor symptoms, which include depression, sleep 
disturbances and memory loss, are also common.1 When attending clinic, patients complete a paper-based 
questionnaire regarding non-motor symptoms. This questionnaire was developed as the non-motor symptoms 
of Parkinson's disease are often poorly recognised and inadequately treated.2 It was identified that electronic 
data collection could be a potential method of data caputure within Parkinson's disease clinics. An iPad 
application was trialled and showed positive results.3 This project discovers the perception of Parkinson's 
patients on using an iPad application within clinic, identifing concerns and providing recommendations. 
Focus group sessions were conducted at Parkinson's disease support groups across South Wales. 
Participants read a project information sheet and signed a consent form to become involved in the study. The 
sessions were conducted in a semi-structured interview approach, and later transcribed. Data analysis was 
conducted via a thematic approach and coding aided the identification of three themes.  
Theme one discovered that many participants had negative experiences with technology, which was blamed 
on the symptoms of Parkinson’s disease and age. Theme two found that numerous participants understood 
very little about technology within healthcare, but recognised it's potential advantages. Theme three highlighted 
concerns that participants had with the iPad application, such as need for training, security and overall usability.  
Many participants felt that the iPad application was a good concept, which could be beneficial to both clinicians 
and people with Parkinson’s disease. However, it was widely expressed that considerations, such as security, 
confidentiality and practical issues need to be addressed. This iPad application has potential to improve data 
collection within clinics, and with recommendations from this study, be successfully introduced throughout 
Parkinson’s disease clinics. 
 NHS Choices. Parkinson’s disease: Overview, 2016 [accessed 27/10/16] Available at: http://www.nhs.uk/Conditions/Parkinsons-
disease/Pages/Introduction.aspx 
 Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson's disease: diagnosis and management. The Lancet 
Neurology 2006 Mar; 5(3):235-245.  
 Mohamed, B et al. iPad-based preassessment questionnaires are feasible in a Parkinson’s service (from the meeting abstracts of 
the 20th international congress of Parkinson’s disease and movement disorders. Berlin; Germany, 19-23 June, 2016). Movement 
disorders 31 (suppl. 2) Available at: http://www.mdsabstracts.org/abstract/ipad-based-preassessment-questionnaires-are-feasible-
in-a-parkinsons-service [accessed 20/11/16] 
 
 
The influence of ageing and gender on oestrogen receptor expression 
Alexandra Entwistle-Thompson, JS Bice and EJ Kidd 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The main aim of this project is to investigate the influence of age and gender on oestrogen receptor (ERα and 
ERβ) expression. Oestrogen has been studied for its role in neuroprotection and its ability to influence the 
development of neurodegenerative diseases, such as Alzheimer’s disease (AD).1,2 There are several 
mechanisms by which oestrogen has been proposed to provide neuroprotection; including protecting 
mitochondria from amyloid beta toxicity and reducing oxidative stress.3 Age and gender are known to be risk 
factors for the development of AD4, and understanding their link to the neuroprotective actions of oestrogen 
may lead to improvements in preventing neurodegeneration.  
Cortical brain samples were analysed from non-diseased men and women aged between 20-99 years. 
Western blotting was used to determine the levels of expression of ERα and ERβ receptors using specific 
antibodies. The blots were then imaged and the results analysed with ImageJ.  
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As women age the expression of ERα was signifcantly reduced in the cortex samples, however, ERα 
expression was not influenced by ageing in male cortical tissue. In comparison to elderly men, elderly women 
had a signifcantly reduced ERα receptor expression. ERβ expression displayed an upward trend for females 
as they aged but remained constant for men.  
There is evidence for a link between gender and ERα expression, suggesting that this receptor plays a part in 
the development or prevention of neurodegeneration. The apparent increase in ERβ expression with age in 
women also suggests that it plays a role in neuroprotection. More work is needed to understand the 
involvement of ERs in AD and how they could be exploited as therapeutic targets.  
 Vargas GK, Milic J, Zaciragic A, Wen K, Jaspers L, Nana J et al. The functions of oestrogen receptor beta in the female brain: A 
systematic review. Maturitas. 2016;93;41-47. [accessed 15th Nov 2016]. Available from: 
http://www.sciencedirect.com/science/article/pii/S0378512216301220 
 YL Lan, J Zhao, S Li. Update on the neuroprotective effect of oestrogen receptor alpha against Alzheimer’s disease. Journal of 
Alzheimer’s Disease. 2015;43;1137-48. [accessed 20th Nov 2016]. Available from: http://content.iospress.com/articles/journal-of-
alzheimers-disease/jad141875 
 Vina L, Lloret A. Why women have more Alzheimer's disease than men: Gender and Mitochondrial Toxicity of Amyloid-beta peptide. 
Journal of Alzheimer's Disease. 2010;20;527-533. [acessed 3rd Dec 2016]. http://content.iospress.com/download/journal-of-
alzheimers-disease/jad100501?id=journal-of-alzheimers-disease%2Fjad100501  
 Alzheimer’s Society. Risk factors for dementia. London; Alzheimer’s Society; 2017. [accessed 2nd Jan 2017]. Available from: 
https://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=102  
 
 
Exploring pharmacists’ views on the Choose Pharmacy platform within the 
community pharmacy setting 
Alice Mary Evans, E Williams, C Way and RE Deslandes 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB and NHS Wales Informatics Service, Brunel House, 12th Floor, 2 Fitzalan Road, Cardiff CF24 0HA, Wales, UK 
The Choose Pharmacy platform is an online application delivered by the NHS Wales Informatics Service 
(NWIS) that enables pharmacists across Wales to electronically manage a number of enhanced services.1 The 
aim is to implement Choose Pharmacy in 400 pharmacies out of the 716 in Wales.2 New services have recently 
been added and are categorised into modules. These are: Seasonal Flu Vaccine (SFV), Emergency Medicine 
Supply (EMS) and Emergency Hormonal Contraception (EHC). There are seven pharmacies piloting these 
modules.  
Qualitiative research was used since this project was an exploratory study. Ethics approval was granted by 
Cardiff School of Pharmacy and Pharmaceutical Sciences Research Ethics Committee. Participants were 
recruited via email by a gatekeeper from NWIS. Participants had experience using these modules and were 
given a participant information sheet and a consent form. Semi-structured interviews were conducted. 
Interviews were audio recorded and transcribed verbatim. Thematic analysis was used to identify themes.3  
Four pharmacists took part in the project. They were face-to-face interviews, conducted in the pharmacy 
consultation room. Five main themes were indentified. These themes were information technology (IT), views 
of the public, workload, consulations and recommendations. 
The results gathered showed two main issues with the Choose Pharmacy platform. They were issues with the 
software and the EHC module. The next step for NWIS is the addition of the patients' GP records which will 
be beneficial for pharmacists. NWIS requires approval from General Practitioners Committee Wales.4 A 
limitation to this project was the small sample size as saturation wasn’t reached. As future research, the draft 
questionnaire produced, as a result of this project will be sent to all pharmacies that will be using the Choose 
Pharmacy application in the future. To conclude, it's clear to see from the study that the views of the 
pharmacists on the Choose Pharmacy application were positive.  
 NHS Wales Informatics Service. New choose pharmacy scheme to be rolled out across wales. 2016 [accessed 4 Nov 2016]. 
Available from: http://www.wales.nhs.uk/nwis/news/40665/. 
 Community Pharmacy Wales. Health, Social Care & Sport Committee’s inquiry into the winter preparedness 2016/17. 2016 
[accessed 22 Nov 2016]. 
Available from: http://www.senedd.assembly.wales/documents/s53591/WP%2005%20Community%20Pharmacy%20Wales.pdf. 
 Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology. 2006;3(2):77-101.  
 NHS Wales Informatics Service. 2016b. Choose Pharmacy E-Learning. [Unpublished PowerPoint presentation]. Cardiff.  
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The knowledge and perceptions of pharmacy students on drugs in sport 
Holly Elizabeth Farr, RS Patel, C Wynne and EL Lane 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK and University of Birmingham School of Pharmacy, Institute of Clinical Sciences, College of Medical and 
Dental Sciences, Edgbaston, Birmingham, B15 2TT, UK 
Many athletes and members of the public abuse medication and dietary supplements to benefit from their 
effects by improving sporting prowess or sustain longer training.1,2 Acting as doping control, pharmacists can 
educate those involved in competition to prevent further incidences of doping.3 Although not all pharmacists 
will specialise in the area of sports pharmacy, a certain level of knowledge in doping is needed on a day-to-
day basis in practice. However, the level of education available in the UK on sports pharmacy in the MPharm 
degree is unknown. The aim of this study was to question the level of knowledge and opinions of MPharm 
students at Cardiff University on drugs in sport and to find out the level of education available at other pharmacy 
schools in the UK to determine if this is adequate for the needs of the sporting industry.  
The research was mainly conduced in the form of a questionnaire, adapted from previous research in Qatar.4 
All MPharm students at Cardiff University had the chance to participate. Additional data was obtained from 
individual schools of pharmacy in the UK. Ethical approval was obtained. Quantitative data was analysed using 
SPSS v23. Knowledge of sports pharmacy was analysed using Pearson correlation coefficient (p<0.01).  
A total of 196 students participated in the questionnaire out of a possible 459 students, a 42.7% response rate. 
Many students believed that doping was ‘unfair’ and ‘is a form of cheating’. Significant evidence showed a 
positive relationship between year of study and knowledge of the prohibited statuses of cannabis, 
amphetamines and anabolic steroids (p<0.01). Errors in knowledge were evident in laws surrounding 
prohibited and non-prohibited substances; insulin, anti-histamines, paracetamol, codeine and caffeine did not 
show a correlation between knowledge and year group. Students believed that healthcare professionals were 
considered the top information source to obtain information about the safe and effective use of drugs in sport. 
95.41% of students believed that sports pharmacy should be on the curriculum, either as a core or elective 
module.  
Despite the current tuition available at Cardiff University, there appears to be insufficient knowledge for 
students to become confident pharmacists in advising the public and athletes in the risks of abusing 
prescriptions medication in doping and the use of additional supplements. Students had strong opinions on 
the topic and many wanted to learn more. This study recommends more education of sports pharmacy on the 
curriculum.   
 Ambrose PJ. Educational Opportunities and Anti-Doping Roles and Responsibilities for Pharmacists. Yakugaku Zasshi. 
2011;131(12):1761–4.  
 Mottram D. Why do Athletes Take Drugs? Aspetar Sports Medical Journal. 2013;590–6. [accessed 10 Jan 2017]. Available from: 
http://www.aspetar.com/journal/upload/PDF/201419101646.pdf  
 Ambrose PJ. An advanced pharmacy practice experience in sports pharmacy. American Journal of Pharmaceutical Education. 
2008;72(1).  
 Awaisu A, Mottram D, Rahhal A, Alemrayat B, Ahmed A, Stuart M, et al. Knowledge and perceptions of pharmacy students in qatar 
on anti-doping in sports and on sports pharmacy in undergraduate curricula. American Journal of Pharmaceutical Education. 
2015;79(8).  
 
 
Numerical approach to investigate adhesion between orthopaedic biomaterials and 
gram-positive bacteria: influence of roughness and surface characteristics 
Georgina Fell and P Prokopovich 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The presence of foreign materials presents a common and opportunistic source of infection in orthopaedic 
surgery1. Bacteria adhere to biomaterial surfaces leading to the subsequent formation of a biofilm, which has 
significant clinical and economic implications.1 With current ageing population increasing incidence of 
orthopaedic surgeries, there’s a strong requirement to investigate other areas that may reduce the likelihood 
of infections.2 Since adherence of bacteria is the initial stage in pathogenesis of infection, an understanding of 
the physical and mechanical factors affecting this can be highly beneficial in the development of novel 
prevention strategies.3 Therefore, the effects of Young’s modulus, Poisson’s ratio, and surface free energy 
(SFE) of biomaterials and bacteria were investigated, in addition to material roughness. 
Surfaces are not truly smooth on an atomic scale; they present some degree of roughness because of rugged 
projections, termed asperities.4 These asperities provide contact points for interactions to occur between 
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particles - including bacteria - and surfaces.4 A previously-developed numerical procedure was employed, 
which models multi-asperity contact adhesion between two surfaces using the Johnson-Kendall-Roberts (JKR) 
model of contact4. A theoretical morphology of a biomaterial surface is recovered by generating random 
asperities. Then, contact and adhesive forces between two surfaces are determined by the JKR model from 
initialised numerical data on physical and mechanical properties. 
The lowest adhesive force was observed with stainless steel and bacterial strain Staphylococcus epidermidis 
3598. By contrast, greatest adhesive abilities were identified with biomaterial polymethyl methylacrylate, and 
bacterial strain Staphylococcus epidermidis 35984. These results could be related back to their physical and 
mechanical properties. 
Overall, effects of physical and mechanical properties have been explored, with low Young’s moduli and high 
SFEs promoting adhesion. Effect of surface roughness was also determined, with significantly increased 
adhesive forces being observed when irregularities were present. 
 Wheldon G, Townsend R. The future of diagnosis and treatment for orthopaedic infections. BOA. 2015;3(3):58-62. 
 NHS England. Standard contract for specialised orthopaedics (adult) 2013 [accessed Nov 22 2016]. Available from: 
https://www.england.nhs.uk/wp-content/uploads/2013/06/d10-spec-orthopaedics.pdf 
 Hori K, Matsumoto S. Bacterial adhesion: from mechanism to control. Biochemical Engineering Yournal. 2010;48(3):424-434. 
 Prokopovich P, Perni S. Multiasperity contact adhesion model for universal asperity height and radius of curvature distributions. 
Langmuir. 2010;26(22):17028-36. 
 
Identifying factors that motivated pharmacy undergraduates for their third year 
assessments at Cardiff University 
Lyndsey Fell, SA Coulman and DN John 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Motivation may be described as “a desire or willingness to do something”.1 When applied to student learning, 
one can understand why such a concept is essential to success. Motivation has been extensively researched, 
with many theories developed to understand the factors that affect it.2 However, research into the motivation 
of pharmacy students in the UK, and more widely, is lacking.3 Therefore, this investigation aimed to explore 
the factors that affected pharmacy student motivation at Cardiff University. 
Due to the explorative nature of the investigation, a qualitative approach was taken. Development of the topic 
guide followed a discussion of third-year assessments. Approval was obtained from Cardiff School of 
Pharmacy and Pharmaceutical Sciences ethics committee. Three pilot interviews took place. Recruitment was 
undertaken using non-probability sampling and invitation emails were sent out. One-to-one, semi-structured 
interviews took place and were audio recorded with the participants written consent. The recordings were then 
transcribed and shared amongst the researchers. Each researcher independently analysed the transcripts 
using inductive thematic analysis.4  
Thirteen interviews took place. Interviews lasted between 30 and 79 minutes. Nine themes were identified: (1) 
Perceived relevance to future, (2) The influence of others, (3) Contribution to degree class, (4) Performance 
in similar assessments, (5) The consequence of not passing, (6) Feedback as feedforward, (7) Interest in the 
subject material, (8) Difficulty of the subject material, and (9) ‘Doing the best I can’. Suggestions to 
improve/enhance student motivation will be made to the school. 
From the interviews conducted, it was clear that a whole host of factors influenced student motivation- no two 
students were the same. The study was limited as it was not known if theoretical saturation was reached. To 
understand pharmacy student motivation, the investigation could be implemented for the other years of the 
Master of Pharmacy (MPharm) degree. 
 Oxford Dictionaries [Internet]. 2016 [cited 6 December 2016]. Available from: https://en.oxforddictionaries.com/definition/motivation 
 Cook D. A and Artino, A. R. (2016), Motivation to learn: an overview of contemporary theories. Med Educ, 50: 997–1014.  
 Alrakaf S, Abdelmageed A, Kiersma M, Coulman S, John N, Tordoff J et al. 2014. An international validation study of two 
achievement goal measures in a pharmacy education context. Advances in Medical Education and Practice 2014(5), pp. 339-345. 
 Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology. 2006;3(2):77-101. 
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Pore forming peptides in droplet-droplet bilayers  
Kirsten Fernandes1, AT Jones1, G Bultynck2 and OK Castell1 
1Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK and KU Leuven, Belgium  
Studies of cellular membranes are essential as they remain the target of pharmaceuticals and are the site of 
disease dysfunction. A major limitation of drug delivery is enabling drugs to pass across a cellular membrane. 
Droplet interface bilayers (DIB) provide an artificial mimic of membranes allowing investigation of membrane-
peptide interaction and suggested mechanisms for pore formation/translocation.1 Pore forming peptides of 
interest included peptides which form biologically related channels and Cell Penetrating Peptides (CPPs). Aims 
set out in this study were to establish if different classes of pore forming peptides had similarities in their 
mechanism of interaction and pore formation when introduced into DIBs.  
DIBs are composed of two aqueous droplets placed onto two electrodes, submerged in a lipid in oil phase. 
The amphiphilic nature of lipids allows for monolayer assembly at the water oil interface. Electrophysiology is 
combined with DIB experiments as the electrodes within droplets allows the application of a potential and 
measurement of ionic current through pores, thus detection of poration.2  
Pore forming peptide current traces were compared against characterised traces of alpha-hemolysin fixed 
conductance pores, and variable conductance electropores. CTP2 resembled electroporation, whilst CTP2 
D4/A had superimposed steps similar to that of the alpha-hemolysin trace. Substitution of Aspartate for an 
Alanine in CTP2 showed a decrease in current through pores. Both CPPs: Penetratin and a synthetic peptide, 
resembled electroporation with lengthened bilayer formation times. Increasing the voltage increased the 
electroporation effect, whilst increasing concentration led to unsuccessful bilayer formation.  
CTP2 and CTP2 D4/A supports a fluctuating toroidal and stable barrel-stave pore formation respectively. A 
decrease in current passed through the membrane with CTP2 D4/A demonstrating the importance of Aspartate 
in forming pores in CTP2. In contrast, Penetratin and the synthetic peptide traces support an ‘inverse micellar 
formation’ with longer bilayer formation times. However, there is no confirmation of translocation across the 
membrane.3  
 Leplhn S, Castell O, Cronin B, Lee E-H, Gross L, Marshall D, et al. Construclng Droplet Interface Bilayers from the Contact of 
Aqueous Droplets in Oil. Nat Protoc. 2013;8(6):1048–57.  
 Bayley H, Cronin B, Heron A, Holden M, Hwang W, Syeda R, et al. Droplet Interface Bilayers. Mol Biosyst. 2008;4(12):1191–208. 
 Bechara C, Sagan S. Cell-penetrating peptides: 20 years later, where do we stand? FEBS Letters. 2017;587(12):1693–702. 
 
 
An evaluation of prescribing trends associated with hypnotic agents in care homes 
Emma Gallichan, M Gumbleton and MW Smith  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The majority of care home residents have two or more long term conditions1 and as such are a vulnerable 
population due to polypharmacy and their susceptibility to drug harm. Approximately two-thirds of residents 
suffer from sleep disturbances2 meaning hypnotic prescribing is high. The aim of this investigation is to identify 
the prevalence and type of hypnotics prescribed within care homes. 
A retrospective study was conducted in South Wales in 2015 over 12 care homes. Over an eight-month period 
anonymised data was collected and received from an electronic medicines management system. Irrespective 
of this data, inclusion criteria were set to a date range of three months, looking at four different drug classes; 
hypnotics, antidepressants, anxiolytics and antipsychotics. Hypnotics were classified using the BNF and the 
type and frequency of hypnotic sorted according to our inclusion criteria in excel. SPSS was then used for 
further data analysis.  
Overall, 10/12 care homes had residents on hypnotics and a total of six hypnotics were identified over the time 
period analysed. A total of 304 residents were prescribed hypnotics, with four on concurrent hypnotic therapy. 
A strong positive Pearson Correlation using SPSS was identified indicating that residents prescribed hypnotics 
are also likely to be prescribed other psychotropic agents. 
The investigation showed over 80% of the care homes had residents on hypnotics, which is supported by 
international studies showing 50-80% of nursing homes with patients on at least one psychotropic medication.2 
Whilst the study showed hypnotic prescribing was high, 16% more residents were prescribed Z drugs over 
benzodiazepines (BZDs), supporting a study in 2016 showing a reduction in BZD prescribing over the past 20 
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years.3 However, future work should investigate why this prevalence is so high and whether hypnotic 
prescribing can be reduced by the implementation of non-pharmacological methods.  
1. Royal Pharmaceutical Society (RPS). Pharmacist improving care in care homes 2014. Available from: 
http://www.rpharms.com/policy-pdfs/pharmacists-improving-care-in-care-homes.pdf [Accessed 10th Nov 2016] 
2. Conn D, Madan R. Use of sleep-promoting medications in nursing home residents. Drugs aging 2006; 23(4): 271-287 
3. Johnson C, Frei C, Downes N, McTaggart S, Akram G. Benzodiazepine and z-hypnotic prescribing for older people in primary care: 
a cross-sectional population-based study. British Journal of General Practice 2016; 66(647): e410-e415. 
 
 
Working towards an LPS imprinted sepsis diagnostic 
Max Gardner, N Dermertzis and JL Bowen 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Sepsis, a syndrome of biochemical, physiological and pathological abnormalities as a result of infection is a 
major public health concern.1 Successful treatment relies on early and prompt diagnosis.2 Lipopolysaccharide 
(LPS), a major constituent of gram negative bacteria has been identified as a possible biomarker for sepsis. 
With the true potential of blood marker detection yet to be fully exploited, the aim was to develop an 
electroimpedance sensor capable of direct and sensitive detection of LPS using molecular imprinting.  
Aminobenzoic acid, dopamine and pyrrole were electropolymerised on the surface of gold macro electrodes 
using cyclic voltammetry (CV) to deposit polymer layers. Their interaction with LPS was assessed using 
electrochemical impedance spectroscopy (EIS), in order to select the most appropriate monomer for imprinting. 
Molecular imprinting involves the polymerisation of monomers around a template molecule to form synthetic 
polymeric receptors. The polymer formed contains specific recognition sites complementary to the template 
and engages in interactions based on molecular recognition. The use of bio-recognition motifs in combination 
with molecular imprinting (hybrid imprinting) has been shown to produce ultra-sensitive sensing platforms, 
therefore both a conventional and hybrid imprinting strategy were employed.3 
Out of the monomers tested poly-dopamine demonstrated the greatest interaction with LPS so was taken 
forward into the imprinting processes. The conventionally imprinted MIP showed increased rebinding of LPS 
compared to the dopamine non-imprinted polymer. To produce a hybrid imprinted system an aptamer was 
introduced to increase binding specificity to the imprinted pocket but demonstrated a poor response to 
rebinding of LPS. 
Some successful imprinting was demonstrated during the conventional imprinting process, however results 
were largely inconclusive with mostly non-specific binding being observed. Using LPS as a template for 
molecular imprinting is notoriously difficult. Future studies could focus on templating Lipid-A, the endotoxin 
centre of LPS.  
 Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith 
CM, Hotchkiss RS. The third international consensus definitions for sepsis and septic shock (sepsis-3). Jama. 2016 Feb 
23;315(8):801-10. 
 Das AP, Kumar PS, Swain S. Recent advances in biosensor based endotoxin detection. Biosensors and Bioelectronics. 2014 Jan 
15;51:62-75. 
 Jolly P et al. Aptamer–MIP hybrid receptor for highly sensitive electrochemical detection of prostate specific antigen. Biosensors and 
Bioelectronics. 2016;75:188–95 
 
 
An evaluation of the role of motivation in final year pharmacy students at Cardiff 
University and its impact in the assessment and feedback processes 
Jaspreet Gill, SA Coulman and DN John 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Motivation can be defined as “the process whereby goal-directed activities are initiated and sustained.”1 
Understanding the nature of motivation is important, as it can be enhanced to produce positive outcomes.2 
Current literature on motivation demonstrates its importance in education, due to its effect on learning 
behaviours.3,4 This study aimed to identify what factors motivate pharmacy students for their Third Year 
assessments and the effect this has on their learning. 
Upon approval of the study by the school’s ethics committee, a qualitative approach was taken to explore 
students’ views. Final Year students were invited to participate in semi-structured interviews using purposive 
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and convenience sampling. Interview questions were developed from a topic guide that was created from the 
literature and through consideration of reasons behind degree of motivation by the researchers. Interviews 
were transcribed, following audio recording and interviewee consent. Transcripts were checked for accuracy 
and confidentiality, and analysed thematically. 
Thirteen students were interviewed, 9 were female. Student attributes included, but were not limited to, 
international students, mature students, external students and future ambitions. Six major themes were 
identified from the transcripts namely; interest in activity, contribution of assessment to degree, relevance to 
future career, fear/consequence of failure, influence of others and feedback. 
The study established that motivation is important in an academic environment and that it is influenced by 
various factors; these differ within and between students depending on the assessment, which affects their 
performance. There were limitations to the study, however, these can be overcome by future work. The 
objectives were met, as intrinsic and extrinsic factors for motivation were determined.2 Suggestions for the 
School of Pharmacy to consider to enhance and/or maintain motivation have been made. Further research of 
its impact in pharmacy education may improve learning and teaching practices. 
 Cook A, Artino R. Motivation To Learn: An Overview Of Contemporary Theories. Medical Education. 2016;50(10):997-1014. 
 Ryan R, Deci E. Self-determination theory and the facilitation of intrinsic motivation, social development, and well-being. American 
Psychologist. 2000;55(1):68-78.  
 Alrakaf S, Abdelmageed A, Kiersma M, Coulman S, John D, Tordoff J et al. An international validation study of two achievement 
goal measures in a pharmacy education context. Advances in Medical Education and Practice. 2014;5:339. 
 Alrakaf S, Anderson C, Coulman S, John D, Tordoff J, Sainsbury E et al. An International Comparison Study of Pharmacy Students’ 
Achievement Goals and their Relationship to Assessment Type and Scores. American Journal of Pharmaceutical Education. 
2015;79(3):35. 
 
 
Interplay between FAK and STAT3 in HER2+ breast cancer cells 
Sophie Green, C Smith and SE Hiscox 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Breast cancer is one of the most common types of cancer in the UK 1, with 20-30% of cases being diagnosed 
as HER2+.2 Cross-talk between the tumour and the surrounding stromal cells is implicated in tumour 
progression and limitation of therapeutic response. Fibroblasts in particular have been associated with an 
increase in aggressive tumour cell behavior likely to favour metastasis; these observations likely arise from 
the ability of fibroblast cells to secrete that activae tumour cells in a pro-metastatic manner. Our aim here was 
to investigate whether focal adhesion kinase (FAK) is involved in fibroblast-induced breast cancer cell 
behaviour and whether FAK-signalling involved STAT3, a transcription factor known to be involved in the 
regulation of genes that control cell proliferation, migration and survival.3 
Fibroblast-conditioned media (‘FCM’) was collected from MRC5 cells (human fibroblasts) after 3 days culture 
and used to stimulate the Her2+ breast cancer cell line, SkBr3. These experiments were performed in the 
presence or absence of the FAK inhibtor, PF271 (1uM). MTT and Boyden chamber assays were used to 
determine the effects of FCM on SkBr3 growth and migration respectively whilst Western blotting was used to 
investigate the activity of FAK and STAT3 in SkBr3 cells. Immunoflourecence microscopy was used to 
determine changes in subcellular localisation of FAK and STAT3 in response to FCM.  
Whilst FCM had little effect on Her2+ breast cancer cell proliferation, it significantly increased migration of the 
cells. FCM also caused an increase in the phoesphorylation of STAT3 (Y705 and S727) and FAK (Y397 and 
Y861) in SkBr3 cells; these changes were reduced in the presence of PF271. 
Our data suggest that FCM prmotes Her2+ breast cancer cell migration in a FAK-dependent manner and 
involves FAK-mediated activaton of STAT3, an observation not widely reported previously. FAK may therefore 
represent an important target to suppress the pro-invasive characterisics of cancer cells which may be 
augmented in a stromal environment. 
1. National Health Service. Breast Cancer (female). 2016 [accessed 15 Nov 2016]. Available from: 
http://www.nhs.uk/Conditions/Cancer-of-the-breast-female/Pages/Introduction.aspx. 
2. Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Frontiers in Oncology. 2012;2:62 
[accessed 1 Dec 2016]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376449/. 
3. Dauer DJ, Ferraro B, Song L, Yu B, Mora L, Buettner R, et al. Stat3 regulates genes common to both wound healing and cancer. 
Oncogene. 2005;24(21):3397-408. 
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The role of BIN1 in endocytosis and its relevance for Alzheimer’s Disease 
Robert Greening, A Burt, CJ Matheson and RS Thomas 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Polymorphisms in the gene locus for bridging integrator-1 (BIN1), a protein believed to play a role in clathrin-
mediated endocytosis (CME),1 were determined to be the second largest contributing risk factor for developing 
Alzheimer’s disease (AD).2 Preliminary work showed an increase in β-CTF in cells which are a model for the 
blood-brain barrier (BBB), depleted of BIN1. The implications of this finding suggest that a change in BIN1 may 
result in a change in the endosomal and amyloidogenic processing of APP in AD. We measured the protein 
expression and distribution of key endocytic, amyloidogenic and lysosomal proteins to determine what effect 
BIN1 depletion had. 
Western blotting was used to analyse protein samples from three treatment groups; a media control, a GFP 
siRNA control and a BIN1 targeting siRNA group of hCMEC/D3 cells, a BBB model. Immunocytochemistry 
was used to examine the intracellular distribution of the proteins. 
Following depletion of BIN1 by siRNA, levels of CME-related proteins, clathrin, PICALM and AP2 remained 
unchanged. Clathrin-independent endocytic (CIE) -related proteins; caveolin 1, flotillin 1, flotillin 2, remained 
unchanged in cells treated with BIN1 siRNA. Caveolin 2 showed a statistically significant increase in protein 
expression in cells treated with BIN1 siRNA. Beta amyloid cleavage enzyme (BACE1) expression showed an 
increasing trend in cells treated with BIN1 targeting siRNA. The cellular distribution of EEA1 and LAMP2b 
appeared to change. EEA1 appeared to become less punctate and LAMP2b appeared more diffuse 
throughout, in cells treated with BIN1 siRNA. 
The depletion of BIN1 in BBB-derived cells appears to have no effect on CME, based on protein expression. 
However an increase in caveolin-2 indicates a possible change in CIE. Alterations in EEA1 and LAMP2b 
distribution suggesting a change in endosomal and lysosomal functionality, along with an increasing trend in 
BACE1 expression, suggest that amyloidogenic processing of APP has increased in cells depleted of BIN1. 
 Popova N, Deyev I, Petrenko A. Clathrin-Mediated Endocytosis and Adaptor Proteins. Acta Naturae. 2013; 5 (18): 62-73 
 Seshadri S, Fitzpatrick A et al. Genome-wide Analysis of Genetic Loci Associated with Alzheimer Disease. Journal of American 
Medical Association. 2010; 303 (18): 1832-1840 
 
 
Evaluation of the Cwm Taf University Health Board Domiciliary Medicines Use 
Review (Dom-MUR) service 
Lauren Grisley, A Manning, H Lee, D McCrae1, E Williams2 and E Mantzourani 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, 1Prince Charles Hospital, Cwm Taf University Health Board, Merthyr Tydfil, CF47 9DT, and 2Royal Glamorgan 
Hospital, Cwm Taf University Health Board, Ynysmaerdy, Llantrisant, CF72 8XR, Wales, UK 
The Medicines Use Review (MUR) Service is an Advanced Service in the community pharmacy contract. It 
involves the pharmacist reviewing a patient’s use of their medication, aiming to improve patient understanding 
and adherence to medication and reduce medication waste.1,2 Since November 2012, the Cwm Taf University 
Health Board (UHB) have commissioned a domiciliary MUR (Dom-MUR) service, providing housebound 
patients with equal access to MURs. The aim of this study was to identify the types of issues and interventions 
carried out by pharmacists as part of the Dom-MUR service and to explore the perceptions of these 
pharmacists in delivering this service.  
A database of Dom-MUR entries from December 2012 to March 2014 was obtained from the UHB. Issues and 
outcomes arising from Dom-MURs were categorised. Data was quantitatively analysed using Microsoft Excel® 
and GraphPad Prism®. A pilot interview using a semi-structured interview guide was also carried out.  
Data from 194 Dom-MURs was included in the database. The mean number of issues identified per patient 
was 1.96 (SD±1.41). The three most commonly identified issues were related to ‘Patient Adherence (29%, 
n=110), ‘Patient Education/ Monitoring’ (21%, n=79) and ‘Medication Excess in Home’ (12%, n=47). The mean 
number of outcomes per patient was 1.97 (SD±1.48). Of the outcomes, 32% (n=122) involved the pharmacist 
contacting the GP surgery i.e. they could not resolve these issues themselves. Issues assigned to ‘Issues with 
Patient’s Condition’ were statistically less likely to be resolved by the pharmacist.  
The Cwm Taf UHB Dom-MUR service has the potential to be of value. Developments within community 
pharmacy, such as access to patients’ health records and pharmacist independent prescribing3, may benefit 
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this service with the potential for pharmacists to resolve more issues themselves. Interviews with pharmacists 
should be carried out with amendments to the interview schedule in order to further evaluate the service.  
 Pharmaceutical Services Negotiating Committee. MURs: the basics. London: Pharmaceutical Services Negotiating Committee 
[accessed 13 Dec 2016]. Available from: http://psnc.org.uk/services-commissioning/advanced-services/murs/murs-the-basics/  
 Blenkinsopp A, Bond C, Raynor DK. Medication Reviews. Br J Clin Pharmacol. 2012;74(4):573-580.  
 Royal Pharmaceutical Society Wales. Improving care for people with long term conditions. Cardiff: Royal Pharmaceutical Society 
Wales; 2016 [accessed: 12 Dec 2016]. Available from: http://www.rpharms.com/policy-pdfs/rps-caredoc-english.pdf  
 
 
To what extent are Welsh medium community pharmacy services being utilised? 
Hanna Gwyn, LJ Doyle, W Davies, EM Jones, A Evans1 and ML Hughes 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff, CF10 3NB, and 1Welsh Government, Cathays Park, Cardiff, CF10 3NQ Wales, UK. 
The Welsh Language Act of 19931 determines that both the Welsh and English language need to be treated 
on the basis of equality. The Act requires public services, including the NHS, to develop a Welsh Language 
Scheme.2 As NHS contractors, community pharmacies are considered private sector and therefore fall outside 
of this requirement. In 2016 the Welsh Government collected data on what language community pharmacy 
services were conducted through. When community pharmacies claim payment through NECAF there are 
currently questions relating to whether or not the consultation was conducted through the medium of Welsh 
and if so, to what extent. The aim was measuring the number of services conducted in Welsh through NECAF. 
A quantitative study was carried out on every Health board from April until September 2016. All seven health 
boards were compared to see how many Welsh consultation were requested and to what extent. Individual 
services were looked at within and across health boards to compare the number of Welsh language 
consultations requested and delivered. 
From the 123,855 consultations conducted between April and September 2016, only 2% were requested for 
in Welsh. Aneurin Bevan Health Board (ABHB) was the health board with the lowest percentage of Welsh 
language consultation request at 0.06% where as Betsi Cadwaladr University Health Board (BCUHB) was the 
highest at 5.2%. Patients requesting a Welsh language consultation in ABHB have a 77% chance of being 
declined, whereas within BCUHB this is only 3%. 
The low uptake of Welsh language consultations could be explained by patients’ reluctance to ask for Welsh 
language services. Another possible reason for this could be that patients don’t always know that Welsh 
language services are available to them. This study shows that locality is a factor in accessing Welsh language 
services. 
1. Office for Natural Statistics. 2011. Census 2011: Key Statistics for Wales, March 2011 [accessed 11 Nov 2016]. Available from: 
https://www.ons.gov.uk/census/2011census 
2. British Government. Office of Public Sector Information Welsh Language Act, 1993. London: The Stationary Office Limited; 1993 
[accessed 11 Nov 2016]. Available from: http://www.legislation.gov.uk/ukpga/1993/38/pdfs/ukpga_19930038_en.pdf 
 
 
The use of an optimised cubosome formulation to enhance transdermal delivery of 
the ovalbumin peptide SIINFEKL 
Emily Hargreaves and MO Ivory 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The skin’s outermost layer, the stratum corneum, limits transdermal drug delivery.1 Microneedles have been 
investigated for pretreatment of the skin to increase permeability.2 Cubosomes possess unique physiochemical 
properties3, which support the encapsulation and delivery of molecules. By using Strat-M membranes along 
with an optimised peptide cubosome formulation, this study aims to build on previous data generated in animal 
models using a synthetic membrane model more representative of human skin.   
Cubosomes were formulated with TAMRA-conjugated ovalbumin peptide SIINFEKL at a range of 
concentrations. To determine stability of formulations, particle size and zeta potential were tested using a 
Zetasizer over a 96 hour storage period. Peptide entrapment was measured using a fluorescence 
spectrophotometer and values were analysed against a concentration calibration curve. Permeation studies 
using Franz diffusion cells assessed the permeation of formulations through untreated and microneedle 
pretreated Strat-M membranes and analysed using a fluorescence spectrophotometer.  
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Stability studies showed no significant difference between any concentrations at each time point, showing that 
peptide did not affect cubosome particle size over 96 hours at the concentrations used. There was no 
significant difference found between the percentage peptide entrapment or the mass of peptide found in the 
lipid phase in any of the formulations. Results from permeation studies showed a significant increase in peptide 
delivery when using 0.2mg/ml peptide cubosome formulation following microneedle pretreatment.  
 Prausnitz, M.R. and Langer, R. Transdermal drug delivery. Routes of Drug Administration: Topics in Pharmacy 2013; 2:78. 
 Paudel KS, Milewski M, Swadley CL, Brogden NK, Ghosh P, Stincomb AL. Challenges and opportunities in dermal / transdermal 
delivery. Therapeutic Delivery. 2010; 1:109–131. 
 Lakshmi, MN, Yalavarthi PR, Vadlamudi HC, Jyotsna T, Gowri Y, Haritha K. Cubosomes as targeted drug delivery systems-A 
biopharmaceutical approach. Current Drug Discovery Technologies. 2014; 11.  
 
 
Oroidin as a lead compound for novel antibiotic drug discovery 
Arandeep Hayer and AW White 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Antimicrobial resistance threatens the effective prevention and treatment of an ever-increasing range of 
infections caused by bacteria, parasites and fungi.1 Oroidin is a bromopyrrole alkaloid which is isolated from 
sponges in the genus Agelas, which occurs in the Mediterranean sea.2 Oroidin has been shown to have 
antimicrobial properties3. This project involved creating an anlogue of oroidin to indetify any antimicrobial 
action.  
The project involved three major experiments. The first expirement looked at reacting ethyl indole-2-
carboxylate with 3-phenyl-1-propylamine. In this experiment different solvents were used. The second 
experiment looked at reacting indole-2-carboxylic acid with 3-phenyl-1-propylamine using pyridine as the 
solvent and isobutyl chloroformate as the reagent. The final experiment involved protecting the indole nitrogen 
on the ethyl indole-2-carboxylate with di-tert-butyl dicarbonate. Following this, the resulting compound was 
reacted with 3-phenyl-1-propylamine.  
The TLC results from the first experiment showed that the reaction did not work and therefore a compound 
with a better leaving group was needed. The NMR result from the second experiment showed that the indole 
nitrogen was reacting with the reagent isobutly chloroformate. It was gathered that the indole nitrogen needed 
protecting. The NMR result from the third experiment showed that the ethyl-indole-2-carboxylate had been 
succesfully protected by the di-tert-butyl dicarbonate. However, when this was reacted with 3-phenyl-1-
propylamine the NMR result showed that the reaction had not worked due to the poor leaving group ability of 
the ethyl indole-2-carboxylate.  
The indole nitrogen proved to be troublesome during the project, it was more nucleophilic than expected. 
However a method for protetcting the indole nitrogen was established. It was concluded that the ethyl indole-
2-carboxylate did not contain a good leaving group and therfore the nucleophilic substitiution reaction did not 
work with 3-phenyl-1- propylamine. Further research is needed to identify compunds with better leaving groups 
to activate this reaction.  
 Antimicrobial resistance [Internet]. World Health Organization. 2017 [cited 16 January 2017]. Available from: 
http://www.who.int/mediacentre/factsheets/fs194/en/ 
 Parra-Velandia FJ, Zea S, Van Soest RWM. Reef sponges of the genus Agelas (Porifera: Demospongiae) from the greater 
Caribbean. Zootaxa. 2014 May 7;3794(3):301. 
 Zidar N, Montalvão S, Hodnik Ž, Nawrot D, Žula A, Ilaš J, Kikelj D, Tammela P, Mašič L. Antimicrobial activity of the marine 
alkaloids, Clathrodin and Oroidin, and their synthetic analogues. Marine Drugs. 2014 Feb 14;12(2):940–63. 
 
 
Synthesis of novel CYP121 inhibitors for the treatment of Mycobacterium 
tuberculosis 
Philip Hook and C Simons 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Tuberculosis (TB) remains a major problem, consistently being one of the leading causes of death due to 
infectious disease.1 The emergence of resistance in tuberculosis and the lack of new medication being 
developed means that tuberculosis had become a major global public health issue.1 When the genome of 
Mycobacterium tuberculosis was sequenced it was observed that it contained a high level of cytochrome P450 
enzymes. CYP121 was of particular interest due to its essentiality, unique binding modes, unusual reaction 
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and high level of characterisation. The aim of this study was to produce a series of compounds based on azole 
antifungals, which are known to strongly bind to CYP121. 
Molecular modelling was undertaken on a library of azole based compounds using FlexX in LeadIT and 
visualised using MOE 2014. FlexX was used as, unlike docking in MOE 2014, it is able to show interactions 
between the iron of the haem in CYP121 and the nitrogen of the imidazole ring via an interstitial water, which 
has been observed previously in CYP121.2 However, this was not observed in the docking of these 
compounds.  
Synthetic routes to imidazole substituted two and three benzene derivatives were devised. A 4-step synthesis 
starting from substituted phenylacetic acids failed to successfully isolate a final product via either of the 
synthesis pathways and preferentially produced elimination products in both cases.  
Further work in optimising the synthesis route is required before the compounds can be screened against 
tuberculosis.  
 WHO. 2016. Global Tuberculosis Report: 2016. Geneva, Switzerland: World Health Organization. Available at: 
http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1 [Accessed: 6 December 2016] 
 McLean, K.J. et al. 2008. Characterization of active site structure in CYP121: A cytochrome P450 essential for viability of 
Mycobacterium tuberculosis h37rv. Journal of Biological Chemistry 283(48), pp. 33406–33416. 
 
 
Evaluation of a community pharmacy-based asthma care plan 
Thahira Hussain, E Ntanganika, JP Lee, L McCoubrey, L Tatnell, ME Jones, TM Chilvers and WR Ford 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB; R&D Department, Clinical Research & Innovation Centre, St Woolos Hospital, Block C, Stow Hill, Newport, NP20 
4SZ, and Mayberry Pharmacy, 173-175 High St, Crumlin, Blackwood NP12 1AA, Wales, UK.  
In the UK asthma affects 5.4 million people and the NHS spends on average 1 billion pounds a year treating 
and caring for people with asthma1 Studies have shown that pharmacy-led interventions are effective in 
improving asthma patient outcomes, these studies are based outside of the UK2 however, current UK-based 
studies have not measured the effect of their interventions on asthma control3 To assess asthma control and 
inhaler technique within a community pharmacy setting and obtain baseline measurements of lung function, 
asthma control and inhaler technique.  
Data was collected from 145 participants, from seven community pharmacies located in South Wales, through 
a semi-structured interview composing of the Asthma control test4, spirometric testing and assessment of 
inhaler technique via the Vitalograph Aerosol Inhalation Monitor (AIM) machine.  
43% (n=62) of the participants had uncontrolled asthma and smokers had significantly less asthma control 
than non-smokers (p=0.0144). Inhaler technique for metered-dose inhalers was significantly worse than inhaler 
technique for dry-powder inhalers (p< <0.0001) and inhaler technique training was predominantly by GP’s and 
nurses. 
Despite the advancement in medicines available to treat asthma, asthma control is poor. There are many 
factors that attribute to poor asthma control, mainly the prevalence of poor inhaler technique, especially for 
metered-dose inhalers. Smoking significantly decreases asthma control as well as other factors, such as 
inhaler technique training, but further research is required to understand the extent of its influence. Pharmacists 
as healthcare professionals have a role to play in improving asthma management. Community pharmacy 
asthma care plans have been successful in the past, further research is required to investigate the 
sustainability and implementation of a community pharmacy-based asthma care plan within the healthcare 
system.  
 Asthma UK. (2017). Asthma facts and statistics. [online] Available at: https://www.asthma.org.uk/about/media/facts-and-statistics/ 
[Accessed 17 Jan. 2017].  
 Armour C et al, Pharmacy Asthma Care Program (PACP) improves outcomes for patients in the community. Thorax, 2007. 62(6): p. 
496-592.. 
 Thornley T et al, A study to investigate the extent of delivery of an intervention in asthma, in a UK national community pharmacy 
chain, using mystery customers. Patient Education and Counseling, 2006. 60(2): p. 246-252  
 Schatz M et al, Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma 
specialists. J Allergy Clin Immunol, 2006. 117(3): p. 549-56 
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Depression and polypharmacy in Lewy body diseases 
Emma Ingram and RS Thomas 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Lewy body disease (LBD) is an umbrella term for Parkinson’s disease (PD), Parkinson’s disease dementia 
(PDD) and dementia with Lewy bodies (DLB).1 LBD has four cardinal motor symptoms and non-motor 
symptoms (NMS) are also prevalent, depression is the most common and is the most debilitating and influential 
NMS on quality of life.2 Recently several studies have identified a link between polypharmacy and elevated 
depressive symptoms.3 Polypharmacy is the use of multiple medications and can increase a patient’s chance 
of hospitalisation and drug-drug interactions, as LBDs are chronic conditions patients are likely to take multiple 
medications and thus experience polypharmacy.4 This study aimed to explore depression demographics and 
determine if high levels of polypharmacy correlate to high incidence of depression.  
A retrospective study was conducted on two movement disorder clinics in South Wales between 2002 and 
2016. Prevalence of LBD and depression, demographics, antidepressant use and polypharmacy were 
examined. 
This study included 1028 patients, 65% PD, 28% PDD and 7% DLB. Prevalence of depression and 
antidepressant usage across all LBD was very similar. SSRIs were the most commonly used antidepressant 
and their proportions of use were extremely similar across all LBD. A wider diversity of antidepressants along 
with a higher proportion of multiple antidepressants were used in DLB. PD patients taking antidepressants 
were prescribed a significantly higher number of drug classes than those who were not. This pattern was not 
identified in PDD or DLB. Motor symptoms of depressed PD patients were more severe than non-depressed 
patients; this was deduced by speculating that anti-parkinsonian drug regimen correlated with disease severity. 
There is a clear link between polypharmacy and antidepressant usage indicating that polypharmacy is more 
dependent on whether PD patients are taking antidepressants. However, this link is not replicated in PDD and 
DLB. Although LED is higher in PDD patients who are taking antidepressants than those not depressed there 
is no relationship between polypharmacy and depression. 
 Aarsland D. Cognitive impairment in Parkinson's disease and dementia with Lewy bodies. Parkinsonism Relat Disord. 2016 Jan;22 
Suppl 1:S144-8. 
 Chaudhuri KR, Healy DG, Schapira AH, Excellence NIfC. Non-motor symptoms of Parkinson's disease: diagnosis and 
management. Lancet Neurol. 2006 Mar;5(3):235-45. 
 Glezer A, Byatt N, Cook R Jr, Rothschild AJ. Polypharmacy prevalence rates in the treatment of unipolar depression in an outpatient 
clinic. J Affect Disord. 2009 Sep;117(1-2):18-23. 
 Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014 Jan;13(1):57-65. 
 
 
Evaluation of the pros and cons of drug re-positioning as a drug discovery strategy 
Ellis James, L Piggott, AD Westwell and JMW Gee 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Drug re-positioning means using existing drugs to treat new indications.1 There is potential of using re-
positioning as a drug discovery strategy, but there are likely clinical and commercial pros and cons to this, 
including limited patenting opportunities.2 The aim was to uncover what industry, clinicians and patient 
representatives perceive are pros and cons of drug re-positioning as a drug discovery strategy to reach a 
consensus on whether re-positioning could be a viable in this context.  
A qualitative research approach was taken using a semi-structured interview schedule, with pre-determined 
open questions focussed on clinical and commercial aspects of re-positioning. Interviewees comprised 4 
industry professionals/drug development researchers, 3 clinicians, and 2 patient representatives who were 
emailed re-positioning information and completed consent forms prior to interview. Interviews were recorded 
and transcribed, anonymising interviewees. Coding was used to collate responses under 5 themes of clinical 
pros, clinical cons, commercial pros, commercial cons, or no consensus of opinion. Responses for each theme 
were then analysed to determine sub-themes with exemplar quotes. To determine a consensus on drug re-
positioning, content and number of sub-themes (and associated numbers of responses and responders) were 
considered for each theme. 
All interviewees overall supported re-positioning from a clinical perspective, providing few negative clinically-
related sub-themes for drug re-positioning. Known safety profile, patients/prescribers being happy to use re-
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positioned drugs, and NHS cost savings were common positive subthemes. In contrast, only 4 interviewees 
were in favour overall for re-positioning from a commercial perspective, with no consensus from others. Many 
commercial problems of drug re-positioning were perceived, with subthemes including patenting issues, but 
there were also some benefits including cheaper drug development. 
Overall, the consensus is that drug re-positioning would be clinically advantageous with few clinical concerns 
raised, but that there is no consensus on the commercial value of this strategy.  
 Deotarse P. Drug-repositioning-a-review. International Journal of Pharma Research and Review. 2015;4(8):27. 
 Smith RB. Repositioned drugs: integrating intellectual property and regulatory strategie. Drug Discovery Today: Therapeutic 
Strategies. 2011;8(3-4). 
 
 
Evaluation of a community pharmacy-based asthma care plan 
Megan Elen Jones, E Ntanganika, JP Lee, L McCoubrey, L Tatnell, T Hussain, TM Chilvers and WR Ford 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Asthma is a prevalent respiratory lung disease with an estimate of around 5.4 million people suffering from 
asthma in the United Kingdom alone.1 Research indicates that around one in every three people are using 
their asthma inhalers incorrectly.1 An estimate of up to 90% of asthma deaths could be prevented2, highlighting 
that poor asthma control and patient education needs addressing, due to uncontrolled asthma possibly 
resulting in increased mortality rates.1,3 The aim of the study is to assess the quality of asthma patients’ inhaler 
technique and asthma control. 
A total of 145 asthmatic participants were recruited across seven different community pharmacies, patient 
recruitment was based on convenient sampling. Participants completed a biometric data questionnaire and an 
asthma control survey (ACS). An aerosol inhalation monitor (AIM device, Vitalograph) was used to assess 
inhaler technique, and a spirometer to assess lung function. Ethical and service evaluation approval was 
attained from the Research and Discovery Department, Aneurin Bevan University Health board.  
Based on the results from the asthma control survey (ACS), 42% of participants had uncontrolled asthma. 
Poor asthma control was highlighted by 40.7% of participants disclosing that they had previously been admitted 
to hospital or taken oral steroids. Smoking also had a significant impact on reducing asthma control in 
comparison to non-smokers (P=0.03). Generally inhaler technique was poor. Metered dose inhalers (MDI) 
were associated with the worst inhaler technique, however significant improvement in technique was seen if a 
spacer was used. Dry powder inhalers (DPI) technique was significantly better in comparison to MDI’s 
(P˂0.01).  
This study fund that participants have poor inhaler techniques and asthma control. Participants are better at 
using DPI and MDI with spacer, compared to MDI alone. Patient education and inhaler technique needs to be 
improved in patients. 
 Asthma UK. Asthma facts and statistics. 2016 [accessed 14 Nov 2016]. Available from: 
https://www.asthma.org.uk/about/media/facts-and-statistics/. 
 Department of health. An outcomes strategy for chronic obstructive pulmonary disease (COPD) and asthma in England. Department 
of health. 2011 [accessed 25 Nov 2016] Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/fi
le/216139/dh_128428.pdf 
 Pharmaceutical Services Negotiating Committee. Inhaler technique services. 2016 [accessed 25 November]. Available from: 
http://psnc.org.uk/wp-content/uploads/2013/04/PSNC-Briefing-064.16-Inhaler-technique-services.pdf  
 
 
Molecular modelling studies of Notch receptors 
Julija Jotautaite, A Brancale and S Ferla 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Notch receptors are transmembrane proteins that play a fundamental role in the cell life cycle.1 Dysfunction of 
Notch receptors can give rise to a multitude of human diseases.2 Notch receptor modulation is novel research 
area aimed to treat the diseases Notch dysfunction can cause. The aim of this project develop structures of all 
Notch family receptors to evaluate and understand the difference in ligand binding .Using generated 3D of 
Notch1-Jagged1, identify small molecules and peptides that are able potentially regulate Notch1 signalling  
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Homology modelling of Notch2-4 binding domain was performed with MOE using crystallised Notch1 structure. 
Protein-protein docking was performed using the generated structures with Jagged1 Notch ligand. Jagged1 
interactions were analysed between the different Notch receptors. Using the structure of Jagged1 DSL region 
and bioactive peptide5, 9 small peptides were generated and docked with MOE. Peptide interactions and 
conformation with Notch1 were compared with the Notch1-Jagged1 model to identify a structure that may 
modulate Notch1. Using Glide and ROCS virtual screening techniques, 3,300,000 small compounds were 
screened to identify theoretically bioactive compounds. Compounds were selected based on their consensus 
score and visual inspection. 
Protein-Protein docking of Notch1 and Jagged1 produced a model with favourable interactions with the binding 
regions. Two peptides showed promising resulting indicating they can theoretically modulate Notch1. A total 
of 117 compounds were selected from both virtual screening techniques due to their favourable interactions 
and conformation with Notch1. 19 of which have been purchased for future biological evaluation. 
Although the work conducted is predictive, the selected compounds and peptides indicated the theoretical 
ability to modulate Notch1. Further experimental work needs to be undertaken to quantify the ability of the 
chosen structures to modulate Notch1 receptors.  
 Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137:216-233 
 Kumar R, Juillerat-Jeanneret L, Golshayan D. Notch antagonists: Potential modulators of cancer and inflammatory diseases. J. 
Med. Chem. 2016;59:7719–7737  
 
 
Design and synthesis of novel human Norovirus RNA-dependent RNA polymerase 
inhibitors 
Dolphius Kareng, A Brancale and M Bassetto 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Noroviruses are members of the Calicivirus family. They have a single stranded, positive sense RNA 
genome.1,2 Norovirus-induced gastroenteritis is estimated to affect 21 million people per annum in the United 
States and causing up to 200 000 deaths per year in developing countries.3 Currently there is no cure or 
vaccine available against this virus hence the need to develop an antiviral drug. RNA-dependent RNA 
polymerase was identified as the most promising target for antiviral drug development due to its crucial role in 
viral replication and synthesis of genomic and sub genomic RNA.1,4 This project aims to design and synthesise 
novel Norovirus RNA-dependent RNA polymerase inhibitors by structural modification of lead compound 1. 
Lead compound 1 was discovered following a docking-based virtual screening on the virus polymerase 4LQ3 
crystal structure. 
Twenty novel compounds were designed by rational modification of Lead 1. Docking studies were conducted 
to evaluate the predicted binding mode of these compound to the enzyme active site. Results showed 
interaction between the designed compounds and the enzyme amino acid residues, giving useful insights for 
the preparation of optimised inhibitors. 
Two synthetic methods were optimised to prepare the designed compounds. First a general synthetic route 
with four reactions was optimised, starting with a Suzuki-Miyaura coupling, followed by a Knoevenagel 
condensation, and finally two type 2 nucleophilic substitution reactions. Then an alternative synthetic route 
involving two steps both of which are type 2 nucleophilic substitution reactions was designed and carried out. 
Nine novel compounds were successfully synthesised and characterised by proton and carbon NMR. 
All the newly synthesised compounds will be sent for bioactivity evaluation against Norovirus RNA-dependent 
RNA polymerase and viral replication in cell based assays. The results will determine which compound(s) 
proceeds to next stage of drug development should any show promising activity against the polymerase. 
 Mastrangelo E, Pezzullo M, Tarantino D, Petazzi R, Germani F, Kramer D, et al. Structure-Based inhibition of Norovirus RNA-
Dependent RNA Polymerases. Journal of Molecular Biology. 2013; 419: 198- 210. 
 Prasad BVV, Shanker S, Muhaxhiri Z, Deng L, Choi J, Estes MK, et al. Antiviral targets of human noroviruses. Current Opinion on 
Virology. 2016; 18: 117 – 125. 
 Tarantino D, Pezzullo M, Mastrangelo E, Croci R, Rohayem J, Robel I, et al. Naphthalene-Sulfonate Inhibitors of Human Norovirus 
RNA-dependent RNA polymerase. Antiviral Research. 2014; 102: 23 – 28. 
 Rocha-Pereira J, Neyts J, Jochmans D. Norovirus: Targets and tools in antiviral drug discovery. Biochemical Pharmacology. 2014; 
91: 1 – 11. 
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Have drug usage trends changed following the introduction of National Prescribing 
Indicators in Wales? 
Olivia Kelly, PN Deslandes and RE Deslandes 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and All Wales Therapeutic and Toxicology Centre, University Hospital Llandough, Penlan Road Llandough, 
Penarth, The Vale of Glamorgan CF64 2XX, Wales, UK 
One of the aims of All Wales Medicines Strategy Group (AWMSG) is to promote rational and cost effective 
prescribing, maximising patient outcomes.1 AWMSG introduced National Prescribing Indicators (NPIs) in 2003, 
their purpose was to monitor prescribing and encourage practices to achieve a target based on the top 25% 
best performing practices2 in Wales. A total of ten NPIs were analysed to investigate whether there was a 
change in prescribing trends following their introduction. 
Data were extracted from the Comparative Analysis System Prescribing Audit (CASPA) database for each 
drug or drug class. CASPA provides a record of prescriptions dispensed and forwarded for pricing. An Auto 
Regressive Integrated Moving Average Interrupted Time Series Analysis was employed to assess whether 
there was statistically significant change in the dispensing trend of each of drug pre and post introduction of 
the NPI. Prescribing measures used included the number of defined daily doses prescribed per 1000 patients 
per month and proportion of drug prescribed as a percentage of a total drug group. 
A statistically significant change was found for four NPIs (co-amoxiclav as a percentage of all antibacterials 
P=0.007, cephalosporins as a percentage of all antibacterials P=0.02, low risk NSAIDs as a percentage of 
total NSAIDs P=0.008, and morphine as a percentage of total strong opioids P=0.000). There was no 
statistically significant change in the dispensing trend of the remaining six NPIs. 
Due to the retrospective, quasi-experimental3 nature of this analysis the changes observed in the dispensing 
trends cannot be directly linked to the introduction of the NPI. Confounding factors and competing 
interventions, may have exerted an influence on dispensing in addition to the NPI. Nevertheless, the temporal 
association between the introduction of the NPI and the changes in drug usage may indicate an influence on 
prescribing.  
 All Wales Medicines Strategy Group. AWMSG in relation to NICE. October 2014 
 All Wales Medicine Strategy Group 2015. National Prescribing Indicators 2015-16. February 2015 
 Penfold RB, Zhang F. Use of interrupted time series analysis in evaluating health care quality improvements. Academic Paediatrics. 
2013 Nov-Dec; 13(6) :s38-44 
 
 
Synthesis of novel chimeric phosphoramidate ProTides with fluorescent probes 
Katie Kemble, S Kandil, A Cavaliere and AD Westwell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Nucleoside analogues (NAs) have been used clinically for the past five decades as both antiviral and 
anticancer agents. However, this class of drugs has limited efficacy, owing to inefficient activation, toxicity 
concerns and emergence of resistance. The prodrug strategy has been applied to improve the delivery of 
monophosphate NAs. In McGuigan’s phosphoramidate ProTide approach, the negative charge of the 
monophosphate group is masked by an aryl motif and amino acid ester, which are cleaved off enzymatically 
to release the monophosphate NA in vivo. The aim of this project was to synthesise, purify and characterise 
four novel ProTides of the NA d4T, also known as stavudine, an approved but toxic anti-HIV agent,1 using L-
alanine esters and coumarin derivatives as masking groups. The use of a coumarin group could increase atom 
economy of ProTides. Coumarins with antiviral activity could work synergistically with d4T, thereby generating 
co-drugs with increased therapeutic efficacy. Coumarins’ fluorescing ability2 could be utilised for the 
visualisation of ProTide uptake, and to prove whether ProTides are activated in vivo. 
To synthesise the ProTides, the phosphorochloridate chemistry approach was employed, as extensively 
reported in the 1990s.3 ProTides were purified using flash column and preparatory thin layer chromatography, 
and characterised and purity confirmed with nuclear magnetic resonance and mass spectrometry. 
Five coumarin-containing ProTides were successfully synthesised, of which four have been isolated, with yield 
in the range of 7-11%. Two phosphorodiamidate compounds, which possess two amino acid ester masking 
groups and have been of interest recently4, were also isolated during the purification of ProTides.  
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As part of a future project, wavelength of absorbance and fluorescence of ProTides should be measured to 
enable visualisation of ProTide uptake and activation. All ProTides and phosphorodiamidates should be 
subjected to biological and toxicological testing, to determine both therapeutic activity and safety profile.  
 Thornton PJ, Kadri H, Miccoli A, Mehellou Y. Nucleoside phosphate and phosphonate prodrug clinical candidates. J Med Chem. 
2016; 59(23):10400-10. 
 Hassan MZ, Osman H, Ali MA, Ahsan MJ. Therapeutic potential of coumarins as antiviral agents. Eur J Med Chem. 2016; 123:236-
55. 
 McGuigan C, Pathirana RN, Balzarini J, De Clercq E. Intracellular delivery of bioactive AZT nucleotides by aryl phosphate 
derivatives of AZT. J Med Chem. 1993; 36(8):1048-52. 
 McGuigan C, Bourdin C, Derudas M, Hamon N, Hinsinger K, Kandil S, et al. Design, synthesis and biological evaluation of 
phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. Eur J Med Chem. 2013; 70:326-40. 
 
 
Identification of combinations of natural products that inhibit the growth of MRSA 
Lateefah Khan and L Baillie 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
It is estimated that 2% of the world’s population is infected by Methicillin-resistant Staphylococcus aureus1. 
MRSA accounts for up to 60% of hospital acquired infections2. Due to the lack of new effective antimicrobials 
in the clinical pipeline, there is an urgent need to find alternative sources of novel antimicrobials. For centuries, 
plants have played a central role in the prevention and treatment of illnesses3. Therefore, using Manuka honey 
as a carrier matrix, extracts of tea, hops and seaweed were tested against MRSA (NCTC 11939) for their 
individual and combined synergistic antibacterial properties. 
Initially, an agar-well diffusion assay was employed to determine the antibacterial activity of all natural products 
alone and in combination. This high-throughput assay allowed for the detection of antimicrobial activity. To 
further characterise this activity, a broth based minimum inhibitory concentration (MIC) assay was used. This 
assay, being more qualitative than the zone of inhibition (ZOI) assay, allowed for inhibitory specific 
concentrations of extracts to be identified. Finally, to identify potential synergistic activity between combinations 
of natural products a checkerboard assay was used.  
ZOIs were measured using a digital caliper and inhibitory zones were observed by all extracts. The methanol 
extracts showed an increased potential, compared to the corresponding hexane extracts (P<0.05). MIC of 
each extract was determined and were as follows: hops (0.0275% w/v), tea (0.09% w/v), seaweed (0.3% w/v) 
and honey (20%). The checkerboard assay identified a synergistic effect when honey was combined with either 
the hop extract or the tea extract. An additive effect was observed when honey was combined with seaweed. 
In conclusion, it was observed that when all extracts were combined in the presence of honey there was an 
increased antibacterial effect, supporting the hypothesis. Thus, opening the possibility of developing honey 
based therapeutics capable of targeting antibiotic resistant bacteria such as MRSA.  
1. MRSA Tracking. Centres for Disease Control and Prevention 2016. https://www.cdc.gov/mrsa/tracking/ (accessed December 29, 
2016) 
2. Ahmad I, Aqil F. New strategies combating bacterial infection. Weinheim: Wiley-Blackwell; 2009. 127. 
3. Mahady, G.B. (2001) Journal of Nutrition, 131 (3s), 1120S-1123 
 
 
Investigation into the formulation factors affecting the precipitation of selenium in 
parenteral nutrition admixtures 
Lau Ying Kit and AG Cosslett 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Despite several studies having been carried out in the past, selenium’s stability in parenteral nutrition (PN) 
formulations is still not very well known. The potential to form precipitates in PN admixtures is a concern for 
PN manufacturers and healthcare professionals, therefore, this research project will be primarily focused on 
identifying any factors or components in PN formulations that could cause precipitation of selenium. 
In this research project, 70 batches of PN samples were produced to test selenium’s compatibility with 4 PN 
nutrients in different pH mediums. All batches were prepared in a laminar flow hood using aseptic techniques 
to minimize contamination. pH and turbidity measurements were undertaken every 24 hours across a total test 
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period of 3 days. Samples were also taken from these batches for visual inspection under fibre optic lighting 
to check whether precipitate presents. 
The results indicated that both amino acid and ascorbic acid were able to cause selenium precipitation, while 
the former can cause precipitation across all pH environments, the latter in comparison, only caused 
precipitation in acidic pH conditions (pH3). It is believed that the amino acid cysteine is responsible for causing 
selenium precipitation, as it contains a sulfhydryl group1 that possess strong reducing power, reducing sodium 
selenite to elemental selenium. Ascorbic acid on the other hand, is also a reducing agent that can reduce 
selenite to selenium as well. 
It was also discovered that copper sulphate can prevent selenium precipitation even in the presence of amino 
acid and ascorbic acid across all pH environments, however due to the limited time available for this study, no 
further investigation could be carried out to identify the mechanism of reaction involved. Nevertheless, this 
finding could still be use as a starting point for any future work looking into such an issue. 
1. J.Leluk. Why cysteine is special? [Accessed 18 Nov 2016]. Available from: 
http://www.cryst.bbk.ac.uk/pps97/assignments/projects/leluk/project.htm 
 
 
Evaluating the TEAD transcription factor in breast cancer 
Matthew Lawson, P Finlay, S Kyme, L Farrow, A Green and JMW Gee 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK and Academic Unit of Oncology, Nottingham City Hospital, Hucknall Road Nottingham, NG51PB, UK. 
In oestrogen receptor (ER) positive breast cancers, endocrine therapy is a major treatment, particularly for 
luminal A (ER+/HER2-) disease, but unfortunately relapse often occurs due to acquired resistance. 
Mechanisms of resistance are poorly-characterised, however VGLL1 is deregulated in luminal A-derived 
models where prolonged anti-hormones have promoted resistance and ER loss.1 The mechanism of VGLL1 
signalling is unexplored in endocrine resistance, but it is a co-activator for TEAD transcription factor which is 
probably present in breast cancer.2,3 This project aimed to evaluate TEAD in clinical breast cancer and in 
luminal A-derived models to establish any link with VGLL1, ER status or endocrine resistance. 
An immunohistochemical (IHC) assay was optimised using pH6 pressure cook retrieval and pan-TEAD 
antibody to detect TEAD protein localisation. It was applied to clinical breast cancer samples (n=24) and T47D-
derived models with acquired resistance to different anti-hormones, H-Scored and analysed versus ER and 
VGLL1 status. MRNA analysis, using microarray data, investigated individual TEAD family members in relation 
to clinical endocrine outcome and in resistant models versus their responsive parental T47D cells. 
TEAD protein was nuclear in clinical breast tumours and in resistant and responsive models irrespective of ER 
or VGLL1 status. MRNA analysis in an endocrine treated luminal A breast cancer microarray dataset found 
increased TEAD1 associated with a shorter relapse time, and TEAD 2 to better prognosis. TEAD1 mRNA was 
upregulated and TEAD2 downregulated in ER- acquired resistance models. 
TEAD may play a role in VGLL1 signalling in breast cancer, but could also interplay with other co-activators4. 
It likely contributes in ER+ and ER- endocrine resistance as well as responsive breast cancer. TEAD1 seems 
more important in endocrine resistance, whereas TEAD2 is implicated in endocrine response. Future studies 
should include consolidating the importance of these TEADs in a larger clinical series with outcome data. 
 Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233-47. 
 Pobbati AV, Chan SW, Lee I, Song H, Hong W. Structural and functional similarity between the Vgll1-TEAD and the YAP-TEAD 
complexes. Structure. 2012 Jul 03;20(7):1135-40. 
 Zhou Y, Huang T, Cheng AS, Yu J, Kang W, To KF. The TEAD Family and Its Oncogenic Role in Promoting Tumorigenesis. Int J 
Mol Sci. 2016 Jan 21;17(1). 
 Pobbati AV, Hong W. Emerging roles of TEAD transcription factors and its coactivators in cancers. Cancer Biol Ther. 2013 
May;14(5):390-8. 
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Evalulation of a community pharmacy-based asthma care plan 
Jessy Lee, E Ntanganika, L McCoubrey, L Tatnell, ME Jones, T Hussain, TM Chilvers and WR Ford 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Inhaler devices are mainly used by asthma patients to treat their medical condition. However, poor inhaler 
technique is still prevalent in about 94% of the asthma population.1 Errors caused when using these devices 
will reduce the deposition of drugs deep in the lungs, meaning they will be less effective.2 
The study evaluated patients’ asthma control using an asthma control survey (ACS) based on a validated 
asthma control test (ACT) questionnaire. Participants’ demographics were obtained. Their inhaler technique 
was assessed and lung function were measured using a Vitalograph AIMTM device and a Vitalograph 
ALPHATM spirometer respectively.3,4 The data collected was recorded in excel anonymously and analysed 
using GraphPad Prism 7. Mann-Whitney U test and Kruskal-Wallis test are used to identify any significant 
results obtained from the study. Results are significant if p < 0.05.  
The results of this study indicates that a large population of the asthma patients (42%) have uncontrolled 
asthma as shown from their asthma control survey score. Smoking has a significant effect on patients’ asthma 
control with 67% of smokers having uncontrolled asthma compared to non-smokers (38%). Patients using DPI 
also have a significantly better inhaler technique compared to those using MDI with a failure rate of only 8% 
for DPI users. For MDI users prescribed with a spacer, their inhaler technique is better compared to those 
using MDI alone. Majority of the inhaler technique were shown by nurses and GP, with only 4% being shown 
by pharmacists.  
Poor asthma control is evident in most of the patients from the study and the main factor is poor inhaler 
technique. The involvement of pharmacists in advising patients on their inhaler technique is still trivial 
compared to nurses and GP. Their role in actively training patients should be maximized in a community 
pharmacy setting.  
 Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, et al. Effect of incorrect use of drug powder inhalers on 
management of patients with asthma and COPD. Respir Med. 2008;102(4):593-604. 
 Murphy A. How to help patients optimise their inhaler technique. Pharm J. 2016;297(7891) [accessed 12 Dec 2016]. Available from: 
http://www.pharmaceutical-journal.com/learning/learning-article/how-to-help-patients-optimise-their-inhaler-
technique/20201442.article. 
 Vitalograph. Vitalograph AIM Aerosol Inhalation Monitor. UK: Vitalograph; 2017 [accessed 21 Dec 2016]. Available from: 
https://vitalograph.co.uk/downloads/view/38. 
 Vitalograph. ALPHA. UK: Vitalograph; 2017 [accessed 21 Dec 2016]. Available from: 
https://vitalograph.co.uk/product/161415/alpha.  
 
 
Synthesis of deshydroxy androgen receptor antagonists for potential prostate 
cancer therapy 
Kok Yung Lee, S Kandil and AD Westwell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Prostate cancer is the most common form of cancer for men in the UK and is also the second most common 
form of cancer for adults in the UK.1 The androgen receptor (AR) plays a major role in promoting prostate 
cancer growth and has been the target of non-steroidal androgen receptor antagonists (NSAA) in the treatment 
of prostate cancer. Bicalutamide is advantageous over other NSAAs due to its lack of central side effects.2 
However, bicalutamide resistance limits its use to short term treatment of prostate cancer.3,4 This project aims 
to synthesise novel deshydroxy derivatives of bicalutamide with bulky substituents on the B ring as new AR 
antagonists that can potentially overcome bicalutamide resistance. 
The synthesis process involves three steps. The first is the formation of an amide between 4-amino-3-
(trifluoromethyl)benzonitrile and methacryloyl chloride. The next step involves the Michael addition of various 
thiophenols onto the amide from step 1 to form sulphide derivatives. The final step oxidizes the sulphide 
derivatives into sulphone derivatives, the final desired compounds. A homology model of the androgen 
receptor in its antagonistic state was generated to predict the antagonist activity of each compound 
synthesised. 
All sulphide and sulphone derivatives where successfully synthesised but two of the sulphides were unable to 
be purified. Yields of the sulphides varied from 19% to 50% yield, while the yields of the sulphones varied 
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largely from 19% to 95% yield. The homology model also predicts that 6 out of 8 of the synthesised compounds 
would have good antagonist activities. 
The successfully purified compounds will be sent for in vitro testing. Overall, the synthesis was successful and 
the three step synthesis process is industrially practical. Hence, these compounds can potentially be 
commercialised in the future should any of them pass clinical trials. 
 Cancer Research UK. Prostate cancer incidence statistics. Cancer Research UK Website. [Accessed 20 Dec 2016] Available from: 
http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence#heading-
Zero 
 Foster WR, Car BD, Shi H, Levesque PC, Obermeier MT, Gan J, et al. Drug safety is a barrier to the discovery and development of 
new androgen receptor antagonists. Prostate. 2011 Apr; 71(5): 480-8. 
 Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. 
Proceedings of the National Academy of Sciences of the United States of America. 2005 Apr; 102(17): 6201-6. 
 Helsen C, Van den Broeck T, Voet A, Prekovic S, Van Poppel H, Joniau S, et al. Androgen receptor antagonists for prostate cancer 
therapy. Endocrine-Related Cancer. 2014 Aug; 21(4): T105-18. 
 
 
Discovering the cellular location of STAT3 during mitosis 
Elinor R Lewis and KM Taylor 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
STAT3 is a transcription factor that is constitutively activated in many cancers and has been linked with high-
grade cancers and poor prognosis 1. Activation of STAT3 occurs at the beginning of mitosis and is independent 
of its transcriptional activities.2 As unregulated mitosis is a hallmark of cancer and an important target for 
therapy, the aim of this study was to investigate the cellular location of STAT3 during mitosis. Previous studies 
have linked STAT3 activity to the functions of the cell cytoskeleton3, therefore our hypothesis was that STAT3 
co-localises with tubulin during the different stages of mitosis.  
Immunofluorescence microscopy was used to detect and image cellular components of MCF-7 breast cancer 
cells. Cells were treated with nocodazole to increase mitotic cell number and then removed to allow cell 
movement through the different stages of mitosis. Cellular components, including STAT3 and tubulin, were 
stained with antibodies to enable images to be taken of different stages of mitosis using a microscope. 
Our results demonstrated that STAT3 was present in significantly higher levels in mitotic cells compared to 
non-mitotic cells and was present throughout all stages of mitosis. STAT3 appeared to co-localise with 𝛾-
tubulin during the different stages of mitosis. Furthermore, both proteins appeared to co-localise at the 
centrosomes during metaphase. 
Our study has established that STAT3 is present at the beginning of mitosis and remains activated throughout 
mitosis. This suggests that STAT3 may play a key role in cell division, especially by association with 𝛾-tubulin. 
We support further research to evaluate whether STAT3 could be a novel biomarker or a target for cancer 
diagnosis and therapy. 
 Gkouveris I, Nikitakis N, Sauk J. STAT3 signaling in cancer. J Cancer Ther. 2015;6:709-26 [accessed 4 Jan 2017] Available from : 
http://dx.doi.org/10.4236/jct.2015.68078  
 Shi X, Zhang H, Paddon H, Lee G, Cao X, Pelech S. Phosphorylation of STAT3 serine-727 by cyclin-dependent kinase 1 is critical 
for nocodazole-induced mitotic arrest. Biochemistry. 2006;45(18):5857-967 
 Walker SR, Chaudhury M, Nelson EA, Frank DA. Microtubule-targeted chemotherapeutic agents inhibit signal transducer and 
activator of transcription 3 (STAT3) signaling. Mol Pharmacol. 2010;78(5):903-8 
 
 
An investigation into the prescribing of anxiolytic agents in care homes 
Rachel Hannah Lewis, M Gumbleton and MW Smith 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Residents of care homes are elderly and often receive several medications for multiple conditions. This 
polypharmacy, as well as changes in pharmacokinetics and pharmacodynamics, contribute to the increased 
likelihood of an adverse drug event occurring.1,2 Anxiolytics can be particularly problematic due to their side 
effects. Since anxiety is said to be the most prevalent psychiatric disorder3, the aim of this project is to look at 
the prevalence of anxiolytic prescribing within care homes. It forms part of a wider group analysis looking at 
the prescribing of other psychotropic agents, including antidepressants, antipsychotics and hypnotics. 
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Drug administration records were collected from twelve care homes across the South Wales region. The data 
was filtered to extract only that relevant to anxiolytic agents within a three month period. Descriptive analysis 
was carried out to examine the extent and nature of anxiolytic prescribing and to quantify the amount of 
prescribed dosing errors. A Pearson’s Correlation statistical test was also carried out to identify whether a 
correlation existed between the prescribing of anxiolytic agents and the prescribing of other psychotropic 
agents. 
14.1% (43 out of 304) of care home residents within the time frame were prescribed at least one anxiolytic 
agent, most of which were benzodiazepines (12%). This was not including a group of serotonin-manipulating 
agents that could have been used for either anxiety or depression. The majority (85%) of prescriptions were 
prescribed at the correct dose. The Pearson’s Correlation test revealed that a strong positive relationship 
existed between the number of distinct anxiolytic prescriptions and the number of other psychotropic agent 
prescriptions. 
Anxiolytic prescribing was widespread among residents and benzodiazepine use appeared high despite 
guidance against their use due to the associated risks.4 More consideration should be put into the prescribing 
process in order to optimise prescribing of anxiolytic agents in care homes. 
 Opondo D, Eslami S, Visscher S, de Rooij SE, Verheij R, Korevaar JC, et al. Inappropriateness of medication prescriptions to 
elderly patients in the primary care setting: A systematic review. PLoS One. 2012;7(8) 
 Lindsey PL. Psychotropic medication use among older adults: What all nurses need to know. J Gerontol Nurs. 2011;35(9):28–38 
 Kjernisted KD, Bleau P. Long-Term goals in the management of acute and chronic anxiety disorders. Can J Psychiatry. 2004;49:51-
63 
 Nazareth, Ken; Burkhardt K. Hypnotics & anxiolytics practice guide. 2008. [Accessed 28 Dec 2016] Available from: 
http://www.wales.nhs.uk/sites3/Documents/582/Guide_Hypnotics%20%26%20Anxiolytics%20Practice%20Guide_version02.pdf 
 
 
Evaluation of the Triage and Treat Service in community pharmacies within  
Hywel Dda University Health Board 
Seema Mahasuria, A Evans, H Blyth and KL Hodson 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Hywel Dda University Health Board (HDUHB) created the Triage and Treat Service after two minor injury units 
in west Wales closed. The service aims to treat low-level injuries in a community pharmacy. It first piloted in 
2014 and is now available in 16 pharmacies across Wales.1 
Objectives:  
• To identify the number and type of Triage and Treat consultations provided in community pharmacies and 
the treatments given; 
• To assess whether patients were satisfied with the service provided;  
• To explore the perception and attitudes of the pharmacy team towards the service;  
• To identify any suggestions for improvements of the service from the pharmacy teams’ perspective. 
The evaluation was performed in three phases. Two phases (phase one: type of consultations and treatment 
provided; phase three: patient feedback) consisted of descriptive analysis of data collected by HDUHB. Phase 
two comprised of semi-structured interviews with the pharmacy members, which were thematically analysed 
inductively and deductively.  
From April 2015 to September 2016, 228 consultations were undertaken with 84% of patients receiving 
treatment within the pharmacy. More residents used the service than tourists with the most common age 
ranging between 66 – 80 years old. Feedback from participants interviewed (n=6) and patients (n=28) were 
positive. Two suggestions for improvements identified from the interviews were the need for additional training 
and enhanced advertising of the service.  
The service has achieved its aim by successfully treating the majority of patients who have suffered minor 
injuries. As more pharmacies are commissioned to undertake this service and as the number of patients 
utilising the service increases, there is potential for this service to reduce admissions to Accident and 
Emergency (A&E). Suggestions for improvement include further training to enhance the pharmacists’ 
confidence when treating through the Triage and Treat service and sustained advertising possibly through 
digital marketing schemes.  
 Evans A, Blyth H. An Interview to Detail the Initiation and Implementation of the Triage and Treat Service in West Wales. Llanelli; 
2016 
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Defining pre-clinical studies and critical quality attributes of solid and hollow 
microneedle devices 
Shibi Marsden, JC Birchall and SA Coulman 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Microneedles (MN) devices have received growing interest as a novel drug delivery system. This has driven 
manufacturers to fabricate a range of MN systems which have now reached clinical trials.1 However, there is 
currently a lack of information and understanding regarding key microneedle (MN) device attributes and the 
quality control testing required throughout MN device production. This project aims to determnine the pre-
clinical tests and critical quality attributes for two specific types of devices, hollow and solid MNs.  
A literature review examined pharmacopoeias, regulatory guidelines and published journal articles to gather 
information on MN device attributes, tests that have been used for micron-sized needles and also 
specifications that existed for comparable medical devices e.g. transdermal patches. The data was used to 
draft two tables that describe suggested (i) pre-clinical studies (PCS) and (ii) critical quality attributes (CQA) to 
be tested for clinical approval. Weekly meetings with the research team assisted iterative development of CQA 
tables prior to a meeting with an MHRA representative that was used to finalise data. 
PCS tables included the following: Perforation Testing; ‘ADME’ studies; Fluid flow testing; In-vitro Penetration 
testing; Integrity of connections (Leakage) testing. CQA tables included the following: Sterility/Endotoxin 
levels/Particulate matter levels; Packaging sterility; Needle axial mechanical strength; Needle shear force 
resistance; Base plate strength; Needle geometry; Needle bore diameter; Array size and density; Integrity of 
connections; Needle blockage. 
The project has successfully constructed a first draft of tables which categorise PCS and CQA testing for solid 
and hollow MN devices. Future work will share this with manufacturers, researchers and relevant regulatory 
bodies including the MHRA and FDA, with the aim of producing guidance that facilitates production of safe, 
efficacious and easily usable SMD and HMD in the forthcoming years. 
 3M. Microneedle Drug Delivery Systems | 3M United States [Internet]. 3m.com. 2017 [cited 13 January 2017]. Available from: 
http://www.3m.com/3M/en_US/drug-delivery-systems-us/technologies/microneedle/ 
 
 
An investigation into the prescribing trends of antidepressant drugs in care homes 
Benjamin Manlai Mason, M Gumbleton and MW Smith 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
There is much evidence of polypharmacy in care homes1 and the high prevalence of depression2; 
antidepressant drugs are associated with dangerous adverse drug reactions3 and are open to abuse. This 
study aimed to evaluate the prescribing trends of antidepressants in care homes. This study is part of a wider 
study into psychotropic drug prescribing in care homes, also looking at antipsychotics, anxiolytics and 
hypnotics. 
Data generated by an electronic dispensing system used in care homes was obtained. It detailed each drug 
admission and was filtered for relevant data on antidepressant prescribing. All antidepressant drugs which 
could be prescribed were searched for. This data was then manipulated using descriptive statistics, to show 
the number of prescriptions of different drugs and in different care homes. Doses prescribed were individually 
assessed to judge appropriateness based upon BNF guidelines. A pearson correlation was carried out to judge 
whether or not a correlation was present between antidepressant prescribing and prescribing of the other 
psychotropic drug classes in care homes. 
Prescribing in the data was generally good, with the majority of prescriptions at appropriate doses and of 
appropriate drugs. Polypharmacy was prevalent within the data. A strong correlation was found between the 
level of antidepressant prescribing in a care home and the level of prescribing of the other 3 psychotropic drug 
classes. 
Depression in care homes is common; therefore the prescribing of drugs to treat depression is important. 
Prescribers are choosing mainly appropriate agents at appropriate doses. The correlation between 
psychotropic drugs may suggest a disparity in prescribing of psychotropic drugs as a whole between care 
homes. This study was held back by lack of data and the small sample size. 
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 Onder G, Liperoti R, Fialova D, Topinkova E, Tosato M, Danese P, Gallo PF, Carpenter I, Finne-Soveri H, Gindin J, Bernabei R, 
Landi F (2012) Polypharmacy in Nursing Home in Europe: results from the SHELTER Study Journal of Gerontology: MEDICAL 
SCIENCES 2012 June;67A p698-704 
 Harris T, Carey IM, Shah SM, Dewilde S, Cook D (2012) Antidepressant Prescribing in older primary care patients in community 
and Care home settings in England and Wales JAMDA January 2012 Volume 13, Issue 1, Pages 41–47 
 Joint Formulary Committee (2016). British National Formulary. [72] ed. London: BMJ Group and Pharmaceutical Press 
 
 
The role of cluster pharmacists in pharmacovigilance  
Viviyana Matanda, A Mathews, TL Stubbs and ML Hughes  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
An adverse drug reaction (ADR), is “a response to a medical product which is noxious and unintended”.1 They 
are a burden patients’ health and well-being and a financial burden on the NHS. To identify and therefore 
prevent ADRs pharmacovigilance systems have been set up.2 They utilise reports from health professionals 
obtained via the Yellow Card Scheme however currently less than 10% of ADRs are being reported.3 Welsh 
Health Boards set out to improve on the safe, effective and prudent use of medicines by recruiting cluster 
pharmacists.4 This project aims to explore how pharmacovigilance and ADR reporting currently fit into the 
cluster pharmacist role in order to identify potential future opportunities for increasing ADR reporting. 
A qualitative approach was adopted. A semi-structured interview schedule consisting of both open and closed 
questions was designed. Ethical and Health Board approval was obtained. Non-probability, purposive sampling 
techniques were used to recruit participants. The interviews were conducted face-to-face or via telephone, 
audio-recorded with consent, and transcribed to give a full verbatim record. Inductive and deductive analysis 
methods was used to identify major themes.  
Nine interviews were conducted. The major themes identified were: the role of the cluster pharmacist in primary 
care, WCPPE training session, the Yellow Card Scheme, Information Technology, reporting and responsibility, 
patient contact, experiences of ADRs, targets, obstacles to reporting, increasing awareness of reporting, 
cluster pharmacists as Yellow Card Champions and recommendations for the future. 
The objectives were met and recommendations were made on how the role of the cluster pharmacist could be 
developed to increase reporting, and thus improve public health and ease the burden on the NHS. This project 
was the first to look at how cluster pharmacists fit into pharmacovigilance and ADR, the results will be of value 
to Yellow Card Centre Wales in developing ongoing initiatives to increase reporting rates. 
1. European Medicines Agency, 2012. Pharmacovigilance legislation. Available at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000491.jsp (Accessed 22 Nov. 
2016). 
2. Hughes L, Whittlesea C, Luscombe DK, 2002. Review of National Spontaneous Reporting Schemes: Strengths and Weaknesses. 
Adverse Drug React Toxicological Reviews; 21(4), pp. 231-241 DOI: 10.1007/BF03256199 
3. Hazell L and Shakir S, 2006. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29(5), pp. 385-396 DOI: 
10.2165/00002018-200629050-00003 
4. NHS Wales, 2016. Health in Wales- Clinical pharmacists in GP practices. Available at: http://www.wales.nhs.uk/news/40188 
(Accessed 22 Dec. 2016). 
 
 
Potential role of BIN1 in Alzheimer’s disease: links with endocytosis 
Catherine Matheson, R Greening, A Burt and RS Thomas 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
A hallmark of Alzheimer’s disease (AD) is the build-up of extracellular, β-amyloid (Aβ)-containing, plaques1. 
Aβ is produced from amyloid precursor protein (APP) cleavage via the amyloidogenic pathway2. This pathway 
internalises cell surface APP, predominantly via clathrin-mediated endocytosis (CME), before being cleaved 
by BACE1 to produce β-CTF. β-CTF is subsequently cleaved, producing Aβ2. BIN1 has been identified as a 
key susceptibility gene implicated in AD and is known to be involved in CME3. Previous unpublished 
experiments showed β-CTF levels were increased in response to BIN1 depletion. We therefore decided to 
investigate the role of BIN1 in endocytosis at the blood-brain barrier (BBB), known to be disrupted in AD, to 
determine if this explained the changes in β-CTF4. 
Levels of BIN1 were depleted in hCMEC/D3 cells (a BBB model) by transfection of siRNA targeting BIN1. 
Western blotting was used to detect any changes in expression levels of endocytic proteins implicated in CME, 
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clathrin-independent endocytosis (CIE) or APP processing. Results were analysed using Student’s t-test. 
Distribution of specific proteins were visualised using immunocytochemistry. 
BIN1 expression was successfully decreased (91.6±4.2%, p<0.01). In response to BIN1 depletion, no 
significant changes in CME-related proteins were seen but there was a significant increase in caveolin-2 
expression (68.4±19.8%, p<0.05), involved in CIE. A trend in BACE1 levels suggested an increase in 
expression. Alterations were seen in the localisation of the late endosomal/lysosomal proteins, RAB9 and 
LAMP2b.  
These findings suggest BIN1 depletion does not affect CME but instead may influence CIE and the late 
endosomal/lysosomal pathway. Alterations to these processes and the possible increased levels of BACE1 
may have been responsible for the increased levels of β-CTF seen. Overall, this suggests BIN1 has an effect 
on endocytosis, which may alter the processing of APP, and has helped to further our understanding of the 
role of BIN1 in AD. 
1. Hardy J and Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends in Pharmacological 
Sciences. 1991;12(10):383-388. 
2. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML et al. Genome-wide association study identifies variants at 
CLU and PICALM associated with Alzheimer’s disease. Nature Genetics. 2009;41(10), pp. 1088 – 1095. 
3. Jiang S, Li Y, Zhang X, Bu G, Xu H, Zhang Y-W. Trafficking regulation proteins in Alzheimer’s disease. Molecular 
Neurodegeneration. 2014;9(6):1-13. 
4. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nature Reviews 
Neuroscience 2014;12(12):723-738. 
 
 
Pharmacovigilance and ADR reporting in the cluster pharmacist role  
Amy Matthews, V Matanda, TL Stubbs and ML Hughes 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Research has revealed that ADRs are a problem within healthcare. ADRs can cause serious health 
complications leading to the hospitalisation of many patients and have an estimated annual cost of £466m.1 
Despite their prevalence, ADRs are under-reported to systems such as the Yellow Card Scheme (YCS).2 The 
YCS has made many developments in its reporting systems to increase the number of ADR reports it receives 
and improve patient safety. In 2015, the Welsh Government developed the cluster pharmacist role to integrate 
into multidisciplinary teams seen in the primary healthcare setting.3 The following project aims to explore how 
pharmacovigilance and ADR reporting fits into the cluster pharmacist role, and thus identify opportunities to 
improve ADR reporting rates.  
A qualitative approach was adopted to explore cluster pharmacists’ perceptions of ADR reporting. A semi-
structured topic guide was developed. Non-probability, purposive sampling was used to recruit participants. 
Face-to-face or telephone interviews were conducted and transcribed ad verbatim. Thematic analysis was 
used to identify major themes and sub-themes. Ethical approval and approval from Health Board Research 
and Development Departments was obtained.  
Nine interviews were conducted; six face-to-face and three telephone interviews. Themes that emerged were 
like those found in previous research and comparable to Inman’s seven deadly sins of reporting.4 Barriers to 
reporting included lack of time and uncertainty. However, the role is facilitating reporting with some cluster 
pharmacists reporting ADRs on behalf of GPs. Suggestions to increase reporting included further education 
of healthcare professionals to increase awareness and introducing pre-populated reports to reduce time taken 
to report.  
This exploratory study found that cluster pharmacists are ideally placed for the recognition and reporting of 
ADRs. Although the research was with limited participants, many important themes emerged which will be 
valuable for the Yellow Card Scheme to improve reporting rates via the cluster pharmacist role.  
1. Pirmohamed, M. et al. 2004. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. 
BMJ 329(7456), pp. 15-19.  
2. Hazell L and Shakir S, 2006. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29(5), pp. 385-396  
3. Welsh Government, 2015. Our plan for a primary care service for Wales up to March 2018. Available from: 
http://gov.wales/docs/dhss/publications/150218primaryen.pdf  
4. Inman, W. 1990. Modern Methods of Clinical Investigation. 1st ed. National Academies Press.  
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Is a binding isotherm really a general tool for comparing molecularly imprinted 
polymers? 
Lauren Maw, S Eppler, OK Castell and JL Bowen 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Molecular imprinted polymers (MIPs) are a synthetic approach trying to mimic natural selective molecular 
interactions 1. Still relatively early in their development, MIPs continue to stimulate considerable research 
interest but due to the significant differences in how performance is evaluated, inter-laboratory comparison is 
challenging.2 Previous research by Castell3 attempted to unify research to aid comparison and facilitate 
progression within the field. A bound analyte per MIP molecule vs absolute free isotherm was proposed [3]. 
However, experimental data by Eppler4 suggested that these isotherms are mass-dependent. Consequently, 
different isotherms were produced for the same polymer, hindering comparison. Therefore, the primary aim of 
this project was to determine if theoretical consideration of binding kinetics could help explain these conflicting 
results. 
A two-dimensional Monte Carlo (MC) model simulated different MIP/analyte concentrations to produce 
isotherms. Following this, MIP re-binding experiments were performed using propranolol imprinted p-MAA-co-
DVB-co-EGDMA polymers. Two different polymer mass loadings were used. Both centrifuging and fitering 
methods were employed to isolate the supernatant and the resulting samples were analysed by measuring UV 
absorbance. 
The computational modelling supported the originally proposed isotherm3 as no divergence was seen between 
different MIP concentrations. However, experimental data did not coincide with this as there was a clear 
divergence seen with an increased polymer mass, supportive of Eppler.4 The method used to produce the 
supernatent affected results; the filtering method showed a higher concentration of propranolol bound 
compared to centrifuging. 
It is unclear as to why the computational results conflict with experimental data. Prehaps the polydiversity 
within real MIPs will change the binding kinetics. On the other hand, there is clear evidence to suggest that the 
way in which MIP re-binding studies are performed affects results obtained. Further research is needed to 
investigate these unanswered questions to unite research and facilitate advances in this exciting technology. 
1. Ramström, O. and Yan, M. 2005. Molecular imprinting - an introduction. In: Yan, M. and Ramström, O. ed. Molecularly imprinted 
materials science and technology. 1st ed. New York: Marcel Dekker, pp. 1-12. 
2. James, P. 2013. Is the molecularly imprinted polymer ‘p(EGDMA-co-MAA)’ superior to other imprinted polymer systems? MSc 
Dissertation, Cardiff University. 
3. Castell, O. K. et al. 2011. Current practices for describing the performance of molecularly imprinted polymers can be misleading and 
may be hampering the development of the field. Journal of Molecular Recognition 24(6), pp. 1115-1122. 
4. Eppler, S. 2014. Advanced strategies for characterizing molecular imprinted polymers. PhD Thesis, University of Ulm. 
 
Assessment of inhaler technique and asthma control in a community pharmacy 
setting 
Laura McCoubrey and WR Ford 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Asthma is a debilitating condition, presently affecting 5.4 million people in the UK, 314,000 in Wales.1 A recent 
survey by Asthma UK, found that around a third of asthma sufferers use inhalers ineffectively.1 This study aims 
to contribute to the assessment of asthma control and inhaler technique. 
Seven fourth-year students collected data over 4 weeks in an allocated community pharmacy. Following 
consent, the data collection involved a modified ACT (named an asthma control survey (ACS)), questions 
about their inhalers and who had shown them inhaler technique, an AIMs test (inhaler technique) and finally a 
Spirometry test.  
According to the ACS 43% of participants had uncontrolled asthma over the past four weeks. Participants 
using MDIs showed poorer inhaler technique, compared with participants using DPIs. Better inhaler technique 
was observed when using a spacer than using MDI alone. There were no statsitical differences in the quality 
of inhaler technique for patients trained by by a nurse, GP or pharmacist. Only a small number of participants 
had been shown by a pharmacist (2%). 56% of participants who smoke (n=27) had uncontrolled asthma 
compared to only 38% of participants who are non-smokers (n=97). 17 out of 145 participants had been 
MPharm 
38 
admitted to hospital this year due to their asthma. 2 of these participants had never been shown how to use 
their inhalers, and both of them failed the AIMs test.  
The main findings were that asthma is uncontrolled in a large proportion of asthma patients and that inhaler 
technique is generally poor. These findings highlight the need for healthcare professionals to prioritize the 
education of asthma patients about their condition and its treatment to reduce the high rates of morbidity and 
mortality. There is potential for pharmacists to be more involved with this as they are conveniently located, 
with regular contact with patients.2,3 
 Asthma UK. Asthma facts and statistics [accessed 2016 Dec 1]. Available from: http://www.asthma.org.uk/about/media/facts-and-
statistics      
 Al-Kharsan Z. PSNC briefing 064/16: Inhaler technique services. PSNC.2016. 
 Mehuys E, Van Bortel L, De Bolle L, Van Tongelen I, Annemans L, Remon JP, Brusselle G. Effectiveness of pharmacist intervention 
for asthma control improvement. European Respiratory Journal. 2008 [cited 2017 Jan 16];31(4):790–9. Available from: 
http://erj.ersjournals.com/content/erj/31/4/790.full.pdf doi: 10.1183/09031936.00112007  
 
 
The evaluation of the Triage and Treat service in community pharmacies in the 
Hywel Dda University Health Board 
Henry McLaughlin, A Evans, H Blyth and KL Hodson 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Two Minor Injury Units in Tenby and Pembrokeshire were closed down due to lack of funding and staff 
shortage.1 This led to the establishment of the Triage and Treat service within Community Pharmacies in the 
area. The service aims to provide the treatment of low level injuries in pharmacies, close to the patient home, 
to take pressure off other local health care services. The project’s aim was to evaluate the Triage and Treat 
service. The objectives were to identify the number of patients seen by the Triage and Treat service between 
April 2015 and September 2016, explore the views of the pharmacy team providing the service and to assess 
patient feedback. 
The evaluation took place in 3 phases, a quantitative analysis of claim forms used to document patient 
information, qualitative analysis of interviews with pharmacy staff that ran the service and an analysis of patient 
feedback forms. 
The results for phase 1 show that the service seems to be increasing in popularity as more patients used the 
service in the 6 months between March and September 2016 than in the previous 12 months. Phase 2 
interviews showed that a lot of the pharmacists found running the service satisfying and beneficial to the 
community, but limitations were identified in training and advertising. The majority of information analysed on 
patient feedback forms was positive. 
Triage and Treat service has shown that it relieves pressure on local healthcare services and fulfils the aim of 
the Royal Pharmaceutical Society to use the pharmacy teams full potential.2 There is the need to address the 
advertising necessary to increase awareness of the service and the addition of a refresher-training course for 
pharmacy staff, but overall the service has been well received in the pharmacies where it is established. 
 BBC. Tenby hospital minor injuries unit closure protest. BBC South West Wales. 2013 Jan 26 [accessed 2017 Jan 11]. Available 
from: http://www.bbc.co.uk/news/uk-wales-south-west-wales-21215095. 
 Royal Pharmaceutical society. Steps to better health and well-being: RPS Policy vision for wales. Unlocking the potential of the 
pharmacy team. 2015;9 [accessed 2 Jan 2017] Available from: http://www.rpharms.com/wales-pdfs/steps-to-better-care-eng-
final.pdf 
 
 
Investigating local infiltration analgesia in total knee arthroplasty 
Naiomi Fflur Morris, S Hiom1 and AG Cosslett 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and 1St Mary's Pharmaceutical Unit, 20 Field Way, Cardiff CF14 4HY, Wales, UK. 
Local Infiltration Analgesia (LIA), a minimally invasive intraoperative technique used to provide post-operative 
analgesia after Total knee Arthroplasty (TKA), involves infiltrating the surgical site with local anaesthetic (LA) 
alongside other agents.1 It is important that patients receive sufficient analgesia postoperatively, increasing 
comfort, aiding earlier mobilisation and shortening recovery time.2 This conforms to the Enhanced Recovery 
After Surgery (ERAS) programme, improving patient satisfaction and reducing costs to the NHS.3 Although 
commonly used, there is no ready-to-use gold standard LIA formulation. LIA has no standardised protocols for 
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its preparation or administration when prepared locally prior to use. Therefore calculation errors, contamination 
and the production of an unstable LIA mixture may occur. Attributable to this, patients are subjected to potential 
avoidable risks;4 a ready-to-use commercial product would reduce this. The aim of this project is to investigate 
current practices to determine the optimal LIA formulation and the potential of a commercially available, ready-
to-use LIA formulation. 
Current literature was reviewed investigating LIA practices. The previous questionnaire (2015/16) underwent 
minor modifications before ethical approval was granted. Data collection was gathered from NHS and private 
UK hospitals via an online questionnaire disseminated by e-mail, including an invitation letter. Participants 
were approached through hospital-listed contacts, ERAS conference and via the Snowballing technique. 
Out of 48 responses the most common participants were orthopaedic surgeons and anaesthetists. 95.7% of 
respondents used LIA. Twenty formulae were reported, the most common being levobupivacaine and 
adrenaline (16.7%). Most LIA mixtures were prepared on site by nurses (59.1%). SPSS statistical analysis 
deemed the results statistically insignificant. 
Professionals preparing LIA mixtures require training to ensure aseptic techniques are utilised. There is an 
evident gap in the market for a pre-prepared LIA mixture, however research on a larger scale is required to 
determine the ideal, rationalised combination of ingredients. A ready-to-use product would reduce the 
associated risks, ensuring patient safety. 
1. Kerr DR, Kohan L. Local infiltration analgesia: A technique for the control of acute postoperative pain following knee and hip 
surgery: A case study of 325 patients. Acta Orthopaedica. 2008 Apr;79(2): 174–83. 
2. Holm B, Kristensen MT, Myhrmann L, Husted H, Andersen LØ, Kristensen B et al. The role of pain for early rehabilitation in fast 
track total knee arthroplasty. Disability and Rehabilitation. 2010 Jan;32(4): 300–6. 
3. Auyong DB, Allen CJ, Pahang JA, Clabeaux JJ, MacDonald KM, Hanson NA. Reduced length of hospitalization in primary total 
knee Arthroplasty patients using an updated enhanced recovery after orthopedic surgery (ERAS) pathway. The Journal of 
Arthroplasty. 2015 Oct;30(10): 1705–9. 
4. Knobben BAS, van Horn JR, van der Mei HC, Busscher HJ. Evaluation of measures to decrease intra-operative bacterial 
contamination in orthopaedic implant surgery. Journal of Hospital Infection. 2006 Feb;62(2): 174–80. 
 
 
Synthesis of novel oroidin analogues and their antimicrobial activity 
Rhys Morris and AW White 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Antimicrobial resistance is an increasing health crisis which can be prevented by expanding the number of 
novel antibiotics being developed.1 One area of interest is the natural product, oroidin — a secondary 
metabolite of the marine sponge, Agelas oroides, first isolated in 1971.2 The aim of this project was to 
synthesize novel oroidin analogues in a two-step process. The newly synthesized compounds were then tested 
against two gram positive (MSSA and MRSA) and two gram negative bacteria (E.coli and P. aeroginosa).  
The first step in the synthesis was to produce the pyrrole-unsubstituted compounds by reacting various amines 
with 2-(trichloro)acetylpyrrole in DMF. The second step consisted of brominating two products, using NBS, in 
order to make them more oroidin-like. These compounds were tested for antimicrobial activity using the disk 
diffusion method. The zones of inhibition were measured and recorded. 
1H NMR and mass spectrometry data showed that 6 novel compounds were synthesised (four unsubstituted 
and two brominated compounds). The zones of inhibition for each compound show very small or no activity 
against one or more bacteria. The largest activity recorded was (7) against MRSA. However, there are several 
limitations which make these results less reliable.3 
(5) produced the highest yield of 80% when using acetonitrile as the solvent. Therefore, a future avenue to 
explore would be to use CH3CN instead of DMF for the lowest yielding reactions. Another future route would 
be to improve the methods of analysis so its possible to identify where exactly on the molecule the bromines 
lie. Because of the limitations of the antimicrobial test, it would be good to use wells diffusion to test these 
compounds further.4 
1. O’Neil J, Review on Antimicrobial Resistance, AMR Review Paper, Dec 2014, https://amr-
review.org/sites/default/files/AMR%20Review%20Paper%20-
%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf [accessed 28/11/2016] 
2. S. Forenza, L. Minale, R. Riccio, E. Fattorusso, New bromo-pyrrole derivatives from the sponge Agelas oroides, J. Chem. Soc. 
1971, p. 1129 
3. Zone of Inhibition Test for Antimicrobial Activity Summary, Microchem Laboratory http://microchemlab.com/test/zone-inhibition-test-
antimicrobial-activity [accessed 05/01/2017] 
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4. Balouiri M, Sadiki M, Ibnsouda S; Methods for in vitro evaluating antimicrobial activity: A review; J. Pharm. Anal, 2016 
http://www.sciencedirect.com/science/article/pii/S2095177915300150 [accessed 05/01/2017] 
 
 
The reconstitution of the anthrax toxin pore (PA63) into droplet interface bilayers 
Heather Munro-Brown1, S Shorter2, L Baillie1, P Dyer2 and OK Castell1 
1Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK and 2Biomedical Sciences, Faculty of Engineering & Science, University of Greenwich, UK 
Membrane proteins such as the anthrax toxin pore (PA63) are challenging to study due to their inherent 
instability. The development of new methods is required to allow research into membrane proteins to become 
simpler and more cost-effective. Droplet interface bilayers (DIBs) are an in-vitro mimic of the cell membrane.1 
By demonstrating that proteins can be reconstituted into DIBs will provide a new, more efficient way to study 
membrane proteins. The aim of this study was to establish a method for the reconstitution of the PA63 pore 
into a DIB and to characterise the behaviour of the pore within the bilayer. Pore blocking agents were also 
investigated. 
DIBs were formed by submerging two aqueous droplets on electrodes in an oil-lipid mixture. The droplets 
acquired a lipid monolayer and when the droplets were brought into contact a bilayer was formed.1,2 Membrane 
proteins dispersed within the droplets incorporated into the bilayer and when a potential was applied the current 
flowing through any pores in the bilayer could be measured.2 Visual inspection of the current traces generated 
allowed pore insertion and pore blocking events to be identified.  
Reconstitution of the PA63 pore into a DIB was achieved using a protein preparation concentration of 50%, 
with potassium chloride buffer in both droplets and a droplet size of 0.2µl at pH 5.5. The current increase on 
pore insertion was small; 0.8pA which reflected the narrow diameter of the pore channel. The amount of time 
the pore spent in an open state was short; on average 2.8 seconds, this was likely to be due to LF; another 
component of anthrax toxin which temporarily blocks the pore.3 A pore blocking agent; fluphenazine was tested 
but the results were inconclusive. Unexpectedly, fluphenazine appeared to interact with the bilayer in the 
presence of certain lipids. 
This project demonstrates the reconstitution of functional PA63 into DIBs. This success should allow research 
into this membrane protein system to become more efficient. Further investigations into fluphenazine as a pore 
blocking agent are recommended.  
1. Leptihn S, Castell OK, Cronin B, Lee EH, Gross LC, Marshall DP, et al. Constructing droplet interface bilayers from the contact of 
aqueous droplets in oil. Nat Protoc. 2013 Jun;8(6):1048-57. 
2. Bayley H, Cronin B, Heron A, Holden MA, Hwang WL, Syeda R, et al. Droplet interface bilayers. Mol Biosyst. 2008 Dec;4(12):1191-
208. 
3. Neumeyer T, Tonello F, Dal Molin F, Schiffler B, Orlik F, Benz R. Anthrax lethal factor (LF) mediated block of the anthrax protective 
antigen (PA) ion channel: effect of ionic strength and voltage. Biochemistry. 2006 Mar;45(9):3060-8. 
 
 
Bacterial adhesion between dental biomaterials and relevant gram-positive and 
gram-negative bacteria: influence of surface roughness and material characteristics 
Kasser Nisar and P Prokopovich 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
In the year 2015, 10,000 dental implant procedures took place in the lower jaw of patients in the UK. 1 A report 
found that 10% of patients with implants in Sweden had developed peri-implantitis2, a bacterial infection that 
leads to loss of bone from the jaw which supports the implant. Additionally, the NHS dental survey found that 
85% patients interviewed, had a dental restoration procedure carried out.3 Out of these patients, 26% had 
secondary decay or an unsound restoration.3  
The aim of this study was to investigate which materials exhibited the least levels of bacterial adhesion and 
the influence of material roughness on bacterial adhesion. Elastic moduli, Poisson’s Ratio and Surface Energy 
values was gathered for three implant materials (nickel chromium, tantalum and titanium) and two dental 
cements (Polymethyl Methacrylate (PMMA) and zinc phosphate). The same values were obtained for bacteria 
which often cause oral infections (Actinobacillus actinomycetemcomitans, Veillonella parvula, Staphylococcus 
aureus, Streptococcus mutans and Streptococcus salivarius). This data was then entered into a previously 
developed algorithm based on the Johnson-Kendall-Roberts (JKR) model of adhesion.4 This calculated the 
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force of adhesion of bacteria to each material. The algorithm was then altered to change the roughness of 
nickel chromium. This was then run against S salivarius and S aureus.  
Zinc phosphate displayed the highest levels of adhesion to all bacteria. S salivarius was the most adhesive 
bacteria. PMMA was the least adhesive of all materials. When surface roughness of nickel chromium was 
increased, adhesive force increased significantly from 9.60µN to 18.87µN. 
Zinc phosphate and PMMA were the most and least adhesive materials respectively. But one major limitation 
with the JKR model is the exclusion of considering non-contact forces. Further studies using the Derjaguin-
Muller-Toparov model would take into account non-contact forces into adhesive force calculations. 
 BBC News. Dentists warn of risks of not looking after implants – BBC News. London; 2015 [Accessed on 10th November 2016] 
Available from: http://www.bbc.co.uk/news/health-32086134 
 Klinge B, Meyle J. Peri-implant tissue destruction. The Third EAO Consensus Conference 2012. Clin Oral Impl. Res. 23 [Suppl. 
6],2012,108-110 
 Steele J, O'Sullivan I. Adult Dental Health Survey 2009: Executive Summary - adul-dent-heal-surv-summ-them-exec-2009-rep2.pdf. 
2011 [accessed 12th Nov 2016]. Available from: http://www.hscic.gov.uk/catalogue/PUB01086/adul-dent-heal-surv-summ-them-
exec-2009-rep2.pdf.  
 Prokopovich P, Perni S. Multiasperity Contact Adhesion Model for Universal Asperity Height and Radius of Curvature Distributions. 
Langmuir. 2010;26(22):17028-17036  
 
 
Measuring the interaction of a short chain polymyxin derivative with 
lipopolysaccharide 
Ben Noble, N Dermertzis and JL Bowen 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Lipopolysaccharide (LPS) is a Gram-negative bacterial endotoxin that is ubiquitously associated with sepsis, 
a process that can cause multi organ failure and death.1 Polymyxin antibiotics are able to bind LPS with high 
affinity, and are therefore useful in the treatment of Gram-negative infections2, however their use has been 
limited by associated neuro and nephro toxicity. This toxicity is believed to be a consequence of the N-terminal 
acyl chain of the molecule3, and so investigations into N-terminal modifications to find a less toxic alternative 
are popular. The aim of this study was to evaluate the interaction of a short chain polymyxin B (scPmB) 
derivative with LPS, with comaprison to polymyxin B (PmB).  
Electrochemical impedance spectroscopy (EIS) was used to measure the interaction. To develop a stable LPS 
functionalised electrode, calcium was used to bridge the LPS molecules. LPS monolayers were challenged 
with increasing concentrations of polymyxin derivative, whilst the impedance of the system was monitored. Rct 
values were calculated from Nyquist plots using an equivalent circuit model. Average ΔRct values were used 
to correlate changes in impedance against concentration.  
Short chain polymyxin B interacted well with LPS, showing relatively higher changes in Rct at all concentrations 
when comapred to polymyxin B. Challenge with conventional polymyxin B resulted in breakdown of the LPS 
monolayer at low concentrations, which was only observed with scPmB at higher concentrations.  
Degradation of the immobilised LPS monolayer will have affected interaction results, particularly for polymyxin 
B. When comparing the interaction results from this study this should be considered. The LPS immobilised 
electrode showed potential for measuring interaction but requires optimsation. ScPmB showed promising 
interaction with LPS, and is an exciting polymyxin derivative requiring more investigation into antibacterial 
activity, toxicity or use in sensing. 
 Ramachandran G. Gram-positive and gram-negative bacterial toxins in sepsis. Virulence. 2014; 5(1):213-218 
 Velkov T, Thompson P, Nation R, Li J. Structure-activity relationships of polymyxin antibiotics. J. Med. Chem. 2010; 53(5):1898-
1916  
 Duwe A, Rupar C, Horsman G, Vas S. In vitro cytotoxicity and antibiotic activity of polymyxin B nonapeptide. Antimicrob. Agents. 
Chemother. 1986; 30:340–341  
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Evaluation of a community pharmacy-based asthma care plan  
Esther Ntanganika, ME Jones, T Hussain, JP Lee, L McCoubrey, L Tatnell, TM Chilvers and WR Ford  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Mayberry Pharmacy, 175 High St, Blackwood, Gwent, NP12 1AA, 
 and Aneurin Bevan Health Board, Newport NP20 2UB Wales, UK 
Asthma is an inflammatory lung disease. Its high prevalence leads to long term morbidity and preventable 
mortality rates.1 Some asthma-associated mortality rates are due to poor asthma control.1 Factors shown to 
facilitate poor asthma control are: low patient adherence to therapy, poor inhaler technique, a lack of education 
and knowledge about the long term management of the disease.2 The aim of this study was to measure and 
assess the level of asthma control and inhaler technique within patients, together with factors that are influential 
to this.  
A consultation using a semi-structured interview approach was carried out with each patient, consisting of: 
assessing the level of asthma control via an asthma control survey (ACS) and assessing inhaler technique 
performance via an Aerosol Inhaled Monitor (AIM) device. Quantitative data was analysed with Prism. Kruskal-
Wallis and Mann-Whitney U statistical tests were used for non-parametric data.  
Altogether, 145 patients were recruited. A high rate of uncontrolled asthma control was found, just under half 
(43%) of the study population failed the ACS. This was amplified by 42% of patients who had been either 
hospitalised or had received oral steroids for their asthma. Patients were more likely to use metered dose 
Inhalers (MDIs) incorrectly (56%) compared to only 4% who used their dry powder inhalers (DPIs) incorrectly. 
Inhaler technique was found to affect asthma control. Factors influencing inhaler technique were: geographical 
location of pharmacies and whether patients had been shown how to use their inhalers. 
Using DPIs instead of MDIs could be a solution in overcoming MDI misuse, but factors such as inspiratory flow 
rate and cost would need to be considered.3 The difference of inhaler technique performance found in localities 
suggests that patients are not receiving consistent training from healthcare professionals. Asthmatic patients 
require more support to achieve better asthma control.  
 National Asthma Education and Prevention Program TEPotaMoA. Expert Panel Report 3: Guidelines for the Diagnosis and 
Management of Asthma. US: National Heart, Lung, and Blood Institute; 2007. 
 Lee JY, Yoo KH, Kim DK, Kim SH, Kim TE, Kim TH, et al. Effects of Educational Interventions for Chronic Airway Disease on 
Primary Care. J Korean Med Sci. 2016 Jul; 31(7):1069-74. 
 Barnes P, Virchow JC, Sanchis J, Welte T, Pedersen S. Asthma management: important issues. European Respiratory Review. 
2005; 14(97):147-51. 
 
 
What impact did the ‘Communicating for Success’ training have on pharmacy 
professionals’ abilities to communicate more effectively in practise?  
Olufemi Omotade, K Hodgson and D Roberts 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB, and Wales Centre for Pharmacy Professional Education, 8 North Road, Cardiff CF10 3DY, Wales, UK 
The role of the pharmacy professional is rapidly evolving, requiring professionals to communicate in new ways, 
to a more diverse audience. The ‘Communicating for Success’ workshop was designed to improve all aspects 
of communication and to equip pharmacy professionals with enhanced presentation skills that would improve 
the quality of their communication.1 The aim of this study was to evaluate the impact that the workshop had on 
pharmacy professionals’ abilities to communicate more effectively in practise. 
Participants who had attended this training programme were invited to participate in the study (n=23) via email. 
Semi-structured telephone interviews were conducted (n=8), recorded then transcribed ad verbatim. The 
qualitative data was analysed using deductive thematic analysis. Ethical approval was obtained from the 
school’s research and ethics committee. A response rate of 34.8% was achieved.  
Overwhelmingly, every respondent now incorporates more visual aids and less text into their presentations, 
as research has strongly suggested that the use of visual aids increase the audience’s retention of the principal 
message, [2] which was arguably the key message of the training day. Another key finding was the storytelling 
technique; with majority of respondents now using this technique when presenting. Every respondent 
unanimously agreed that the workshop was highly beneficial in providing skills to make presentations more 
engaging, yet a few of the respondents still said that they were partially or not confident at all in presenting to 
an audience. 
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The ‘Communicating for Success’ workshop was useful in teaching skills that enhance the quality of 
communication and presentations. As more pharmacy professionals routinely deliver presentations, such as 
primary care pharmacists, this workshop has a unique place in pharmacy and should therefore be continued 
in the future. 
 Hayes, J. ‘Communicating for Success’ workshop. June, 2016. Cardiff, United Kingdom.  
 Hargie O and Morrow N. Evaluation of a presentation skills course for pharmacists. March 1995; 3 (2): 101 – 105 [accessed 10th 
October, 2016]. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.2042-7174.1995.tb00798.x/epdf  
 
 
Welsh language use within community pharmacy services: pharmacists’ 
perspectives 
Rebecca O’Neill, EM Jones, W Davies, LJ Doyle and ML Hughes 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
19% of the population in Wales are Welsh speakers.1 In 2011, the Welsh language (Wales) measure was 
introduced to promote the use of the Welsh language and established the role of the Welsh Commissioner.2 
The results of the commissioner’s first inquiry showed that only 29% of fluent Welsh speakers had their last 
conversation with a pharmacist in Welsh.3 In response to this, new questions have been added to the National 
Electronic Claims and Audit Forms (NECAF) in community pharmacies to track the utilisation of Welsh within 
pharmacy services. Good communication with patients is a key part of a pharmacists’ role as set out in the 
standards of conduct, ethics and performance.4 The aim of this study was to explore the views of pharmacists 
about Welsh language medium provision of community pharmacy services. 
Qualitative research methods were used and ethical approval was obtained. Six semi-structured interviews 
were conducted. Pharmacists were sampled from the data submitted to NECAF using purposive and 
convenience methods. A topic guide was devised and was used in interviews following piloting. Consent was 
obtained from participants following distribution of a participation information sheet. Interviews were 
transcribed verbatim, coded manually and analysed thematically. 
Four themes were identified: Pharmacists’ awareness, pharmacists’ willingness, technology and barriers to 
services. Interviewees felt confident in their ability to conduct Welsh medium service provision, but suggested 
that a lack of confidence could be a barrier to more Welsh language pharmacy services overall. All pharmacists 
interviewed agreed that further training would be beneficial. Pharmacists highlighted the benefits of Welsh 
language services to patients. Not one service was perceived to be easier to conduct than another through the 
medium of Welsh. The new questions on NECAF did not seem to encourage pharmacists to conduct services 
in Welsh. 
Several areas for improvement were identified for future including the increased availability of resources and 
further training opportunities. Further evaluation of the data submitted to NECAF should be considered in 
future.  
 Welsh Government. Welsh speakers by local authority, gender and detailed age groups, 2011 census. Cardiff; 2011. [Accessed 1 
Dec 2016] Available from: https://statswales.gov.wales/Catalogue/Welsh-Language/WelshSpeakers-by-LocalAuthority-Gender-
DetailedAgeGroups-2011Census.  
 UK government. Welsh Language (Wales) measure 2011. Cardiff; 2014. [Accessed 1 Dec 2016] Available at: 
http://www.legislation.gov.uk/mwa/2011/1/pdfs/mwa_20110001_en.pdf.  
 Welsh Language Commissioner. My language, my health: The Welsh Commissioner’s inquiry into the Welsh Language in primary 
care. Cardiff; 2014. [Accessed 1 Dec 2016] available from: 
http://www.comisiynyddygymraeg.cymru/English/Publications%20List/Health%20inquiry%20full%20report.pdf.  
 General Pharmaceutical Council. Standards of Conduct, ethics and performance. London: 2012. [Accessed 1 Dec 2016] Available 
from: https://www.pharmacyregulation.org/sites/default/files/standards_of_conduct_ethics_and_performance_july_2014.pdf.  
 
 
Design and synthesis of novel natural product derivatives from a daffodil source  
Francesca Padday and AW White 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Narciclasine activates fibres in glioblastoma multiforme cells, significantly increasing human survival in 
glioblastoma preclinical models.1 BioExtractions Wales Limited provided a 5g sample of waste from 
galantamine production, thought to contain ~80% narciclasine. The aim was to isolate the samples' main 
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constituent, and from this design and semi-synthesise a novel derivative that can penetrate the blood-brain 
barrier (BBB) and treat glioma.  
Crude sample isolation, via base extraction, revealed 46% galantamine rather than 80% narciclasine. 
Galantamine is a reversible acetylcholinesterase inhibitor used in the treatment of mild to moderate dementia 
in Alzheimer's disease. It has a low BBB penetration2, and is poorly tolerated at high doses compared to other 
drugs in its class.3 A novel derivative was designed to optimize galantamine's characteristics, this was 
produced using a 2-step synthesis. First the oxidation of the secondary alcohol on galantamine to a ketone. 
Then reacting the ketone with O-benzyl hydroxylamine to form the novel derivative.  
In step-one of synthesis manganese dioxide was unsuccesful as an oxidising agent for all equivalents and 
conditions. Potassium permangante succesfully oxidised galantamine to a ketone, however a higher quantity 
of ketone and epoxide product, than ketone product was produced. Yields 2% to <1% respectively. The second 
step had a 56% yield. 
Dioctyl phthalate was found in step 2 of synthesis, it has the same molecular weight as the novel derivative. 
The novel derivative is distinguishable due to its polarity, and yield. The prevelance of Alzheimer's disease is 
increasing; the disease currently has no cure and the symptomatic therapies are far from flawless.4 A derivative 
of galantamine with increased BBB partitioning may aid drug delivery to the active site, thus improving 
tolerability. If a method with increased yield could be found for step one of synthesis this compound could be 
a step towards a promising lead compound. 
 Lefranc F, Sauvage S, Goietsenoven G, Megalizzi V, Lamoral-Theys D, Debeir O et al. Narciclasine, a plant growth modulator, 
activates Rho and stress fibers in glioblastoma cells. Molecular Cancer Therapeutics. 2009;8 [accessed: 15 Oct 2016]. Available 
from: http://mct.aacrjournals.org/content/8/7/1739.long  
 Maelicke, A. Derivatives of galantamine as pro-drugs for the treatment of human brain diseases [Online]. Google Patents; 2009 
[accessed: 9 Dec 2016]. Available from: https://www.google.com/patents/CA2721007A1?cl=en#classifications  
 Ritchie C, Ames D, Clayton T, Lai R. Metaanalysis Of Randomized Trials Of The Efficacy And Safety Of Donepezil, Galantamine, 
And Rivastigmine For The Treatment Of Alzheimer’s Disease. The American Journal of Geriatric Psychiatry. 2004;12:358-369.  
 Winblad, B. et al. 2016. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. The 
Lancet Neurology Commission [Online] 15. Available at: http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(16)00062-
4/abstract [Accessed: 11 January 2017].  
 
 
Exosomes: discovering new insights into their definition, characterisation, 
biological function and therapeutic potential 
Laura Palmer and AT Jones 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Exosomes are a product of the endocytic pathway and can be loosely defined as ‘small membrane vesicles of 
endocytic origin that are released into the extracellular environment on fusion of multivesicular bodies (MVB) 
with the plasma membrane’.1 The structure of an exosome is ‘limited by a lipid bilayer’ and they are known to 
contain certain components’2 such as proteins. Since their first discovery, in the early 1980’s, they have also 
been discovered to contain functioning messenger RNAs (mRNAs) and micro RNAs (miRNAs) and are 
believed to be powerful mediators of cell-to-cell communication.3 ‘Exosome’ is a term often used to discuss 
extracellular structures released by cells, but its actual meaning is often interpreted differently by different 
researchers.4 Other extracellular vesicles include microvesicles and apoptopic blebs. This study was designed 
to investigate how exosome research has evolved since they were first discovered, how they are isolated and 
characterised and discover proteins commonly enriched on exosomes. 
A thorough literature search was carried out to gather information about key exosome milestones, analyse 
publication dates of exosome research and discover data related to exosome characterisation. As well as 
conducting literature searches, discussions with exosome experts were also organised to aid objectives. 
Exosome research is a rapidly expanding field and the definition of exosomes has evolved with time. Cancer 
is the leading field in terms of exosome research which is surprising as they are present in almost all cell types 
and eukaryotic fluids. There are currently many isolation and characterisation methods and this potentially 
poses a danger to the field if impure exosomes are used in studies. It was discovered that the three most 
common protein families enriched on exosomes are antigen presenting proteins, tetraspanins and annexin. 
This study proposes that exosomes be referred to as nanovesicles, derived from late endosomes, loaded with 
various cargo, that are released into the extracellular space when multivesicular bodies fuse with the plasma 
membrane. In order to differentiate between other extracellular vesicles, five main factors; size, shape, density, 
sedimentation and biogenesis, should all be considered. 
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 Valadi H, Karin E, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel 
mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654-59. 
 Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009;9(8):581-93. 
 Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P, et al. Embryonic stem cell-derived microvesicles reprogram 
hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia. 2006;20(5):847-56. 
 Lötvall JO, Hill AF, Hochberg F, Buzas EI, Di Vizio D, Gardiner C, et al. Minimal experimental requirements for definition of 
extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell 
Vesicles. 2014;3:26913 
 
 
The knowledge and views of pharmacy students on drugs in sport 
Rishma Samir Patel, H Farr and EL Lane  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Doping is considered to be the use of prohibited drugs, prohibited methods, refusal to take a drug test or 
attempt to interfere with doping controls to improve results.1 A lot of medication, including over the counter 
medicines, contain banned substances in sport. Pharmacists should be aware of this and be able to give 
advice to patients who participate in sport. The main aim of this study was designed to explore the knowledge 
and views of pharmacy students at UK universities towards the use of drugs in sport. 
A cross sectional survey was conducted through Cardiff University Pharmacy School. The questionnaire used 
was adapted, designed and validated to be distributed to all undergraduate students. The questions were split 
into four sections covering the knowledge on doping, views on healthcare professionals in sports and sports 
pharmacy content within the MPharm curricula. Also, twenty-nine pharmacy schools across the UK were 
approached to acquire information about the content regarding drugs in sports within their MPharm course. 
196 responses were received across all 4 years of the course and coded appropriately to be entered in to IBM 
SPSS to be analysed. 90% of students supported the banning of drugs in sport. The majority of students knew 
the legal status of the drugs in sport but some gaps were observed when asked about the legailty of the use 
of prescription medications insulin and codeine.2 82% of respondents thought that healthcare professionals 
should be the most likely used source of information for safe and effective use of drugs in sport. 
Most students had a basic level of knowledge though it wasn’t entirely due to the training provided at university. 
Playing and watching sport had a significant correlation to the knowledge. WADA encourages more education 
for healthcare professionals through its code which lines up with the responses from students wanting more 
training.3 Overall, students need more training on this subject which could be provided through their MPharm 
course. 
1. United Nations Educational, Scientific and Cultural Organization. What is Doping? Paris: UNESCO; 2016 [accessed 21 Oct 2016]. 
Available from: http://www.unesco.org/new/en/social-and-human-sciences/themes/anti-doping/youth-space/what-is-doping/ 
2. World Anti-Doping Agency. The World Anti-Doping Code International Standard, Prohibited List. WADA; 2017 [Accessed 20 
October 2016]. Available from: https://www.wada-ama.org/sites/default/files/resources/files/2016-09-29_-
_wada_prohibited_list_2017_eng_final.pdf 
3. Sport and Medicine. The Role of the Pharmacist in the Fight Against Doping in Sports. Australia: Sports and Medicine, The 
pharmacists role and responsibilities; 2014 [accessed 1 Nov 2016]. Available from: 
https://sportsandmedicinethepharmacistsrole.wordpress.com/2014/04/17/fip-statement-of-professional-stthe-role-of-the-
pharmacist-in-the-fight-against-doping-in-sport/ 
 
 
Investigations into the physical stability of lipid emulsions in multi-layered mini 
bags compared to plastic syringes over an extended storage period 
Isabel Portergill, P Spark,1 S Hiom1 and AG Cosslett 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and 1St Marys Pharmaceutical Unit, Cardiff and Vale NHS Trust, 20 Fieldway Cardiff, CF14 4HY, Wales, UK. 
Parenteral nutrition (PN) lipid emulsions provide fundamental energy to neonatal patients1 and are typically 
stored in 50ml plastic syringes allowing a 7-day shelf life. Following the deaths of three babies who received 
contaminated PN2, Cardiff and Vale NHS Trust (C&V) are implementing rapid microbe testing that identifies 
contamination within 48 hours. To aid this implementation C&V want to store and deliver PN lipid emulsions 
from 50ml mini-bags that will extend the clinical shelf life and improve patient safety. The aim of this study was 
to generate physical stability data for two PN lipid emulsions (40ml Intralipid® or SMOFlipid® with 10ml 
reconstituted vitamins) in 125ml mini-bags (50ml unavailable) over 7 or 14 days at storage and administration 
temperatures, using 50ml syringes for comparison. 
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Visual inspection, pH, microscopy and laser diffraction were used to study the stability of samples on days 0, 
7 and 14 (after storage at 2-8°C) and 8, 9, 15 and 16 (after storage at 35°C). Linear regression graphs with 
95% confidence intervals were used to assess statistical differences in results. 
Visual changes were redispersible and neither formulation or device dropped below the required pH range of 
6 to 9.3 Laser diffraction results for both formulations and devices showed no globules greater than 0.34µm 
which is below the threshold of 5µm that defines stability.4 Microscopy results showed an unexpected decrease 
in globule size over time. 
The majority of results showed no statistical differences in stability over time whilst results which indicated 
differences showed only marginal changes. Both formulations and devices remained physically stable at 
storage and administration temperatures over the time period tested. Future work on chemical stability is 
recommended as only physical stability was assessed. Additionally, in the interest of patient safety testing with 
the correct mini-bag size must happen before mini-bags use is initiated. 
 Krohn K, Koletzko B. Parenteral lipid emulsions in paediatrics. Current opinion in clinical nutrition and metabolic care. 2006;9(3): 
319–23 
 Andalo, D. Third baby dies following TPN contamination. The Pharmaceutical Journal. 2014 July 12;293(7818) [Accessed 29 Sept 
2016] Available from: DOI:10.1211/PJ.2014.20065659 
 Driscoll DF. Pharmaceutical and Clinical Aspects of Lipid Injectable Emulsions. Journal of Parenteral and Enteral Nutrition. 
2016;41:125-134. [Accessed: 30 Nov 2016]. Available from: http://pen.sagepub.com/cgi/doi/10.1177/0148607116673187 
 Driscoll DF, Bhargava HN, Li L, Zaim RH, Babayan VK, Bistrian BR. Physicochemical stability of two types of intravenous lipid 
emulsion as Total Nutrient Admixtures. Journal of Parenteral and Enteral Nutrition. 2000;21(1): 15–22 
 
 
Are long-term parenteral nutrition patients receiving enough selenium? A 
retrospective database analysis 
Amy Powell, SR Dodington1 and R Price-Davies 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and 1St Mary’s Pharmaceutical Unit, Cardiff & Vale UHB, 20 Field Way, Cardiff, CF14 4HY Wales, UK 
Parenteral nutrition (PN) provides nutrients intravenously to patients who are unable to digest or absorb 
sufficient nutrition.1 Additrace® is the standard micronutrient preparation used in PN to provide the nine 
essential trace elements (TE).2 Patients on long-term (LT) PN have demonstrated nutritional abnormalities, 
particularly the TE selenium.3 The project aim was to investigate the selenium dosing requirements for LT PN 
patients in correlation to patients’ blood test (BT) results.  
Patients on the intestinal failure clinic list at Cardiff and Vale were identified and data was collected from their 
PN prescriptions and BT results from January 2015 until October 2016. Each BT was matched with a 
prescription the patient had been receiving for at least 3 months. Matched data was separated into four main 
categories according to the inclusion of Additrace® and/or extra selenium. Selenium BT results and prescribed 
doses of selenium were reviewed and analysed.  
As of each patients’ latest prescription, 74% of patients did not receive Additrace®. As of each patients’ latest 
selenium BT result, 23% were deficient. Upon further analysis, selenium BT results were deficient more 
frequently when Additrace® was included in the PN formulations than without. The dose of selenium when 
directly manipulated was almost twice the dose provided by Additrace® alone. However, the percentage of 
maximum dose of selenium prescribed was low in many cases. 
High numbers of LT PN patients are not being prescribed Additrace® although the preparation is marketed to 
provide basal TE requirements. BT results were more frequently in range when doses were directly 
manipulated, suggesting clinician prescribed dosing is more efficient. Low percentage of maximum dose of 
selenium prescribed raises the question why the dose is not being increased particularly to those deficient, as 
physical stability is not the limitation.  
 Alexandropoulou K, et al. Parenteral Nutrition Support Policy for Adults, 2012. [Accessed: 04/12/2016]. Available from: 
http://www.surreyandsussex.nhs.uk/wp-content/uploads/2013/04/PARENTERAL-NUTRITION-SUPPORT-POLICY-FOR-ADULT.pdf 
 Supplementary preparations, Additrace (Fresenius Kabi) (2016). [Accessed: 04/12/2016]. Available from: 
https://www.evidence.nhs.uk/formulary/bnf/current/9-nutrition-and-blood/93-intravenous-nutrition/supplementary-preparations  
 Fleming CR. Trace element metabolism in adults requiring total parenteral nutrition. American Journal of Clinical Nutrition. 1989 Mar 
1;49(3):573-9. 
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What are the attitudes of community pharmacists in Wales towards the provision of 
Welsh language resources? 
Lowri Haf Puw, LJ Doyle, ML Hughes, EM Jones and W Davies 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Language barriers can drastically affect a patient’s ability to communicate and engage in their own health, it’s 
therefore important that patients receive their care in their first language.1 In 2012 the Welsh Government 
launched the strategic framework ‘More than just words….’ to improve the provision of the Welsh language in 
health and social care settings in Wales.2 The Welsh Language Commissioner highlighted a lack of Welsh 
language resources in community pharmacies in her ‘My Language, My Health’ inquiry.3 Language barriers 
can be reduced through the use of bilingual resources, this has been demonstrated in previous studies 
concentrating on Hispanics in the USA.4 This study aims to investigate the attitudes of community pharmacists 
in Wales towards the provision of Welsh language resources. 
Semi-structured interviews with a convenience sample of both Welsh speaking and non-Welsh speaking 
community pharmacists were conducted. Interviews were tape-recorded, transcribed verbatim, coded 
manually and analysed thematically. 
Results from interviews (n=9) showed that there is currently a lack of Welsh language resources availabile in 
community pharmacy. Participants believed that Welsh language resources were important for the provision 
of the Welsh language to patients, especially in cases where the pharmacist did not speak Welsh. Participants 
believed that further developments in Welsh language resources were needed to further improve the provision 
to patients and ease future practice. 
Welsh language resources are an important tool to increase patient engagement and understanding of their 
own health. Further development is necessary to increase resource availability and accessibility in order to 
improve patient care and meet the needs of Welsh-speaking patients. 
1. Missel A. Welsh in the Health Service: The Scope, Nature and Adequacy of Welsh Language Provision in the National Health 
Service in Wales. 2000 [accessed 14 Jan 2017]. Available from: 
http://www.wales.nhs.uk/sites3/documents/415/WelshintheHealthService.pdf 
2. Welsh Government. Strategic Framework for Welsh Language Services in Health, Social Services and Social Care. Cardiff: Welsh 
Government;2012 [accessed 14 Jan 2017]. Available from:: http://www.wales.nhs.uk/sites3/Documents/415/WEB%20-
%2016184_Narrative_e_WEB.pdf  
3. Welsh Language Commissioner. My Language, My Health: The Welsh Language Commissioner’s Inquiry into the Welsh Language 
in Primary Care. Cardiff: The Welsh Language Commissioner; 2014 [accessed 14 Jan 2017]. Available from: 
http://www.comisiynyddygymraeg.cymru/English/Publications%20List/Health%20inquiry%20full%20report.pdf  
4. Sansgiry S, Chanda S and Shringarpure G. Impact of bilingual product information labels on Spanish-speaking adults’ ability to 
comprehend OTC information. Research in Social and Administrative Pharmacy. 2007;3:410-425.  
 
 
Investigating the antibacterial effect of red clover (Trifolium pratense) against 
methicillin-resistant Staphylococcus aureus 
Stephanie Rees, JA Blaxland and L Baillie 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The aim of this project was to determine whether red clover (Trifolium pratense) has antibacterial activity 
against methicillin-resistant Staphylococcus aureus (MRSA) and then isolate and identify the compounds 
responsible. MRSA poses a serious threat to health and it is estimated that people infected with MRSA are 
64% more likely to die as a result than their counterparts with a non-resistant Staphylococcus aureus infection. 
1 Although research into red clover as an antibacterial against MRSA is currently limited, the utilisation of plants 
and other natural products in therapeutics has been successfully documented throughout history.2  
Red clover flowers were tested following solvent extraction with methanol and hexane, respectively. Two 
commercial forms of red clover were also tested. An agar disc diffusion assay3 was employed to screen each 
preparation for inhibitory activity against MRSA. Separation and identification of antibacterial compounds was 
initiated using thin layer chromatography (TLC) and a bacterial overlay assay.4 Rf values of compounds 
responsible for antibacterial activity were noted and the antibacterial analytes identified then underwent LC-
MS analysis to determine their molecular masses.  
All preparations demonstrated antibacterial activity against MRSA, with the exception of commercial red clover 
capsules. The methanol extract of the flowers produced significantly (p<0.05) greater zones of inhibition in the 
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agar disc diffusion assay than the hexane extract, indicating that polar compounds are responsible for the 
majority of the antibacterial activity observed. Results of the LC-MS analysis indicated the presence of five 
principal peaks. Identification of the compounds responsible proved difficult within the timescale of this project. 
Red clover extracts demonstrated inhibitory activity against MRSA and thus red clover has promise as a 
potential antibacterial against it. Additional studies need to be undertaken to identify the compounds 
responsible for the antibacterial activity and to explore the activity further.  
 World Health Organization. Antimicrobial resistance. Geneva: World Health Organization; 2016. [accessed 29 Dec 2016]. Available 
from: http://www.who.int/mediacentre/factsheets/fs194/en/ 
 Farnsworth NR, Akerele O, Bingel AS, Soejarto DD, Guo Z. Medicinal plants in therapy. Bull World Health Organ. 1985; 63(6): 965-
981. 
 Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 
1966; 45(4): 493-496. 
 Blaxland, JA. The antibacterial activity of Humulus lupulus against mycobacteria [PhD Thesis]. Cardiff: Cardiff University; 2015. 
 
 
What impact did skills based training have on the pharmacy professionals’ self-
perceived behaviours in practice? 
Victoria Roden and G Stafford  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Pharmacy professionals use leadership skills on a daily basis in practice. This does not just apply to mangers 
or pharmacists, but to every member of the team. Effective leadership leads to better service. ‘Effective 
governance, leadership and accountability in keeping with the size and complexity of the health service are 
essential for the sustainable delivery of safe, effective person-centred care.’1 To assist with the development 
of leadership within pharmacy, the Wales Centre for Pharmacy Professional Education run a six-month 
Introduction to Leadership programme, where participants explore their strengths and weaknesses and aim to 
develop their leadership skills. This project aims to determine whether the leadership programme had an effect 
on the participants’ behaviour in practice.  
Data was collected previously and was retrospectively analysed. Inductive thematic analysis was used to 
analyse participant reflections and the online questionnaire and basic quantitative methods were used to 
analyse the self-ratings. Ethics approval was obtained.  
86% of participants improved across the self-ratings after the programme and the online questionnaire and 
reflections on programme generated very positive outcomes, where participants gave various examples of 
how they have developed as professionals. Themes were identified including increased self-awareness, 
increased self-confidence, better delegation and better management skills.  
The objectives of the project were met as participants showed a clear development of skills and gave examples 
of changes in their interaction with patients and colleagues after the programme. The findings can facilitate the 
development of future skills based training programmes and recommendations, such as feedback from peers 
on improvement of skills being included in programme results.  
 NHS Wales. Health and Care standards, April 2015, p.8 (Accessed 4 November 2016) Available from: 
http://www.wales.nhs.uk/sitesplus/documents/1064/24729_Health%20Standards%20Framework_2015_E1.pdf 
 
Factors affecting copper and zinc precipitation in parenteral nutrition admixtures 
Ayoub Sabrane-Conroy, SE Emery and AG Cosslett 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Parenteral nutrition (PN) is the administration of nutrients, electrolytes and fluids, intravenously to a patient. 
Trace elements (TE), are also required in PN formulations to avoid associated deficiencies.1 Precipitation has 
been observed in PN and is a significant clinical and stability risk. TE’s are being noted as being involved in 
precipitation, particularly copper. The aims of this study were to investigate what factors affected copper and 
zinc precipitation in PN formulations. 
Eight separate 100ml batches, were aseptically prepared over the course of the experiment. Each batch had 
an overall variation regarding the TE present. Each batch was divided into 8 separate sub-batches which had 
variations in their components. These sub-batches contained a varying amino acid, glucose and TE component 
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in alternating ratios and combinations. These batches were tested for precipitation every 24 hours until 72 
hours had passed. The tests comprised of three methods; visual inspection using fibre optic lights, turbidity 
with a Hach Turbidmeter and pH with an Orion pH meter. 
The main results of this study of interest were batches 5, 6 and 7. Batches 5 and 6 (with increased copper and 
zinc respectively) batches showed signs of precipitation observable by visual inspection and also showed 
corresponding large increases in turbidity. Also batch 7 sub-batches displayed a very clear and selective 
pattern of precipitation observable by both visual inspection and turbidity with the increases in copper only 
batches clearly highlighting an interaction between cysteine i.e. Vaminolact® and copper. 
Based on these results the hypothesis that the presence of Vaminolact®, compared to Aminoven 25®, would 
result in greater precipitation in PN was correct. These results are in accordance with previous studies 
indicating that cysteine-containing amino acid solutions, i.e. Vaminolact®, complexes with trace elements 
resulting in precipitation, and in particular copper.2,3 
 Shenkin A. Adult Micronutrient requirements. In: Payne-James J, Grimble G, Silk D. Artificial nutrition support in clinical practice. 
Greenwich Medical Media; 2001. 
 Foinard A, Perez M, Barthélémy C, Lannoy D, Flamein F, Storme L, et al. In vitro assessment of interaction between amino acids 
and copper in neonatal parenteral nutrition. Journal of Parenteral and Enteral Nutrition. 2015 Feb 23: 40(6): 827-34. 
 Thibault M. Possible Incompatibility between amino acids and copper in solutions for pediatric parenteral nutrition. The Canadian 
journal of hospital pharmacy. 2014 Mar;67(2): 160. 
 
Perception of Parkinson’s patients on the utility of iPad based apps to collect data 
in a Parkinson’s clinic 
Nia Samuel, ML Hughes and EL Lane 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
An iPad application has been developed for use in Parkinson’s clinics to provide clinicians with additional 
information about their patients. Previous pilot research found that the application is easy to navigate and 
complete within clinic timeframes and age appears to be no barrier to using the device.1 This project aims to 
gather the opinions of people with Parkinson’s and their carers regarding the application in order to refine and 
develop it further.  
Qualitative methods were deemed to be the most appropriate for this study.2 Six focus groups were conducted 
in Parkinson’s support groups across South Wales to elicit views of patients and carers about the use of the 
iPad application at Parkinson’s clinics and identify potential developments. The focus groups were audio-
recorded and transcribed. The qualitative data generated was analysed thematically by coding and linking 
excerpts to establish meaning. Ethics approval was obtained.  
Dexterity and cognitive impairment were found to be potential issues for the patient group. Some were 
concerned about confidentiality of electronically-held data and the suitability of the waiting room environment 
to complete the application. The increased value of the application compared to paper was noted by 
participants and formatting alterations were suggested to improve its accessibility. The content of the 
application was well received but additional sections and remote access were suggested as possible features 
for development. Comparison to other studies in the field was not always possible due to a small literature 
base. 
The project found generally positive views of the application but also highlighted several potential issues of 
practicality, especially for use in this particular patient group. Clarification of the proposed alterations is needed 
to ensure that the application is optimised for clinical use. Views of others who will be involved in the 
implementation of the application such as clinic staff should also be consulted. 
1. Mohamed, B. et al. 2016. iPad-based preassessment questionnaires are feasible in a Parkinson’s service (from the meeting 
abstracts of the 20th international congress of Parkinson’s disease and movement disorders. Berlin; Germany, 19-23 June, 2016). 
Movement Disorders 31 (suppl. 2) Available at: http://www.mdsabstracts.org/abstract/ipad-based-preassessment-questionnaires-
are-feasible-in-a-parkinsons-service [Accessed: 27 November 2016]  
2. Smith, F.J. 2002. Research Methods in Pharmacy Practice. London: Pharmaceutical Press. 
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Statins and breast cancer 
Fiona Smith, C Smith and SE Hiscox 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Statins, typically indicated for hypercholestroleamia, may exert a novel anti-cancer effect in breast cancer 1 
and clinical studies appear to support this with a retrospective study on 40,421 USA female veterans 
deminstrating a 51% risk reduction of breast cancer in women taking statins compared to those who didn't.2 
One potential mechanisms for this effect is down regulation of the MAPK/ERK pathway.3 The aim of this project 
was to investigate whether Pravastatin can suppress growth of different types of breast cancer and how this 
may happen at a molecular level.  
Five breast cancer cell models were used that collectively reflected the main clinical subtypes: MCF7 (ER+, 
‘luminal A’), BT474 (ER+/Her2+, ‘luminal B’), SKBR4 (ER-/Her2+, ‘Her2’)) and two cell lines modelling triple 
negative breast cancer (ER-/Her2-): MDAMB231 and MDAMB468. Initial Pravastatic dose response 
experiemnets using MTT assays were conducted to identify Pravastatin-sensitive cells for subsequent analysis 
(Ki67 prolioferation marker expression and Western blotting). Where possible, statistical analysis was carried 
out using IBM SPSS Version 20.  
MTT assays revealed that Pravastatin induced a significant decline in cell proliferation in MDA231 and 
MDA468 cells with the greatest effect in MDA231 cells; this was was also reflected in the Ki67 staining. 
Western Blotting showed a decrease in pEGFR (Y845), tEGFR, pSTAT3 (Y705), pSRC (Y416) and tAkt but 
an increase in pMAPK (S202/T204) and tMAPK following three-day treatment with the statin. Little change 
was seen in EGFR, tEGFR, STAT3 snd tAkt.  
In conclusion, our data shows that Parvastatin suppresses the proliferative capacity of triple negative breast 
cancer, a particularly aggressive form of breast cancer, through a mechanism that may involve disruption of 
the MAPK/ERK signalling pathway. These data may thus suggest that repurposing of statins might represent 
a potential approach to the treatment of an aggressive form of breast cancer. 
 Joint Formulary Committee. British National Formulary. 72 ed. London: BMJ Group and Pharmaceutical Press; 2016.  
 Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sørensen HT, Lash TL. Statin prescriptions and breast 
cancer recurrence risk: A Danish nationwide prospective cohort study. Journal of the National Cancer Institute. 2011;8(19):1461-8 
[accessed 17 December 2016]. Available from: http://jnci.oxfordjournals.org/content/early/2011/08/01/jnci.djr291.full. 
 Wang T, Seah S, Loh X, Chan C, Hartman M, Goh B, Lee S. Simvastatin-induced breast cancer cell death and deactivation of 
PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. Oncotarget. 2015;7(3):2532-44 
[accessed 18 December 2016]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823053/.  
 
 
The effect of triboelectric charging on drug release and deposition into the lung 
when an inhalation formulation is released from hard shell capsules using a dry 
powder inhaler 
Leah Stroud-Drinkwater and JC Birchall 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Triboelectric charging occurs when two materials are rubbed together and can result in unsatisfactory 
aerodynamic performance properties of inhaled powders 1. This issue arises in transport, manufacturing and 
potentially during patient use.2 The aim of this study is to investigate the effect of tribocharging on the lung 
deposition of inhalable formulations delivered via a dry power inhaler (DPI) using two different capsule 
materials, hydroxypropyl methyl cellulose (HPMC) and gelatin. 
A binary mixing method was used to create a drug-carrier formulation using an inhalation grade lactose and 
the micronised corticosteroid, budesonide. The two capsule materials were filled with either 20mg ± 5% lactose 
alone or the budesonide/lactose blended formulation. Half of the capsules were electrically charged using a 
tablet friability machine.2 Capsules were loaded into an RS01 DPI, punctured and subjected to a flow rate of 
60L/min for 4 seconds.3 Powder collection utilised a Next Generation Impactor (NGI) for budesonide 
formulation samples, or Dosage Unit Sampling Apparatus for lactose samples. The NGI plates were washed 
with 2 x 5mL of methanol and anaylsed using a UV-VIS spectrometer set at a 243nm wavelength to determine 
important aerosol characteristics. 
Capsules filled with lactose showed tribocharging reduced the amount of powder released from gelatin 
capsules, although not from HPMC. The capsules filled with budesonide formulation showed no significant 
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differences in Emited Dose. However, the Fine Particle Dose (FPD) and Fine Particle Fraction (FPF) results 
show HPMC capsules emit more fine particles than gelatin (p=0.0028).  
HPMC capsules, whether they have undergone tribocharging or not, generate a higher FPD and FPF than 
gelatin capsules. This is more desirable for maximum pulmonary drug deposition.4 In conclusion, the powder 
contained within gelatin capsules is more adversely affected by tribocharing than the powder contained in 
HPMC capsules, therefore HPMC capsules would be the most suitable choice for DPI drug delivery.  
 Watanabe H, Ghadiri M, Matsuyama T, Long Ding Y, Pitt KG, Maruyama H et al. Triboelectrification of pharmaceutical powders by 
particle impact. International Journal of Pharmaceutics. 2007; 334(1-2):149-155. 
 Theilmann F, Nakao T, Usui T, Kokubo T, Diez F, Heng JY et al. Electrostatic charging behavior of gelatin and HPMC hard 
capsules. AAPS conference Poster. 2006. 
 British Pharmacopoeia Commission. British Pharmacopoeia 2016. London: TSO; 2016. 
 Mitchell JP, Nagel MW. Particle size analysis of aerosols from medicinal inhalers. KONA Powder and Particle Journal. 2004; 22:32-
65. 
 
 
The role of the cluster pharmacist in pharmacovigilance 
Tilly Stubbs, V Matanda, A Matthews and ML Hughes 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Adverse Drug Reactions (ADRs) place a significant burden on the NHS costing around £466 million annually. 
Over 70% of ADRs are considered preventable.1 ADRs are reported to the MHRA via the Yellow Card Scheme 
which suffers from underreporting as only 6% of ADRs are reported.2 With over 40 primary care clusters within 
Wales currently employing a pharmacist3, cluster pharmacists are in a prime position to identify and report 
ADRs. This project aims to explore the perceptions and experiences of cluster pharmacsts of the Yellow Card 
Scheme and the barriers to ADR reporting.  
After obtaining ethical and Research and Development (R&D) approval, qualitative methods were used to 
explore the views of the cluster pharmacists in order to obtain rich, detailed data. A combination of open and 
closed questions were used during semi-structured interviews. The interviews were audio-recorded (with 
consent) and transcribed ad verbatim. They were then anaslysed using a combination of deductive and 
inductive thematic analysis.  
A total of nine participants were interviewed: six face-to-face and three via the telephone. The themes were: 
the cluster pharmacist role, choosing to report an ADR, submitting a yellow card report, cluster pharmacists' 
views on the Yellow Card Scheme, the importance of education in pharmacovigilance, uncertainty over 
reporting an ADR, time as a hindrance to pharmacovigilance and improving communication to increase ADR 
reporting.  
A lack of time and uncertainty over reporting ADRs have been identified as the main barriers to ADR reporting. 
Suggestions have been made with a view to overcoming these barriers and encouraging yellow card reporting 
and ultimately increasing patient safety. Suggestions included enabling ADR reporting directly from within a 
patient’s record in GP practices and further educational interventions. The findings will be useful in developing 
both the Yellow Card Scheme and the cluster pharmacist role.  
1. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to 
hospital: prospective analysis of 18 820 patients. BMJ. 2004 Jul;329(7456):15-19.  
2. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. 
Drug Saf. 2009;32(1):19-31.  
3. GP-One. Clinical pharmacists in GP practices. Wales; 2016 [accessed 01 Nov 2016]. Available from: 
www.wales.nhs.uk/news/40188  
 
 
Can microwaves be to increase the detection of viral RNA, as a step towards 
developing a rapid norovirus detector? 
Mark Sweeney, LT Joshi and L Baillie 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Norovirus, known as the winter vomiting bug, is the most common cause of gastroenteritis in humans. Acute 
gastroenteritis (diarrhoea and vomiting) bears the second greatest burden of any infectious disease globally. 
It is increasingly a problem with an ageing population and a larger number of patients in healthcare settings.1 
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There is no treatment or vaccine for norovirus, so rapid detection is key in reducing the spread and burden of 
disease caused by the virus. Microwave technology has been shown to be effective in increasing the amount 
of nucleic acid available for detection from Clostridium difficile, Bacillus anthracis and MRSA.2,3 It is 
hypothesised that this microwave technology can be applied to increase the amount of genetic material 
released from MS2, a norovirus substitute, as a step in developing a rapid, handheld norovirus detector. 
Microwaves can be pulsed at different percentage powers, called duty cycles (DC’s). These microwaves are 
thought to disrupt membrane structures, and could be used to increase release contents from a sample. A key 
step in the development of this detector is determining the most effective duty cycle for the release of genetic 
material.  
MS2 was cultured in Escherichia coli host, before being exposed to microwaves of varying duty cycles. 
Microwaved samples and a non-microwaved control were then quantified using fluorometry, a real time 
electrochemical Vantix assay and then examined under Scanning Electron Microscopy (SEM), to determine 
the RNA release after microwave treatment. Pure MS2 RNA was also exposed to microwaves to determine if 
microwave treatment effects RNA.  
An increase in MS2 RNA recovery was seen at all duty cycles, compared to no microwave treatment. 10% 
duty cycle was determined to be the most effective for releasing RNA. A statistically significant reduction in 
particle size was seen under SEM after microwave treatment, suggesting that microwave treatment was 
responsible for a reduction in particle size.  
This work has the potential to be clinically significant. Rapid detection is key in reducing the spread of and 
burden of disease caused by norovirus. This technology should be tested in faecal and vomit samples, as 
these are the most common samples for testing. Once verified, tests should be completed using norovirus, to 
confirm that this technology is clinically applicable.  
1. de Graaf M, van Beek J, Koopmans MPG. Human norovirus transmission and evolution in a changing world. Nat Rev Microbiol. 2016 
Jul;14(7):421–33. 
2. Aslan K, Zhang Y, Hibbs S, Baillie L, Previte MJR, Geddes CD. Microwave-accelerated metal-enhanced fluorescence: application to 
detection of genomic and exosporium anthrax DNA in <30 seconds. Analyst. 2007 Nov;132(11):1130–8.  
3. Joshi LT, Mali BL, Geddes CD, Baillie L. Extraction and sensitive detection of toxins A and B from the human pathogen clostridium 
difficile in 40 seconds using microwave-accelerated metal-enhanced fluorescence. PLoS ONE. 2014 [cited 2016 Dec 4];9(8). Available 
from: http://dx.doi.org/10.1371/journal.pone.0104334 
 
 
The development of a questionnaire to measure patient views on the redistribution 
of patient returned medication 
Jonathan A Tagoe1, D McRae2, DH James3 and R Price-Davies1 
1Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, 2Pharmacy Department, Prince Charles Hospital, Cwm Taf Medicines Management Directorate, 
Merthyr Tydfil, and 3Cardiff School of Health Sciences, Cardiff Metropolitan University, Wales, UK. 
The Redistribution of Patient Returned Medication (ROPRM) is defined as the idea of dispensing medicines 
that have been previously returned by the patient and undergone the appropriate safety check requirements. 
Recent estimates state that across the UK, £400 million is being wasted on drug wastage.1 Due to the current 
state of the NHS a funding gap of £30 billion must be closed by 20212 thus the ROPRM may be a good 
opportunity for making the NHS more sustainable. The aim of this project is to build and pilot a questionnaire 
to measure patient views on the ROPRM.  
A thematic analysis was conducted from patient statements extracted from transcribed semi-structured 
interviews and public article discussions. From the data collected in the thematic analysis a questionnaire was 
then produced. The questionnaire mainly consisted of closed-questions and 5-point Likert scales in order to 
aid in improved response rates and allow the data to be easily quantitatively analyzed.3 
From the thematic analysis 11 themes were identified and segregated within a table with their corresponding 
statements. The themes identified were: Waste, Packaging, Tampering, Storage, Form, Cross-Contamination, 
Cost, Consent, Opportunity for Fraud, Safety Check Requirements, and Educating the Public. Several drafts 
of the questionnaire were made and a final draft was also produced after feedback given from patients on their 
interpretation of the questionnaire had been received. Maximum variation sampling was used in piloting to 
allow the data produced from it to be more representative of the wider population. 
This questionnaire is to be posted on Health Wise Wales in Spring 2017 for quantitative analysis of patient 
views. From patient comments, all patients seemed to agree that the cost of drug wastage is a tremendous 
waste however ROPRM may present too many barriers for it to be widely accepted as a potential solution.  
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 Triggle N. Drug wastage is costing the NHS millions - BBC News [Internet]. BBC News. 2011 [cited 15 December 2016]. Available 
from: http://www.bbc.co.uk/news/health-13042794Barret S. 2013. 
 Barrett, S. 2013. Prescribing Mrs Smith’s medication to Mr Jones: The Views of Patients and Professionals on the Reuse of 
Returned Medicines [Lecture]. Northumbria NHS Foundation Trust. 
 Thwaites Bee D, Murdoch-Eaton D. Questionnaire design: the good, the bad and the pitfalls. Archives of disease in childhood - 
Education & practice edition. 2016;101(4):210-212. 
 
 
Discovering the cellular location of the zinc transporter ZIP7 
Declan Tan, S Ziliotto, E Boothby and KM Taylor 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The zinc transporter ZIP7 (SLC39A7) is a member of the LIV-1 subfamily of zinc transporters and is currently 
only known to be on the endoplasmic reticulum (ER). ZIP7 mediated zinc release and ZIP7 overexpression 
has been associated with widespread phosphatase inhibition that is associated with aggressive forms of breast 
cancer.1 Fluorescent dyes of ZIP7 show perinuclear staining which is unusual for an ER only protein. Although 
zinc is known to be found in abundance in the nucleus2,currently no zinc transporters are known to be located 
in the inner nuclear membrane that is able to contribute to the nuclear pool of zinc. In this study, we aim to 
investigate if ZIP7 is able to access the inner nuclear membrane of MCF-7 cells.  
Using fluorescent microscopy, we imaged ZIP7 alongside inner nuclear membrane proteins to discover if ZIP7 
is localised in the inner nuclear membrane of MCF-7 cells.  
We found evidence of association of ZIP7 and three proteins associated with the inner nuclear membrane: 
Lamin A/C, Lamin B and the Lamin B receptor.  
These data suggests that ZIP7 has access to the inner nuclear membrane, though further studies are required 
to confirm it. The confirmation of the location of ZIP7 in the inner nuclear membrane will have implications for 
future research seeking to discover novel therapeutic strategies relevant to ZIP7's role in breast cancer.  
 Taylor K, Gee J, Kille P. Zinc and Cancer. Zinc in Human Health. 2011;76(1):283-304.  
 MacDonald R. The Role of Zinc in Growth and Cell Proliferation. J Nutr. 2000;130(5):1500S-1508S 
 
 
Evaluating the effect of moisture content on puncturing performance of gelatin 
capsules and inhalation grade hydroxypropyl methycellulose (HPMC) capsules used 
in dry powder inhalers 
Swee Mei Tan and BE Jones 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Dry powder inhalers (DPIs) are designed to puncture hard shell capsule to release the drug. 1 Gelatin capsules 
have been traditionally used in marketed DPI for many years2 but it was reported that there have been an 
issues with brittleness of gelatin capsules stored in low humidity. HPMC is an alternative material that has 
better functional properties than gelatin when used in DPI.3,4 The aim of this study is to study the effect on 
puncture force of storing HPMC and gelatin capsules in a high humidity and comparing with those conditioned 
at a low and normal humidity. 
A puncture testing method was used to generate force displacement curves for both HPMC capsules (Quali-
V®-I) and gelatin capsules (Quali-G), which were conditioned in desiccators over saturated solutions of four 
different salts to modify the moisture content of the capsules. A single pin from a DPI was mounted in a material 
testing machine. HPMC and gelatin capsule samples were placed in a special capsule bush with the cap 
uppermost directly under the pin. Puncture tests were carried out and each puncture event was recorded as 
force displacement curve.  
The results showed that the higher the moisture content, the lower the force required to puncture both gelatin 
and HPMC capsules. Gelatin capsules required higher puncture forces than HPMC capsules at four different 
humidities. Different capsule materials produced their own signature puncture profiles. Methodology which 
employed from previous study was proven to be robust as reproducible puncture profiles were produced in 
this study.4 
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In conclusion, moisture content of capsules at adverse storage conditions is the key influence of capsules 
physical properties (either too brittle or too soft). Puncturing performance of HPMC capsules is more stable 
over a range of storage conditions compared to gelatin capsules that are more affected by changes in their 
moisture content. 
 Jones BE. Quali-V®-I: a new key for dry powder inhalers. Drug Deliv Technol. 2003;3(6):52-7. 
 Hoppentocht M, Hagedoorn P, Frijlink HW, Deboer AH. Technological and practical challenges of dry powder inhalers and 
formulations. Adv Drug Deliv Rev. 2014;75:18-31.  
 Nagata S. Advantages to HPMC capsules: a new generation's hard capsule. Int J Pharm. 2002;2(2):34-9  
 Torrisi BM, Birchall JC, Jones BE, Díez F, Coulman SA. The development of a sensitive methodology to characterise hard shell 
capsule puncture by dry powder inhaler pins. Int J Pharm. 2013;456(2):545-52. 
 
 
Assessment of inhaler technique and implementation of an extended asthma care 
plan in a community pharmacy setting 
Lewis Tatnell, TM Chilvers, T Hussain, ME Jones, JP Lee, L McCoubrey, E Ntanganika and R Price-Davies 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
In the UK, respiratory diseases such as asthma are extremely common and increasing1: one in eleven children 
and 1 in 12 adults is asthmatic.2 Inhaled therapies are the most popular treatments for asthma sufferers. This 
study focuses on the impact of several factors, (age, gender, inhaler technique tuition, inhaler type, and 
smoking status) which are all claimed to influence inhaler technique and asthma control.  
In an interviewer led consultation study, participants were asked to demonstrate their inhaler technique, using 
a Vitalograph AIM™ machine3, and also underwent asthma control and spirometry tests. 
Participants (145) were recruited, and demonstrated a total of 201 inhaler techniques, (12 metered dose inhaler 
(MDI), 40 MDI plus spacer and 53 dry powder inhaler (DPI)). Results indicated that age was not a controlling 
factor for MDI inhaler technique. However for DPI, age appeared to have a marginal influence; younger age 
groups (<50 years) exhibited better technique compared to older participants (>50 years). Male participants 
expressed a marginally better technique compared to females for only MDIs. No difference was apparent when 
either gender used a DPI or a MDI plus spacer. No significant trend was observed for inhaler technique 
irrespective of which health care professional (nurse or GP) performed the tuition. Regarding the influence of 
inhaler type on inhaler technique, this study demonstrated that the use of DPIs outperformed both MDI and 
MDI plus spacer. However, the inclusion of a spacer to MDI significantly improved participant’s inhaler 
technique. The influence of smoking status on asthma control indicated that the ACT score of non-smokers 
and ex-smoker were equivalent, whilst that for current smokers was significantly lower.  
The key findings from this study is that inhaler type and smoking status are the most important influencing 
factors that determine good inhaler technique and asthma control.  
 Seaton, D. Godden, K. Brown; Increase in asthma: a more toxic environment or a more susceptible population?; Thorax 
1994;49:171-174  
 Asthma UK; Asthma Facts and Statistics; London; 2015; [Accessed 01/11/2016]. Available at: 
https://www.asthma.org.uk/about/media/facts-and-statistics/ 
 Vitalograph; AIMs Machine; UK; 2016. [Accessed:11/01/17] Available at: https://vitalograph.co.uk/product/162430/aim  
 
 
The best approach for WCPPE to deliver live CPD events in rural Wales 
Megan Treharne and K Hodgson 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and Wales Centre for Professional Pharmacy Education, 8 North Road, Cardiff, CF10 3DY, Wales, UK 
Continuing Professional Development (CPD) ensures the ongoing competency of pharmacy professionals.1 
WCPPE (the Wales Centre for Pharmacy Professional Education) offer CPD events to pharmacists, pharmacy 
technicians, and pre-registration pharmacists.2 ‘Live’ events include events like expert speaker presentations 
and service delivery events, as well as webinars, live streaming, and video conferences. In rural Wales (here 
defined as the Mid and West), attendance at these has been low.3 My research aim was to increase 
engagement of pharmacy professionals with them. Objectives involved discovery of preferences using a 
previously drafted questionnaire. 
After obtaining ethical approval and piloting, the questionnaire was distributed to 575 pharmacists, pharmacy 
technicians and pre-registration pharmacists registered with WCPPE as living or practising in these areas. A 
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reminder email was distributed one week prior to the deadline. Non probability and convenience sampling was 
used and responses were collated using Microsoft Excel. SPSS was used to compare results by profession 
and health board. 
The questionnaire achieved a 29% response rate. Analysis of the data and wider literature regarding the health 
system in Wales resulted in suggestions for WCPPE to: Pilot shorter and earlier evening events, host events 
in Llanelli and Builth Wells; Better communicate on how to access webinars, live streaming and video 
conferences (as well as the differences between them); Offer recordings for post-event and home access; 
Improve the design and navigation of the WCPPE website; Promote multidisciplinary, interprofessional and 
professionalism events through working with the government and local health boards. 
WCPPE need to implement respondent preferences around event frequency duration, location, topic and 
delivery method to improve engagement of their pharmacy professionals. 
1. GPhC. Continuing Professional Development. London: GPhC; 2017 [accessed 17/01/16]. Available from: 
2. https://www.pharmacyregulation.org/education/continuing-professional-development 
3. WCCPE website. About Us. Cardiff: WCPPE; 2016. [accessed 5/12/16] Available from: http://www.wcppe.org.uk/about-us 
4. Alexander C. To investigate the barriers to Continuous Professional Development for pharmacy staff living and/or working in rural 
locations in Wales. Cardiff: WCPPE; 2014 
 
 
Oestrogen receptor downstream signalling differences between males and females 
with Alzheimer’s Disease 
Jermaine Twum-Danso, EJ Kidd and JS Bice 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Apart from their influence in the reproductive system, recent studies document the neuroprotective effects of 
oestrogens from memory loss, cognitive decline and neurodegenerative diseases such as Alzheimer’s disease 
(AD).1 AD is characterised by the formation of insoluble amyloid- β peptide (Aβ) and neurofibrillary tangles 
(NFTs) composed phosphorylated tau.2 Studies propose a link between the decline of oestrogen levels in post-
menopausal women and the prevalence of AD as studies show that two-thirds of AD patients are women.3 
The objective of this study was to explore the activity of protein-kinases involved in downstream oestrogen 
signalling in order to determine potential differences in oestrogen signalling between males and females with 
AD. 
Western blotting was carried out to analyse the change in phosphorylation status of mitogen-activated protein 
kinase (MAPK), Protein Kinase B (AKT) and Glycogen synthase kinase 3β (GSK3β); proteins involved in 
oestrogen downstream signalling. Proteins were transferred onto a nitrocellulose membrane and detected 
using chemiluminescence. Light intensity from the chemiluminescence, relative to the amount of protein 
present in each sample, was quantified using image J software. 
Data showed greater phosphorylation of MAPK, AKT and GSK3β in male AD tissues relative to female AD 
tissues. Additionally data showed greater phosphorylation of MAPK, AKT and GSK3β in male AD tissues 
relative to male Non-AD tissues. Results on the other hand showed less phosphorylation of MAPK, AKT and 
GSK3β in female AD tissues relative to female Non-AD tissues. 
Themes within the data suggest potential differences in oestrogen signalling between males and females. It is 
however premature to make any definitive claims of differences in oestrogen signalling between genders. As 
a result, further experiments must be performed to fully explore and understand oestrogen signalling in AD 
and how gender influences it’s signalling. 
 Haines CJ. Oestrogen and Alzheimer's disease. Current Obstetrics & Gynaecology. 1998;8:49-53 
 Alzheimer's Society. What is Alzheimer's disease? 2009 
https://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=100. 
 Grimm A, Lim YA, Mensah-Nyagan AG, Götz J, Eckert A. Alzheimer's Disease, Oestrogen and Mitochondria: an Ambiguous 
Relationship. Mol Neurobiol. 2012;46(1):151-60 
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Investigating the sporicidal activity of blue light (401 nm) against clinical isolates of 
Clostridium difficile 
Dillan Vaghela, D Malyshev and L Baillie 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Clostridium difficile infection is the primary cause of antibiotic associated diarrhoea in the UK with each case 
costing the NHS an additional £4,000-£10,000.1,2 It has recently been reported that blue light can inactivate 
C.difficile spores3. The aims of this study were to determine the sensitivity of spores of two different strains of 
C.difficile (CD630 and R20291) which have been dried onto stainless steel discs to inactivation by blue light 
and to determine if the presence of organic material modelled by bovine serum albumin (BSA) influenced the 
sensitivity of the spores to the sporicidal activity of blue light. 
Testing involved seeding spores onto a stainless steel disc then exposing them to blue light. As a control, 
spores were exposed to light and dark. At the time points 30, 60, 90, 120, 240 minutes a disc was attached to 
a 100g weight and pressed down onto a BHIS agar plate. These plates were incubated for 24 hours 
anaerobically and colony forming units present were counted. This was conducted for both strains both in the 
presence and absence of BSA. 
A less than 1-log10 reduction of spores was observed after 240 minutes of blue light exposure for both strains 
in the presence and absence of BSA. All results were not statistically different to the controls except for R20291 
in the absence of BSA. A comparison of the two strains to blue light inactivation revealed a lack of difference. 
A comparison of the sensitivity of each strain to blue light in the presence and absence of BSA revealed that 
the presence of BSA inhibited spore inactivation. 
These results suggest that this technology in its current configuration is ineffective against C.difficile spores. 
Further research is warranted in exploring the sporicidal activity of alternative wavelengths of blue light and 
optimisation of this technology. 
 St Georges Healthcare NHS Trust. Protocol for the Prevention and Management of Clostridium difficile. London. Selma Mehdi. 
(2012). [accessed 11 December 2016] Available from:https://www.stgeorges.nhs.uk/wp-
content/uploads/2013/09/Clin_2_0_AppD_Prot14.pdf  
 Joshi LT, Phillips DS, Williams CF, Alyousef A, Baillie L. Contribution of Spores to the Ability of Clostridium difficile To Adhere to 
Surfaces. (2012) Appl Environ Microbiol 78(21):7671-79  
 Moorhead S, Maclean M, Coia JE, MacGregor SJ, Anderson JG. (2016). Synergistic efficacy of 405nm light and chlorinated 
disinfectants for the enhanced decontamination of Clostridium difficile spores. Anaerobe, 37, 72-77.  
 
 
Invertebrate haemolymph as an untapped source of natural bioactive antimicrobial 
peptides to combat antimicrobial resistant (AMR) bacteria 
Olivia Wan, L Baillie and LT Joshi 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Antimicrobial resistance occurs when microorganisms are no longer susceptible to antimicrobials. It is 
estimated that by 2050, antimicrobial resistance could cost $100 trillion globally and, deaths attributable to 
resistance could reach 10 million per year.1 Therefore it is crucial to develop alternative antimicrobial 
treatments to prevent a global relapse into a pre-antibiotic era. In response to an immune challenge the 
Manduca sexta caterpillar releases antimicrobial peptides (AMPs) into its haemolymph (invertebrate blood 
stream).2 Previous research has involved study of specific peptides3 whereas this study investigated the whole 
haemolymph extract upon challenge with a range of microorganisms. In this study we sought to determine if 
exposure of the caterpillar to clinically relevant organisms would stimulate the production of peptides with 
activity against the organisms themselves; Clostridium difficile, Bacillus anthracis SdT and Sterne, Klebsiella 
pneumoniae and Escherichia coli.  
Groups of caterpillars were individually challenged with the above wild-type strains, and 9 naïve larvae served 
as the control. Their haemolymph was extracted 21 hours post-challenge and cross-tested against the panel 
of above bacteria in well diffusion assays (n=3). [4] A broth-microdilution assay of the active haemolymph 
against the affected strain (5 concentrations) was performed and absorbance recorded over 19 hours.4  
Activity was not present in all diffusion assays with one exception; AMR resistant K. pneumoniae-induced 
haemolymph produced 2.3mm zones of inhibition (n=6) against E. coli. A reduction in E. coli growth (0 to 8 
hours) was observed from results of the broth-microdilution assay. Furthermore, the growth reduction was 
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sustained at different cell concentrations, suggesting that haemolymph activity was not proportionally affected 
by the 10-fold increases in E.coli cells.  
These results suggest that the haemolymph exhibits a bacteriostatic effect on E. coli and provides a basis for 
future investigations. The next step would be to isolate the bioactive peptide, and to determine the extent of 
the activity.  
 Welcome Trust and HM Government. Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: Final report 
and recommendations; 2016 [accessed 6 Dec 2016]. Available from: https://amr-
review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf  
 Mylonakis E, Podsiadlowski L, Muhammed M, Vilcinskas A. Diversity, evolution and medical applications of insect antimicrobial 
peptides. Philos Trans R Soc B-Biol Sci. 2016;371(1695):11.  
 Xu X-X, Zhong X, Yi H-Y, Yu X-Q. Manduca sexta gloverin binds microbial components and is active against bacteria and fungi. 
Dev Comp Immunol. 2012;38(2):275-84.  
 Balouiri M, Sadiki M, Ibnsouda SK. Methods for in vitro evaluating antimicrobial activity: A review. J Pharm Anal. 2016;6(2):71-9.  
 
 
Adhesive interactions between antimicrobial coatings and gram positive and gram 
negative bacteria: influence of surface roughness and material properties 
Julia Whiteley and P Prokopovich 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Healthcare associated infections (HAI) such as pneumonia are estimated to cost the NHS £1 billion a year.1 
The rise in these infections deem it necessary to investigate methods in preventing bacterial adhesion to 
hospital surfaces and so prevent the spread of pathogenic bacteria. This project investigates which 
antimicrobial coatings are most effective at preventing bacterial adhesion, biofilm formation and so spread of 
HAIs and whether material properties or surface roughness have an influence.  
Six antimicrobial coatings were chosen; triclosan, zinc, silver, copper, polyethylene glycols (PEG) and 
diamond-like carbon films (DLC), to test against 3 gram positive (S. aureus, S. epidermidis and S. salivarius) 
and 3 gram negative bacteria (E. coli, P. aeruginosa and A. baumannii). A numerical procedure previously 
developed by Prokopovich, based on the Johnson-Kendall-Roberts multi-asperity adhesion model, was used 
to estimate adhesive forces between biomaterial-bacteria sets.2 Biomaterial surface roughness was then 
altered to study its effect on adhesive interactions. 
PEG was found to be the least adhesive biomaterial with a mean adhesive force of 4.14mN ± 0.08 against all 
bacteria. Copper was the most adhesive with a mean adhesive force of 66.96mN +/0 0.99 against all bacteria. 
A.baumannii had low adhesion compared to the other bacteria, indicating its bacterial physico-chemical 
properties such as fibrilar appendages had a role. Asperity radius on the biomaterial surface was then 
narrowed to represent increasing surface roughness, which increased bacterial adhesion. However decreasing 
roughness didn’t have any conclusive effect.  
The most effective antimicrobial coatings use the antifouling method to prevent bacterial adhesion, therefore 
more work should be done investigating this mechanism.3 The representation of roughness used in this project 
is not a complete model of altering a rough surface. Future work should be done to see the effect changing 
asperity height or using an alternate adhesion model such as Derjaguin-Muller-Toporov would have on 
bacterial adhesion. 
 Public Health England. Healthcare Associated Infections (HAI): Point Prevalence Survey. England;2016 [accessed 1 Dec 2016]. 
Available from: https://www.gov.uk/government/publications/healthcare-associated-infections-hcai-point-prevalence-survey-england 
 Prokopovich P, Perni S. Multiasperity Contact Adhesion Model for Universal Asperity Height and Radius of Curvature Distributions. 
Langmuir. 2010 October;26(22):17028-36 
 Sileika T, Kim H, Maniak P, Messersmith P. Antibacterial Performance of Polydopmaine-Modified Polymer Surfaces Containing 
Passive and Active Components. Appl Mater Interfaces. 2011;3(12):4602-4610 
 
 
Rivastigmine usage in Lewy body dementias 
 
Christopher Williams and RS Thomas 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) are two different presentations of 
a single underlying disease process which both cause cognitive and motor impairments.1 Dopaminergic 
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neuronal loss produces motor symptoms while reduced cholinergic transmission is the pivotal mechanism in 
cognitive dysfunction.1,2 Evidence suggests that cholinesterase inhibitors are an effective option for 
symptomatic treatment for dementia.2,3 The aim of this study was to explore the use and effectiveness of 
rivastigmine, a cholinesterase inhibitor, in PDD and DLB, as this is yet to be thoroughly investigated.4 
A retrospective analysis was conducted using data from ‘The Electronic Clinical Network Parkinson’s Disease 
and Related Disorders Database’ collected from patients attending two movement disorder clinics in South 
Wales. Prevalence of dementia, basic demographics and cognitive test scores were explored in relation to 
rivastigmine use.  
This study included 364 patients, 79% PDD and 21% DLB. Both diseases were more prevalent in males. Most 
patients were currently taking rivastigmine with only 121 not taking a cholinesterase inhibitor. 24% of PDD 
patients were living in nursing homes compared to 33% in DLB. Of the patients living in their own homes, most 
were taking rivastigmine in both diseases, 58% and 79%. In both diseases mortality rates were lower in patients 
taking rivastigmine. Rivastigmine slowed cognitive deterioration in both diseases as more patients showed an 
increase or no change in Mini-Mental State Examination (MMSE) scores and fewer patients showed a decline 
if they were taking it. Patients who were taking rivastigmine also had more comments from consultants or 
carers that indicated an improvement in their condition. 
Although patient numbers were small in some analyses, rivastigmine appeared to be linked with a reduction 
in cognitive decline and with improved performance of daily living activities. This may have contributed to a 
reduced need for residential care. 
 Dodel R, Csoti I, Ebersbach G, Fuchs G, Hahne M, Kuhn W, et al. Lewy body dementia and Parkinson's disease with dementia. 
Journal of Neurology. 2008;255:39-47. 
 Terry AV, Jr., Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges 
and their implications for novel drug development. J Pharmacol Exp Ther. 2003 Sep;306(3):821-7. 
 Mosimann U, McKeith I. Dementia with lewy bodies-diagnosis and treatment. Swiss Medical Weekly. 2003;133(9):131-42. 
 Raha S, Hathway C, Ebenezer L. Role of rivastigmine in treatment of Parkinson's disease and lewy body dementia. Movement 
Disorders. 2014;29(1):601. 
 
 
Investigating the mechanical performance of capsules to be used in dry powder 
inhalers 
Daisy Williams, JC Birchall, BE Jones and SA Coulman 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Gelatin (Quali-GTM) and HPMC (Quali-V® and Quali-V®-I) capsules are used in dry powder inhalers (DPIs) 
to deliver micronized drugs to the respiratory system. At low humidities, gelatin capsules become brittle, 
causing aerosolised fragments to be inhaled and irritate patients’ throats when pierced.1,2 There are no 
pharmacopoeia tests designed specifically for the quality assurance of hard shell capsules for inhalation. This 
study aims to develop a simple compression test to assess the mechanical properties of hard shell capsules, 
to determine how humidity and formulation impact on capsule mechanical performance and to investigate 
capsule integrity during a simulated inhalation event from a DPI. 
Compression tests were developed to assess the mechanical properties of Quali-GTM, Quali-V® and Quali-
V®-I capsules stored at three different humidities. Capsules were compressed at a quasi-static speed, 
10mm/min, with a flat metal compression plate and a force-displacement curve was generated (n=20). In a 
simulated inhalation event the studied capsules were pierced and rotated to predict capsule fragmentation 
during patient inhalation (n=10). The number of fragments generated in the event were visualised by light 
microscopy and manually counted and sized. 
Force-displacement curves were a consistent shape for all capsule materials and at all studied humidities. 
Quali-GTM capsules required a statistically significant greater compression force than Quali-V® and Quali-
V®-I capsules, which required compression forces of comparable magnitude. Compression forces increased 
for capsules stored at low humidity. In the inhalation event, Quali-V® and Quali-V®-I capsules showed minimal 
fragmentation. Quali-GTM capsules, however, fragmented extensively, with the degree of fragmentation 
increasing as humidity decreased. 
Simple compression tests may be able to predict capsule integrity during inhalation and be employed as a 
valuable tool for quality assurance of hard shell capsules for DPIs. Further work is recommended to ascertain 
a definitive correlation between capsule compression forces and their inhalational integrity. 
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 Nagata S. Advantages to HPMC capsules: a new generation’s hard capsule. Drug Devel Deliv. 2002;2:34-39. 
 Jones BE. Quali-V®-I: a new key for dry powder inhalers. Drug Deliv Technol. 2003;3:2-7 
 
 
CYP121 inhibitors as potential tuberculosis therapeutics 
Gwenno Williams and C Simons 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium tuberculosis (Mtb).1 As TB 
is considered one of the deadliest diseases on the planet2, a major concern is the rise in Mtb strains that are 
resistant to current therapies1, therefore there is an urgent need to develop new drugs and to research novel 
targets within Mtb to control this disease. One such target is the cytochrome P450 enzyme, CYP121, which 
has shown promise as an anti-TB target. [3] The aim of this project was to design and synthesise molecules 
which act as CYP121 inhibitors, with the view that these molecules could then be developed into anti-TB drugs. 
The molecular modelling programmes, MOE and LeadIT, were used to design potential inhibitors based on 
the structures of CYP121's natural substrate, dicyclotyrosine, and the azole antifungals, clotrimazole and 
fluconazole. Docking studies were then conducted to evaluate which molecules best interacted with the haem 
group of CYP121, an action that is essential for inhibition to occur.3 The synthesis of these compounds was 
attempted in the laboratory using a four-step method comprising a Steiglich esterification, Grignard reaction, 
tosylate formation and nucleophilic substitution to obtain the final compound. 
The docking studies revealed that the compounds where R= F or Br best interacted with the haem group. 
Difficulties with some reactions meant that both the synthesis method and desired final compound were 
amended to avoid a Grignard reaction. The revised method seemed promising at first, giving good yields 
(>50%). However, the final synthesis step did not yield the desired final compound.  
No desired final compounds were successfully synthesised. An elimination reaction had occurred during the 
final synthesis step, producing an alkene as opposed to the desired imidazole. Attempts were made to refine 
the method to improve yields, however more work is required to generate a method that can reliably produce 
the desired final compound.  
 World Health Organization. Global tuberculosis report. World Health Organization; 2015 [accessed 27 Nov 2016]. Available from: 
file:///C:/Users/User/Downloads/TB_WHO2015.pdf.  
 Dormandy T. The white death: a history of tuberculosis. London: The Hambledon Press; 1999. 
 El-Wahab H, Aboraia A, Abdel-Rahman H, et al. Mycobacterial CYP121 as a target for anti-TB drug discovery. Der Pharma Chemica. 
2016; 8(6): 179-188. 
 
 
Phenylalanyl-tRNA synthetase (PheRS) inhibitors as potential agents for the 
treatment of MRSA 
 
Clare Williamson, S Elbermawi and C Simons 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
MRSA (methicillin resistant Staphylococcus aureus) is a multidrug resistant bacterium of growing clinical 
concern due to bacterial resistance to antibiotic treatments.1 To combat this problem, new antibiotics need to 
be developed which have a novel mechanism of action.2 An example of this, is the enzyme phenylalanyl-tRNA 
synthetase (PheRS). This target enzyme is vital for MRSAs survival3, and an inhibitor for this target could fulfil 
this need. Therefore the aim of this project is to design and synthesise a novel compound to competitively 
inhibit two sites, the phenylalanine and ATP sites, on the PheRS to provide a new treatment for MRSA. 
 
A molecular modelling program was used to model the novel compounds with the PheRS enzyme. This was 
to determine the suitability of the compounds to bind to the active site of the PheRS. Four compounds were 
synthesised using a three step synthesis (a crossed aldol type reaction with Knoevenagel condensation 
(Doebner modification), an amide synthesis via TBTU/T3P coupling, and a Boc deprotection under acidic 
conditions). Intermediates and the final compounds were checked by TLC, 1H NMR and 13C NMR to ensure 
the structures were correct, and purity was suitable. 1H NMR, 13C NMR and melting points were used to 
characterise the compounds. 
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Three of the four compounds synthesised made it to the final compound. None of these was pure, and one 
was lost while attempting purification due to solubility issues. The results showed there were two stages which 
could be optimised, the coupling stage and the deprotection stage of the synthesis.  
 
Alternative coupling reagents/methods and alternative deprotecting agents/conditions could be used for 
optimisation. The three step synthesis was not completely successful, however, with the modifications and 
optimisation, it is probable that pure final compounds could be achieved by this method. 
 
 Antimicrobial Resistance. Global Report on Surveillance. World Health Organisation; 2014 [accessed 25 Sep 2016]. Available from: 
http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1 
 Gualerzi CO, Brandi L, Fabbretti A, Pon CL. Antibiotics: Targets, Mechanisms and Resistance. Wiley-VCH Verlag GmbH & 
Co.;2014 
 Vondenhoff GHM, Aerschot AV. Aminoacyl-tRNA synthetase inhibitors as potential antibiotics. Eur J Med Chem. 2011;46:5227-
5236 
 
 
A study to explore and identify factors influencing motivation of final year Cardiff 
University students in relation to the assessments within the MPharm degree 
 
Emma Wilmer, SA Coulman and DN John 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Motivation is “a reason or reasons for acting or behaving in a particular way”.1 There is a vast amount of 
literature surrounding motivation, particularly in educational contexts, yet few studies focus on undergraduate 
pharmacy students. The Self Determination Theory describes two sources of motivation, intrinsic and 
extrinsic.2 Motivation has been shown to positively influence academic performance therefore, understanding 
motivation may enable educators to facilitate positive learning behaviours.3 The aim of this study was to explore 
and identify factors influencing final year pharmacy students motivation, with regards to assessments within 
the MPharm at Cardiff School of Pharmacy and Pharmaceutical Sciences (CSPPS).  
A qualitative, semi-structured approach was used. The researchers, including three final year pharmacy 
students and the project supervisor developed a topic guide having reviewed the relevant literature. Following 
ethical approval, participants were recruited via convenience and purposive sampling. Informed consent was 
obtained prior to participation. Three pilot interviews were undertaken although these were not included in the 
data analysis. One-to-one interviews were audio-recorded and transcribed verbatim. Transcripts were 
anonymised and analysed inductvely using thematic analysis.4  
Thirteen interveiws were undertaken and seven themes were derived, namely “how the school helps the cohort 
prepare for assessments’, ‘impact of group assessments’, ‘influence of others’, ‘assessment contribution to the 
degree’, ‘fear of failure’, ‘assessment topic’ and ‘effect of feedback’.  
This study found that students motivation was multifactorial. The factors vary and show overlap amongst 
students therefore, changing one aspect may improve motivation for some but not others. The findings have 
identified potiential areas for improvement to maintain or enhance students motivation in assessments. As a 
result, a variety of recommendations have been put forward to CSPPS. Further research is needed into the 
motivation of MPharm students at other UK Pharmacy Schools. 
 Oxford Dictionary of English. 3rd Ed. Oxford: Oxford University Press; 2010.  
 Ryan R, Deci, E. Self-determination theory and the facilitation of intrinsic motivation, social development, and well-being. American 
Psychologist. 2000;55:68-78. 
 Vansteenkiste M, Lens W, Deci, E L. Intrinsic versus extrinsic goal contents in self determination theory: Another look at the quality 
of academic motivation. Educational Psychologist. 2006;41:19-31.  
 Braun, V, Clarke, V. Using thematic analysis in psychology. Qualitative Research in Psychology. 2006;3:77-101. 
 
 
Amaryllidaceae alkaloids extraction from Narcissus pseudonarcissus cv. ‘Carlton’ 
and synthesis of novel galanthamine derivatives 
Zalikha Zainuddin and AW White 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
This project focuses on finding a suitable method to extract galanthamine and other Amaryllidaceae alkaloids 
from aerial parts of Narcissus pseudonarcissus cv. ‘Carlton’. Subsequent work focuses on the derivatization 
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of galanthamine at the hydroxyl group. Galanthamine has a low blood-to-brain ratio (<2)1 therefore the aim of 
the derivative synthesis is to enhance brain penetration by increasing the lipophilicity and conjugating 
galanthamine with phenylalanine using the ethylamino group as a linker to make it a substrate of LAT1 for 
treatment of Alzheimer’s disease. 
Two methods were attempted for alkaloid extraction namely base extraction and non-base extraction. 
Saturated NaHCO3 was used in base extraction before the solvent separation step. The organic layer was 
obtained, dried with a rotary evaporator and washed with diethyl ether to yield galanthamine. For non-base 
extraction, the crude sample was dissolved in methanol and compounds were separated via preparative TLC. 
All samples were analysed by ESI-MS and NMR for structure elucidation. Furthermore, the hydroxyl group 
was alkylated via SN2 reaction. A series of test reactions with varying solvents and schemes were attempted 
to find the right conditions. ESI-MS would be the major analytical tool for compound identification. 
Base-extraction was found to the method that extracted more galanthamine (46% w/w) than non-base 
extraction (0.98%). Galanthamine was the major alkaloid extracted. Other alkaloids, possibly roserine, 
narcidine or 9-O-methylpseudolycorine2, were observed on ESI-MS, albeit in low intensity. The methyl and 
cycloalkyl derivatives were successfully synthesised although with poor yields (12% and 18% respectively). 
The reactions to conjugate galanthamine with phenylalanine were not accomplished. 
The base is a key substance to achieve higher yield of galanthamine.3 The method used was relatively simple 
too. Furthermore, this project illustrated the challenge in modifying hydroxyl group of galanthamine that 
possibly signify its relative inertness.4 However, these derivatives are novel hence further investigations are 
worthwhile. 
1. Maelicke A. Galantos Pharma Gmbh. Cholinergic enhancers with improved blood-brain barrier permeabillity for the treatment of 
diseases accompanied by cognitive impairment. [Patent Application] US20070213318 A1; 13 Sep 2007 
2. Kreh M. Studies on galanthamine extraction from Narcissus and other Amaryllidaceae. In: GR H, editor. Narcissus and daffodil: the 
genus narcissus. London: Taylor and Francis; 2002. p. 259-72 
3. Rachmaniah O, Choi YH, Arruabarrena I, Vermeulen B, van Spronsen J, Verpoorte R, et al. Environmentally benign supercritical 
CO2 extraction of galanthamine from floricultural crop waste of Narcissus pseudonarcissus. J Supercrit Fluids. 2014;93:7-1 
4. Burke E. Isolation, identification and chemical modification of Narcissus alkaloids [PhD Thesis]. Manchester: University of 
Manchester; 2015 
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Synthesis of new Bcl-3 inhibitors as potential anti-metastatic agents 
Tiba Alhani, C Bordoni and AD Westwell  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
 
Potassium permanganate as a treatment of chronically infected wounds 
Thao Huynh and D Houston 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
 
Demonstrating the presence of dry bacterial biofilms on healthcare surfaces 
Kiran Johal and J-Y Maillard 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
Developing optical assays for application in artificial bilayers 
Elgan Mathias, DK Baxani, WD Jamieson and OK Castell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
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Efficacy of disinfectant solutions to inhibit recovery and transfer of Staphylococcus 
aureus NCIMB 9518 dry biofilms 
Nik Aisyah Najwa Nik Mustaffa Shapri, J Said and J-Y Maillard 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
Demonstrating the presence of dry bacterial biofilms on healthcare surfaces 
Alysha Poole and J-Y Maillard 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
 
Investigating the susceptibility of dry bacterial biofilm to disinfection 
Rebecca Pritchard, J Said and J-Y Maillard 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
 
The synthesis of novel Bcl-3 inhibitors: A potential therapy for metastatic breast 
cancer 
Scott Smith, C Bordoni, T Alhani and A Brancale 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
 
The development of novel FAK inhibitors for potential treatment of metastatic breast 
cancer 
Sonia Smith, S Kandil and AD Westwell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
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Motivation of pharmacy students for academic study: a review of the literature 
Huw Anthony Jones and DN John 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Motivation has been linked to student learning and academic achievement in a wide range of educational 
settings. It can inform teaching practice and influence student achievement. However, there is relatively little 
research in this area relating to pharmacy students. The aim of this project was to undertake a review of studies 
relating to pharmacy students and motivation, using a systematic approach, to investigate the relationship 
between student motivation and educational achievement. 
A search strategy was developed using a logical and iterative approach. Search terms were formed with 
reference to keywords in the research question. Using these terms, Web of Science, PubMed, Embase, 
Scopus, PsychInfo, British Education Index, and ASSIA databases were searched. The results from each 
database were uploaded into EndNote™ online and duplicates were removed. The articles were then screened 
at abstract level using the inclusion and exclusion criteria. The remaining articles were then screened at full-
text level. Subject to confirmation by the project supervisor, those studies deemed appropriate were included 
in the review. 
The database searches identified 176 potentially relevant articles. At abstract level, 136 articles were 
screened. Then, 25 articles were screened at full-text level. Finally, eighteen articles, comprising seventeen 
studies, were included in the review and were analysed and discussed. 
The studies indicated that motivation influenced student learning and academic achievement. However, there 
was a paucity of research in this area relating to pharmacy students during a period when pharmacy practice 
is undergoing significant change. Four recurrent themes were identified from studies that used different 
contemporary theories of motivation. These were goal orientation, teacher qualities, relating teaching to 
pharmacy practice, and performance anxiety. 
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A Phase II randomized double blind placebo-controlled dose ranging pilot study, 
investigating the efficacy and safety of an extract of Artemesia annua in improving 
symptoms of hip and knee osteoarthritis 
Elizabeth Beattie, WR Ford and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The objective/aim of this study was to investigate the safety and efficacy of the dietary supplement, Arthrem 
(ART), on pain, stiffness and functional limitation in osteoarthritis (OA) of the hip or knee. ART contains an 
extract from the medicinal plant Artemisia annua. 
In this randomized placebo controlled double blind (DB), parallel, single-centre, 12-week Phase II pilot study, 
a total of 42 patients were randomized to one of three treatment groups with a total of 14 in each of the 
following: one capsule of 150 mg Artemisia annua extract (ART) twice daily (BD) (ART low dose), one capsule 
300 mg ART BD (ART high dose) or one placebo capsule BD administered (all capsules were taken 8 hours 
apart) over 12 weeks. The percent change from baseline (CfB) was used to assess any changes or reductions 
in pain, stiffness and functional limitation in OA of the hip or knee at week 12. In order to assess the efficacy, 
the Western Ontario and McMaster University Osteoarthritis Index (WOMAC©) and visual analogue scale 
(VAS) for pain was used. The clinical response (WOMAC© responder rate was measured by percent changes 
from baseline; a comparison of ART groups individually were compared statistically to the placebo group. 
No statistical differences in the percent change from baseline of WOMAC© total scores, WOMAC© pain 
scores, WOMAC© stiffness, WOMAC© physical function scores or VAS pain scores were found between either 
the ART dose groups (low or high ART dose group) or placebo at week 12. The low dose ART group did 
appear to show improvements in pain at week 12. However, this improvement was not statistically significant 
for any efficacy parameter compared to placebo. The most common adverse events were gastrointestinal 
disorders, musculoskeletal and connective tissue disorders and infections or infestations. The aftertaste of the 
capsular herbal supplement was noted by one patient in the high dose ART group which led to withdrawal from 
the clinical trial. 
Safety revealed low dose ART to be well tolerated in the 12 week study. The anti-inflammatory/analgesic 
benefits of Atemisia annua extract verified ART to have potential as a treatment in the OA arena. Treatment 
with ART 150 mg BD (low dose) in patients with OA of the hip or knee demonstrated reductions in pain over 
12 weeks compared with baseline. However, no statistical differences between the low dose ART group and 
placebo were deduced in percent change from baseline at week 12. This pilot study is the first of its kind in 
this therapeutic area and further studies to demonstrate clinically relevant conclusions are warranted. 
 
 
A single centre pilot study to identify and establish hospital staff engagement for 
the consent of Trust patients to be approached to register their interest in clinical 
trials 
Helen Bowyer, AG Cosslett and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
This single centre pilot study was conducted to establish staff engagement in maximizing recruitment strategies 
for clinical trials in a local District General Hospital. This specific strategy was to obtain baseline universal 
consent from patients to be approached to receive research information before a specific trial commenced. 
This would aid in offering patients the opportunity to take part in research as per the NHS constitution 
(Department of Health, 2013). A qualitative research method was adopted for this study. The views and 
experience of hospital Trust staff members were captured using a focus group as well as semi-structured one-
to-one interviews. The advantage of using these two qualitative approaches were that the participants were 
given the freedom to describe, explore and express their own opinion on this topic allowing the researcher to 
gather descriptive information and gain insight into the research topic from the participants perspective. A 
manual colour coding system was used to analyse the data. 
Five robust themes were evident post data analysis. No particular theme was more significant to the 
participants and it was imperative that all themes were discussed equally. The recruited participant 
experiences and opinions on the topic of patients giving baseline universal consent to be approached for 
clinical research, was centred on the following five themes: increased awareness of clinical research, 
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terminology, opt out versus opt in, data protection and timeframes. A common thread across all themes 
identified was that further investigation of some highlighted issues would need to be addressed prior to the 
implementation of this recruitment strategy and that lessons could be learned from other hospitals and 
institutions that adopt this approach. 
Overall, the results of this single centre pilot study demonstrated that the participants involved felt that 
approaching patients for consent to be contacted about clinical research being conducted at the hospital, was 
a positive thing to do. This scheme would improve patient awareness in clinical trials, establish better 
communications between the hospital Trust and patients potentially improving patient recruitment to hospital 
based clinical research trials. Finally, it would encourage future research projects to answer the questions 
generated from this pilot study. The researcher felt that the aim of the study, to establish Trust engagement 
with this topic was achieved.  
 
 
Hospital pharmacy staff awareness and perceptions of adverse reaction reporting 
via the Yellow Card Scheme at the Royal Brompton and Harefield NHS Foundation 
Trust 
Kwok Fai Man, ML Hughes and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Adverse drug reactions (ADRs) are of great clinical importance. In Europe, it is estimated that over 5% of 
hospital admissions and about 197,000 deaths annually are attributed to ADRs. The cost of this is thought to 
be in the region of €79 billion per year. The Medicines and Healthcare products Regulatory Agency (MHRA) 
has responsibility for pharmacovigilance in the UK and the Yellow Card Scheme (YCS) is the cornerstone of 
this activity, accepting spontaneous reports of ADRs from professionals and patients. Existing evidence 
suggests that there is gross under-reporting of ADRs via the YCS overall, including that by hospital 
pharmacists. The aims of this research project were to gain an understanding of the extent of, and reasons 
for, under-reporting of ADRs and to identify channels for improving ADR reporting rates. 
A qualitative approach was used to answer the goal-based questions of the study. Following ethics approval, 
focus groups and one-to-one semi-structured interviews were undertaken with pharmacy staff within the Trust. 
Data was also audio-recorded, transcribed verbatim and analysed via a thematic approach using a 
combination of deductive and inductive coding.  
Nineteen participants were recruited into four focus group sessions and four one-to-one semi-structured 
interviews. The size of the focus groups ranged between three to five participants per session. Attitudes to 
reporting were found to be positive, though activity was found to be poor. Experiences of reporting were stated 
to be straightforward, but also onerous and time-consuming. There was seen to be lack of clarity in knowing 
when to report and little awareness of current developments. Barriers to reporting and perceived reasons for 
under-reporting were found to be poor awareness, lack of profile, time constraints , follow-up burden, uncertain 
association, limited access to clinical information and a perceived lack of importance. Suggestions for 
improvement included raising the profile of awareness, education and training, feedback and the establishment 
of a central coordinating point. 
The extent of under-reporting is wide and a multidisciplinary culture change needs to be driven at a senior 
level. Real improvements to ADR reporting can only be realized if featured higher on the medication safety 
agenda. Finite clinical staffing capacity to support reporting means that policy and guidance will need to 
continually challenge the value of competing commitments and reassess priorities for improving patient safety. 
 
 
A quantitative study of attitudes and awareness of clinical trials amongst health 
care professionals in a district hospital in order to inform future recruitment 
Kerry Rennie and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
There are clear gains and benefits to be made to the NHS, the District Hospital and local population by 
engaging with clinical trials. The local population can access high quality clinical research opportunities and 
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gain access to new and novel treatments as a standard of care at their hospital. The establishment itself 
becomes a contributor to evidence based practice within the NHS via collaboration opportunities with academic 
institutions and the commercial sector. 
A service evaluation was conducted using a web based seventeen point anonymous questionnaire designed 
to capture the attitudes and awareness of clinical trials in Yeovil District Hospital where it was administered. 
The methodology used a combined end-weighted five-point Likert scale measure to capture frequency and a 
selection of open questions designed to obtain current levels of attitude and awareness of clinical trials 
amongst staff at the District Hospital. This combination methodology enabled quantitative analysis with a 
qualitative outcome. Following an initial pilot study, the main questionnaire was administered and responses 
were received from one hundred and seventeen staff that had provided consent. The data yielded qualitative 
information of the various attitudes and overall, awareness of clinical trials. Themes and frequency from a 
multidisciplinary cohort of responders were identified. 
Attitudes and awareness were clearly demonstrated and the data highlighted areas perceived as barriers to 
recruitment into clinical trials, matters of success and areas where further support could be beneficial. The 
information collated could indeed inform robust recruitment strategies for the future which has the potential to 
increase patient recruitment into clinical trials. Through identification, consideration and understanding of the 
current levels of awareness and attitudes of clinical trials amongst health care professionals in a District 
Hospital, it would be possible to inform future recruitment strategies by identifying areas of the unmet 
requirements of health care professionals to be actively involved in trials. 
  
 
The delays in gaining Research and Development approval in multicentre clinical 
trials and whether the Health Research Authority approval will impact on these 
delays 
Chloe Smith, WR Ford and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
This research aimed to investigate where the longest delays occur in the R and D approval process when 
opening an NHS site to recruitment in a trial and what the reasons are for these delays. Along with the 
introduction of the HRA approval to replace R and D approval, this research study explored whether there was 
a belief that this implementation would have a positive impact on the current delays experienced. 
Four trials were selected to take part in the data collection of key milestone metrics to opening participating 
sites. Two of these trials took part in the data collection for recording delay reasons. A questionnaire was 
designed to capture opinion on the HRA approval and whether it would positively impact on the current delays, 
Overall times to open a site were excessive, ranging from a mean of 5.9 to 13.6 months per trial. The longest 
delay for opening a site to recruitment occurred whilst waiting for the site specific information (SSI) form to be 
submitted. The main reasons recorded for delays were waiting for authorisation on the SSI form, contract 
execution and essential documents returned from the site. The majority of responders on the questionnaire 
did not think that the HRA approval would have a positive effect on the current delays. 
The process of obtaining R and D approval at sites is causing unnecessarily long delays for multicentre 
research studies. The HRA approval is a step in the right direction, creating a much needed global review. 
However, in order that the process is effective on the delays, the HRA must consider introducing timelines. 
This would bring it in line with other UK approval processes such as Research Ethics Committee favourable 
opinion and Medicines and Healthcare Products Regulatory Agency clinical trial approval 
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Do oral HMG-CoA reductase inhibitors (statins) reduce the incidence of surgical site 
infections (SSIs) in patients who have undergone an elective primary hip or knee 
arthroplasty procedure? 
Harjit Kaur Virdee and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Hip and knee replacement surgery is the most prevalent and successful type of surgical intervention that is 
performed on both the majority of the elderly and some young NHS and private patients who have experienced 
the debilitating symptoms of osteoarthritis (OA). The majority of OA patients find that the clinical symptoms of 
OA are alleviated after they have had primary hip or knee arthroplasty. However, even though a total hip or 
knee arthroplasty is normally a safe and effective surgical procedure, this type of surgery carries the risk of 
patients developing post-operative surgical site infection (SSI). SSIs can be very difficult to treat and there 
have not been many possible preventative treatment options available until quite recently. A potential treatment 
involves the use of HMG-CoA reductase inhibitors which are more commonly known as statins. 
This retrospective clinical study used the Royal Orthopaedic Hospital (Birmingham) surgical site infection 
database which contained 202 surgically infected primary hip and knee patients and these were matched with 
202 non-surgically infected primary hip and knee patients from the Royal Orthopaedic Hospital’s health 
informatics hip and knee database using specific risk factors and propensity score matching to analyse if there 
was a difference in statin use. The results from the study demonstrated that the non-SSI hip and knee cohort 
were less likely to develop a surgical site infection because they were undergoing statin treatment (95% 
confidence interval, P<0.0001) and that those in the SSI and non-SSI hip and knee cohort that did take a statin 
(52 patients and 68 patients) 58% in the SSI knee and hip cohort and 75% in the non-SSI knee and hip cohort 
took simvastatin at night. 
This indicated that statin use was associated with a reduced incidence in the development of a surgical site 
infection in those patients who had undergone an elective primary hip or knee arthroplasty procedure. 
 
 
Analysis of oncology clinical trial start-up and recruitment within the European 
Union with comparison to global metrics from 2012-2015 
Jodie Wilkes, WR Ford and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The European Commission determined that between 2007 and 2011, EU clinical trial applications fell by 
twenty-five percent. Diverse delays (including start-up and recruitment) within studies rose to a staggering 
ninety percent with associated cost increases. Ultimately, this meant a decrease in innovation and reduced 
competition within the EU affecting patient access to new medicines, a trend that appeared to be continuing.1 
Clinical trials are becoming more complex and additional delays in start-up can add to already tight timelines 
resulting in an increased cost of executing such projects. Additional concerns with dropout rates and 
subsequent overenrolment into clinical trials to allow for this in order to ensure statistical validity adds to the 
financial burden.  
Data in the Clinical Trials Operational Scorecard (COS) is derived from various systems: the Clinical Trials 
Management System (CTMS), PlanSource (resource tool), PharmaRes and the Country Clinical Operations 
Annual Recruitment tool. Data was captured from this scorecard (2012-15) and European data was compared 
with global data for study start-up and recruitment for all oncology studies run during this timeframe. 
Clinical trial applications in North America and the Asia Pacific region were growing at a faster rate than 
Europe2 in addition, to the development of the emerging markets. This suggested that Europe may be losing 
some of its competitive edge within the industry. Therefore, decreasing study start-up timelines and ensuring 
rapid recruitment rates within Europe are of vital importance to ensure that the region continues to be one of 
the most “desirable” environments for clinical research in order to continue to compete on the global stage. 
Pharmaceutical companies, as well as other drug developers are seeking to improve efficacy of process and 
performance in all areas. This includes study start-up and recruitment with the overall goal of speeding up 
clinical product development bringing medicines to patients quickly at reduced cost to the developer ultimately 
with general benefit to the patient. 
1. NHS European Office, 2014 
2. Gehring, BMJ 2013;3:2957 
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An investigation of a new compound for the treatment of Alzheimer’s disease 
Richard Addis and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
 
Prevention of ductal carcinoma in situ (DCIS): A comparison of prevention 
programmes in the UK and Iran 
Mahsa Moghaddam, JMW Gee and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
 
 
A survey to establish the reasons for non-participation of primary care patients in 
commercial research studies 
Samantha Warren, MW Smith and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
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Discovery of Bcl-3 inhibitors for the potential treatment of metastatic breast cancer 
Cinzia Bordoni and A Brancale 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
In HER-2 positive metastatic breast cancer, the proto-oncogene Bcl-3 was found to be overexpressed. Bcl-3 
acts as a transcriptional co-activator: it forms a ternary complex with DNA and homodimer (p50)2 and 
stimulates the transcription of a different panel of genes in the metastatic progression of the breast cancer. Its 
exact role in endogenous tumours is still unknown. In vivo knockdown studies shown, that Bcl-3 deficiency did 
not affect the primary tumour, but it reduced the occurrence of metastases by 80% without any effects on the 
normal mammary gland function. Patients with this type of tumour have a poor prognosis, do not respond to 
the typical treatment or show resistance and side effects to the usual therapeutic options. Hence, there is an 
urgent need to find new candidate drugs. A virtual screening targeted against a newly identified Bcl-3 binding 
pocket allowed the identification of 10 molecules, tested in vitro cell based assays. Four molecules were active. 
In this thesis, different analogues of these four hit compounds were synthesised. Based on docking studies, 
another two scaffolds were designed. The non-cytotoxic profile of the new analogues was assessed using the 
cell titer blue assay. The activity of the compounds was established using the colony forming assay (CFA). To 
prove the Bcl-3/p50 interaction, immunoprecipitation and co-immunoprecipitation were performed. None of the 
compounds was cytotoxic. Some of them exhibited a promising activity in the CFA. One molecule exhibited an 
interesting activity profile both in vitro and in vivo and in pharmacokinetic studies and it has been forwarded 
into full pre-clinical development. 
 
 
Computer-aided design and synthesis of novel anti-DENV nucleoside analogues 
Cecelia Cima and A Brancale 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Dengue virus (DENV) is one of the most important human pathogens among the genus flavivirus, with 3.9 
billion people at risk of infection through mosquitoes, such as the widely spread ‘Asian tiger’ mosquitoes, and 
the four serotypes of DENV are endemic in over 100 countries in tropical and subtropical regions. Clinical 
manifestations of infection with DENV range from flu-like symptoms to the life-threatening dengue 
haemorrhagic fever. The dramatic increase in the incidence of the DENV infection, the rapid spread of DENV 
to new areas and the recent re-emergence of another member of the genus flavivirus, Zika virus (ZIKV), have 
highlighted the urgent need for specific antiviral therapies against infections with DENV and related viruses, 
which are not currently available. DENV RNA-dependent RNA polymerase (RdRp), the enzyme responsible 
for the synthesis of the viral genome, is one of the most attractive targets for the development of direct acting 
antiviral agents but its molecular mechanisms are poorly understood. Therefore, the aims of this PhD project 
were i) to build a model of the de novo initiation complex of DENV RdRp, of which there is currently no crystal 
structure available, ii) in silico design and synthesis of novel nucleoside and nucleotide analogues as potential 
inhibitors of DENV replication, iii) and finally to investigate the mechanism of the RNA synthesis by DENV 
RdRp. 
Molecular modelling techniques allowed for the creation of a model of the de novo initiation complex. The 
application of in silico drug design approaches resulted in the identification of three families of promising 
adenosine analogues: ribose-modified, nucleobase-modified and acyclic adenosine analogues. Strategies for 
the preparation of these nucleosides were investigated and ten adenosine analogues and eight nucleotide 
prodrugs, which are phosphoramidate ProTides, of specific nucleosides were synthesised and sent for 
biological evaluation in vitro. Innovative microwave irradiation conditions for the preparation of 
phosphoramidate ProTides were developed and successfully applied to synthesised nucleoside analogues. 
Finally, the application of molecular dynamics simulation methods on different complexes of DENV RdRp 
provided insights on the conformational changes of DENV RdRp during the synthesis of the viral genome. 
These results contributed to the understanding of DENV RdRp activity and will aid the design of inhibitors of 
the viral replication. 
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Phosphorus prodrugs of S1P receptor modulators as a novel therapeutic 
opportunity 
Edward James and C McGuigan 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The sphingosine 1--‐phosphate receptor modulator fingolimod / Gilenya / FTY720 has become an effective 
and commercially available therapeutic agent for the treatment of relapsing--‐remitting multiple sclerosis. 
Fingolimod is phosphorylated by sphingosine kinase in vivo to the pharmacologically active S--‐fingolimod 
phosphate. The original aim of the work was to synthesise novel phosphate delivery prodrug analogues of 
fingolimod and determine whether or not these novel analogues could provide an improved therapeutic profile. 
The principal phosphate delivery prodrug method to be investigated was phosphoramidate “ProTide” 
chemistry. ProTide fingolimod analogues were found to have a poor level of stability and readily degrade to 
unwanted cyclised structures at room temperature and when exposed to very mildly basic conditions. In order 
to mitigate the poor stability issues it was considered possible that forming ProTide analogues of mono--‐
alcohol S1P receptor modulators, as opposed to diol fingolimod, would lead to greater stability. The synthesis 
of mono--‐alcohol S1P receptor modulator benzyl ether derivative analogues published by Tsuji et al was 
attempted and successfully achieved. Previously reported ProTide synthesis and in vitro testing methods were 
employed. Carboxypeptidase, human serum, base stability, acid stability and cell lysate processing 
experiments were conducted in the School of Pharmacy. Homology modelling was employed to determine 
S1P1 selectivity of benzyl ether derivative analogues and novel structures. ProTide benzyl ether derivative 
analogues were found to have a far greater level of stability than ProTide fingolimod analogues and in vitro 
processing experiments showed that they are processed to the desired pharmacologically active 
monophosphate. The research signifies the development of an entirely new family of potential therapeutic 
agents. 
 
 
Design, synthesis and biological evaluation of nucleoside phosphoramidates with 
potential anticancer activity 
Carmen Jimenez Antunez and C McGuigan 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
One in seven approved anticancer drugs in the UK are nucleoside analogues (NA). However, frequent 
development of resistances and unpredictable toxicity are crucial drawbacks of these compounds. Some of 
the main resistance mechanisms against NAs include limited cellular permeability and decreased initial 
phosphorylation of the NAs, thus limiting the concentration of active NAs inside the target cells. The ProTide 
approach is a pronucleotide technology that successfully overcomes these drawbacks by releasing the 
monophosphorylated NA into the cell and has led to multiple clinical candidate drugs. 
This work was focussed on the application of the ProTide approach to novel and known anticancer NAs with 
the aim of improving their performance and pharmacological properties. Herein, new synthesis and 
optimisation of selected pyridine and purine NA with modifications in the base and / or in the sugar moieties, 
along with different synthetic approaches to build the prodrugs are reported. 
The anticancer activity of the compounds was evaluated via cell viability assays, and the activation of the 
prodrugs and resistance to enzymatic degradation was proved via enzymatic assays involving Nuclear 
Magnetic Resonance (NMR) or spectrophotometric methods. Molecular modelling studies were performed in 
order to understand the interaction of the ProTides and their metabolites with the enzymes. 
Finally, the family with the best in vitro activity results was enlarged by developing novel ProTide-related 
nucleoside diamidate prodrugs, which aimed to further improve their bioavailability and stability characteristics. 
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Resistance mechanisms during endocrine treatment in breast cancer 
Benyamin Ertefai, RA McClelland, RI Nicholson, and JMW Gee 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Prolonged endocrine therapy is the mainstay of treatment for ER+ breast cancer patients. However, resistance 
develops in many patients which leads to more aggressive disease. Understanding the mechanisms of 
acquired resistance that emerge as a consequence of prolonged endocrine treatment remains critical. This 
study aimed to use gene expression profiling to discover induced mechanisms shared by a panel of MCF7-
derived acquired resistant cells that underpin endocrine resistant growth. The in vitro panel represents 
resistance to oestrogen deprivation, tamoxifen or fulvestrant and includes long-term (3year) models to better-
mimic clinical endocrine exposure. Affymetrix 1.0ST microarrays detected 572 genes induced in all resistant 
models versus MCF7. Over-represented ontologies, pathways and functional classification for these genes 
revealed induction of oxidative phosphorylation (OxPhos) and TCA cycle enzymes in the resistant models, a 
finding further confirmed by mass spectrometry. Increased oxygen consumption, NADH dehydrogenase and/or 
cytochrome C oxidase activity was detected in resistant cells, and targeting with OxPhos inhibitors Metformin 
or Antimycin A confirmed growth-dependency on OxPhos. Western blotting for AMPK (energy sensor) activity 
and its downstream anabolic targets (ACC, mTOR/P70S6K) showed Metformin reduced fatty acid and protein 
synthesis in growth-sensitive endocrine resistant cells. In silico analysis inferred clinical relevance since many 
TCA/OxPhos genes associated with earlier relapse in ER+ and/or tamoxifen treated patients. Monitoring basal 
glycolysis (extracellular lactate) and growth impact of 2DG or glutamine restriction demonstrated glycolysis 
and glutaminolysis also contribute to endocrine resistance. The microarrays furthermore revealed that 
metabolic kinases PCK2, ALDH18A1 and PFKFB2, and components of cell response to Zn were commonly-
induced which may additionally help endocrine resistant growth. This study has revealed increased OxPhos 
arises as a consequence of prolonged endocrine treatment and is a key bioenergetic pathway sustaining 
resistance. Since resistant growth is Metformin-sensitive, such targeting of this energy pathway (alongside 
further antihormones or glycolysis/glutaminolysis inhibitors) could help treat resistance. 
 
 
Factors influencing discharge decisions in dermatology outpatients: checklist and 
educational methods to support appropriate discharge 
Nur Ainita Harun and RDE Sewell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
The decision whether or not to discharge an outpatient is vital in determining outpatient clinic attendance 
numbers, directly affecting overall patient care efficiency. A review of the factors influencing discharge 
decisions revealed that there was limited evidence of these factors and a lack of understanding as to how 
clinicians take discharge decisions. This project’s objectives were to describe the influential factors on 
discharge decisions from the clinicians’ and patients’ perspectives, to demonstrate the development and 
clinical evaluation of a novel "Traffic-light” design dermatology outpatient discharge information checklist to 
improve appropriateness and consistency in discharge decision-making. Semi-structured interviews were 
carried out with 40 consultant dermatologists across England. One hundred and forty-eight influences were 
generated and thematically analysed both manually and also using NVivo10 software. A wide array of 
nonclinical factors (clinician-based, patient-based, practice-based and policy-based factors) influence 
discharge decision-making. Observations of 64 consultations and 56 semi-structured interviews with 
dermatology outpatients were carried out to understand their experience concerning the decision for their 
discharge. Twelve of the 31 patients (39%) who were discharged, considered their discharge inappropriate. A 
three-round Delphi exercise with 17 dermatology consultants (100% response) was carried out to reach 
agreement on what a high quality discharge information checklist should contain. There was strong inter-rater 
reliability (ICC=0.958) and fair inter-rater agreement (Fleiss Kappa=0.269). Thirteen items were identified that 
formed the "Traffic-light" design checklist. Twelve (67%) dermatology clinicians who evaluated the checklist 
found it useful. This study has demonstrated the importance of approaching discharge decision taking in an 
informed, structured manner. The checklist provides the basis for making discharge decisions more 
systematic, auditable and transparent, improving patient safety and optimising healthcare costs. These 
methods are potentially useful in other clinical disciplines. 
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Defining the role of the actin cytoskeleton in cellular uptake of cell penetrating 
peptides 
Lin He1, P Watson2 and AT Jones1 
1Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and 2School of Biosciences, Cardiff University, Cardiff, CF10 3AX, Wales, UK 
The increased need for macromolecular therapeutics, such as proteins and nucleotides, to reach intracellular 
targets asks for more effective delivery vectors and a higher level of understanding of their mechanism of 
action. Cell Penetrating Peptides (CPPs) have been shown to deliver a range of macromolecules into cells 
either through direct plasma membrane translocation or by endocytosis. All known endocytic pathways involve 
cell cortex remodelling, a process shown to be regulated by reorganisation of the actin cytoskeleton. Links 
between actin remodelling and CPP uptake has been shown but more information is required to determine the 
extent of this association and how it could influence further research into improving the delivery capacity of 
these entities. This project, by using the CPP octaarginine (R8) investigated how actin disorganisation 
influences the cellular entry of this peptide when attached to a model fluorophore Alexa 488 or Enhanced 
Green Fluorescent Protein (EGFP). A confocal microscopy technique was initially developed, allowing for high-
resolution and spatial characterization of the actin cytoskeleton at different cell depths. Analysis using this 
developed method was used to highlight that serum starvation has a strong influence on the capacity of R8 to 
cause membrane blebs and possibly macropinocytosis. Using a range of direct or indirect actin inhibitors this 
work also highlighted how they can rapidly cause dramatic cellular deformities beyond the level of actin or 
more subtly affect actin organisation. Further confocal studies revealed that choice of cell line significantly 
affects the effect of actin disruption on CPP entry and that this is highly dependent on the nature of the probe. 
This was exemplified by results showing inhibition of EGFP-R8 uptake in HeLa cells treated with cytochalasin 
D, latrunculin B and jasplakinolide but a dramatic increase in uptake in A431 cells when they were treated with 
these drugs. The regulation of actin dynamics involves various kinases including Rho–associated kinases 
ROCKs, and Src family kinases. The ROCK inhibitor Y27632 induced the formation of actin needles running 
perpendicular to the plasma membrane of A431 cells and increased EGFP-R8 internalisation. By contrast, Src 
inhibitor PP2 had little effect on both the actin cytoskeleton and EGFP-R8 uptake. Overall this study highlights 
the importance of analysing actin in detail to identify how CPPs and possibly other drug delivery vectors and 
formulations interact with cells to gain entry. Under defined experimental conditions R8 can modify the actin 
cytoskeleton and requires a functional or dysfunctional actin network to allow for maximal cellular entry. 
 
 
Characterising skin immune cells to inform development of intradermal vaccines 
and therapeutics 
Matthew Ivory, SA Coulman, V Piguet1 and J Birchall 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, and 1School of Medicine, Cardiff University, Cardiff, Wales, UK 
Epidermal Langerhans cells (LCs) and multiple subsets of dermal dendritic cells (dDCs) make skin a valuable 
route for vaccination, offering the potential for antigen-sparing immunisation. The interconnected 
immunological functions of dDC subsets and LCs are not fully understood however. This Thesis therefore 
aimed to explore the interactions of skin immune cells with viral pathogens and vaccines to inform the 
development of future therapeutics and intradermal vaccines. LCs and dDCs were isolated from ex vivo human 
skin tissue using a walkout protocol which allowed the enrichment of the migratory cells from the tissue. LCs 
and dDCs were infected with a lentiviral vector encoding GFP, allowing study of post-entry HIV viral restriction. 
The study uncovered the existence of a SAMHD-1-independent antiviral factor unique to LCs. LCs and dDCs 
from ex vivo skin were used to examine the cross-presentation of an inactivated influenza virus-derived matrix 
peptide to CD8+ T-cells. Two CD11c+ subsets of dDCs were found to potently cross present the antigen. 
Delivery of VLPs, which lack genetic material, markedly reduced cross-presentation, suggesting that viral 
genetic material is vital for dDCs to activate cross-presentation pathways. Future work is required to determine 
if this is true of other influenza peptides or pathogens. Vaccine delivery studies performed using murine and 
human models found that dDCs were responsible for the greatest uptake of ovalbumin peptide antigen and 
LCs did not migrate out of the epidermis in the first 4 hours after inactivated influenza virus vaccine delivery 
respectively. Collectively, this work highlighted the importance of dDCs in antigen uptake and cross-
presentation to prime cytotoxic T-cell responses. Innovative delivery methods such as microneedles offer a 
means of accessing the dermal compartment in a pain-free manner, though further work is required to 
determine the optimal combination of vaccine formulation and delivery method to harness the 
immunostimulatory abilities of dDCs. 
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Characterization and mechanisms of thiol-induced protection against myocardial 
infarction 
Karwi Qutuba and GF Baxter 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue,  
Cardiff CF10 3NB, Wales, UK 
Hydrogen sulfide (H2S) is the simplest endogenously produced thiol and has an indispensable role in 
cardiovascular homeostasis. It has been shown that exogenous H2S supplementation protected the heart 
against myocardial ischaemia/reperfusion injury through a mechanism which is yet to be defined.  
In this thesis, it was hypothesised that controlled application of thiol/H2S donors at reperfusion would mitigate 
acute myocardial infarction. We sought to characterise the cardioprotection and molecular targets of three H2S 
donors (mesna, GYY4137 (a slow-releasing, non-mitochondrial targeted H2S donor) and AP39 (a 
mitochondria-targeting H2S donor). This characterisation was conducted using a broad range of experimental 
models and techniques including anaesthetised rat model of ischaemia/reperfusion injury, Western blotting 
and mitochondrial studies using isolated cardiomyocyte mitochondria, namely subsarcolemmal and 
interfibrillar mitochondria.  
Mesna did not limit infarct size when it was given pre-ischaemia or at reperfusion. GYY4137 and AP39 
significantly limited infarct size when given specifically at the time of reperfusion through different mechanisms. 
Cardioprotection established by GYY4137 was mediated mainly by triggering of PI3K/Akt/GSK-3β signalling 
at reperfusion with partial dependency on eNOS activity. Selective mitochondrial delivery of H2S at reperfusion 
using AP39 had no effect on Akt, eNOS, GSK-3β and ERK1/2. In isolated mitochondria, AP39 inhibited Ca2+-
sensitive opening of PTP in subsarcolemmal and interfibrillar mitochondria through attenuation of 
mitochondrial reactive oxygen species generation.  
The studies presented in this thesis provided novel mechanistic insights into cardioprotection by H2S. These 
studies suggest that targeted delivery of H2S represents a novel and effective adjunctive therapy to ameliorate 
the injurious effects of reperfusion which contribute to acute myocardial infarction.  
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